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Worldwide, colorectal cancer (CRC) is the third most prevalent cancer and prostate 
cancer (PCa) is the second most prominent cancer in men. Treatments for both CRC 
and PCa have greatly improved over the last 10-20 years; however, there is still a 
high mortality rate for both cancers. There is therefore a great need to better 
understand the factors that drive disease development and progression, and 
therapy resistance.  
Long non-coding RNAs (lncRNAs) have gained attention in recent years as 
potential therapeutic targets for cancer. HOTTIP is one such lncRNA that has 
previously been implicated in CRC and PCa. HOTTIP is located on the 5’ end of the 
HOXA locus and regulates nearby HOXA genes including HOXA13 in cis. It has 
previously been shown that HOTTIP and HOXA genes are regulated by the oncogenic 
PSIP1 protein. Using both siRNA mediated knockdown and CRISPR-Cas9 mediated 
genetic knockout approaches, the role of HOTTIP, HOXA13 and PSIP1 were 
investigated in both CRC and PCa.  
Through loss of function studies, depletion of HOTTIP, HOXA13 and PSIP1 led 
to increased sensitivity to chemotherapeutic drugs. This has not previously been 
observed for HOXA13 in PCa, or HOTTIP, HOXA13 and PSIP1 in CRC. These 
observations suggest that further study of these genes may help with understanding 
therapy resistance in CRC and PCa. More in-depth characterisation of how these 
genes are regulated may identify methods to enhance therapy response or re-
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1  General Introduction 
 
1.1 Colorectal cancer 
1.1.1 Diseases of the bowel and colon 
The human colon forms part of the gastrointestinal tract (Wolpin and Mayer, 2008) 
and is often referred to as the large intestine. The colon is home to the largest part 
of the human microbiota and as a result has a crucial role in maintaining a balance 
between the host (human) and the microbiome at the mucosal barrier; a balance 
that is important for maintaining a healthy immune system (Longley, Harkin and 
Johnston, 2003). When this balance is interrupted, certain diseases of the bowel and 
colon can arise. These can include inflammatory bowel diseases (IBD), the most 
common being Crohn’s disease (CD) and ulcerative colitis (UC) (Zhang et al., 2008; 
Wyatt and Wilson, 2009). CD affects both the small and large intestine, whereas UC 
only affects the colon (Longley, Harkin and Johnston, 2003). Other diseases that 
affect the bowel and colon include celiac disease, irritable bowel syndrome (IBS) and 
infections with pathogens such as Clostridium difficile (C. difficile) (Peters et al., 
2002) or Helicobacter pylori (H. pylori). Some of these inflammatory diseases can 
result in a predisposition to developing colorectal cancer (CRC) (Rose, Farrell and 
Schmitz, 2002). 
1.1.2 Colorectal cancer statistics 
Worldwide, CRC is the third most prevalent cancer (Peters et al., 2002) and is 
responsible for at least 600,000 deaths every year (Chu and Allegra, 1996). CRC is a 




It also includes some other less common cancers such as carcinoid tumours, 
gastrointestinal stromal tumours, as well as some forms of lymphoma and sarcoma 
that develop in the colorectal region (Van Triest et al., 1999). It is a frequently 
occurring cancer with 1 in 20 people developing the disease in their lifetime 
(Longley, Harkin and Johnston, 2003). It is a highly metastatic cancer, with only 40 % 
of cases being diagnosed at the primary site (Arango et al., 2004). Remaining cases 
are diagnosed at secondary or further metastatic sites.  
The most common secondary site is the liver, with up to 70 % of patients 
presenting with liver metastasis (Gonçalves-Ribeiro et al., 2016; McQuade et al., 
2017; García-Alfonso et al., 2019), followed by lung metastasis, with approximately 
5-15 % of CRC cases (Almeida et al., 2006). As with any cancer, the stage at which 
CRC is diagnosed is an important indicator of survival rate (Oppelt et al., 2019). For 
example, in the USA the 5-year survival rate of CRC between 2001 and 2007 was 
90.1 % for patients with localised disease, 69.2 % for patients with regional spread, 
and only 11.7 % for patients with distant tumour spread (Brenner, Kloor and Pox, 
2014). 
1.1.2.1 Epidemiology of colorectal cancer 
The increasing incidence of CRC has been associated with changes in risk factors 
such as a more Westernised diet in some developing countries (Kolligs, 2016), with 
the highest incidence rates found in the most Westernised countries such as 
Australia and Central and Eastern Europe, and the lowest incidence rates found in 




more economically-developed countries as a result of better screening and earlier 
detection methods, as well as prevention and reduction of risk factors, such as 
improving diets (Gandomani et al., 2017). 
1.1.2.2 Symptoms and diagnosis of colorectal cancer 
A diagnosis of CRC is usually a result of a patient presenting with a particular set of 
symptoms, or after a routine screen for the disease (Schroder et al., 2004). 
Symptoms can include blood in the stool, a change in bowel habits, abdominal pain, 
fatigue, sudden weight loss and anaemia-related symptoms (Teo, Rathkopf and 
Kantoff, 2019). Genetic material originating from primary and/or secondary 
metastatic lesions can be used as non-invasive, blood-based biomarkers to diagnose 
and personalise treatment options for a patient with CRC (Tabaczar et al., 2010; 
Nader, El Amm and Aragon-Ching, 2018). The faecal occult blood test (FOBT) (Nader, 
El Amm and Aragon-Ching, 2018) is the gold standard for identifying blood in the 
stool. This can indicate the presence of pre-cancerous polyps or early stage cancer. 
In the UK, persons between the ages of 60 and 74 are provided with an at-home 
screening kit biannually to complete (Masoodi et al., 2017). If results are positive, 
patients are invited for a colonoscopy. This type of screening has resulted in a 15 % 
reduction in colorectal cancer mortality (Nader, El Amm and Aragon-Ching, 2018) as 






1.1.2.3 Histology and grading of colorectal cancer 
The majority (60 %) of CRC cases are diagnosed at secondary or metastatic sites 
(Placzek et al., 2010). CRC is generally a slow developing cancer that begins as an 
abnormal growth, called a polyp that starts to grow on the wall of the rectum or 
colon (Lin et al., 2007). As CRC develops, the polyp progresses from an adenomatous 
polyp, to a pre-cancerous polyp; it is then defined as an adenocarcinoma before fully 
progressing to a tumour (Figure 1.1). It can take over ten years for the disease to 
develop fully (Nguyen and Duong, 2018).  As the cancer progresses, the polyp 
proliferates and starts to grow into blood or lymph vessels increasing the risk of 
metastasis, allowing the cancer to spread to other regions of the body, mainly to the 
liver and lungs (Nguyen and Duong, 2018). CRC cases are classified according to the 
following three stages: T stage, which represents local invasion depth; N stage, if 
lymph node involvement has occurred; and M stage, whether distant metastases are 
present (Table 1.1). Together, these stages are combined to produce one overall 







Figure 1.1 Schematic showing the progression of colorectal cancer: from a non-cancerous 
polyp to a cancerous tumour. 







Tx No information about local tumour infiltration available 
Tis Tumour restricted to mucosa, no infiltration of lamina muscularis mucosae 
T1 Infiltration through lamina muscularis mucosae into submucosa, no 
infiltration of lamina muscularis propria 
T2 Infiltration into, but not beyond, lamina muscularis propia 
T3 Infiltration into subserosa or non-peritonealised pericolic or perirectal 
tissue, or both; no infiltration of serosa or neighbouring organs 
T4a Infiltration of the serosa 
T4b Infiltration of neighbouring tissues or organs 
Nx No information about lymph node involvement available 
N0 No lymph node involvement 
N1a Cancer cells detectable in 1 regional lymph node 
N1b Cancer cells detectable in 2-3 regional lymph nodes 
N1c Tumour satellites in subserosa or pericolicor periectal fat tissue, regional 
lymph nodes not involved 
N2a Cancer cells detectable in 4-6 regional lymph nodes 
N2b Cancer cells detectable in 7 or greater regional lymph nodes 
Mx No information about distant metastases available 
M0 No distant metastases detectable 
M1a Metastasis to 1 distant organ or distant lymph nodes 
M1b Metastasis to more than 1 distant organ or set of distant lymph nodes or 
peritoneal metastasis 




1.1.2.4 Colorectal cancer risk factors 
Many risk factors have been linked to an increased risk of developing CRC. CRC is 
increasing in individuals over the age of 50 (Nguyen and Duong, 2018), however the 
mean age of CRC diagnosis is 72 years (female) and 75 years (male) (Nguyen and 
Duong, 2018). It is estimated that lifestyle plays a role in up to 71 % cases of CRC in 
the Western world (Testa, Pelosi and Castelli, 2018). This ‘Western lifestyle’ can 
include many factors such as obesity, sedentary behaviour, smoking, alcohol 
consumption and a diet high in calories, fat and low in fibre (Nguyen and Duong, 
2018). 
A 2-3 % increased risk of CRC has been described with every unit increase of 
the body mass index (BMI) (Fearon and Vogelstein, 1990). Those with type 2 
diabetes are also at an increased risk of developing CRC (Nguyen and Duong, 2018). 
Infection with some types of bacteria such as H.  pylori has also been shown to 
increase CRC risk (Testa, Pelosi and Castelli, 2018). A family history of CRC can also 
increase a person’s risk of developing the disease, with the risk being strongest for 
those with a first-degree relative with CRC (Testa, Pelosi and Castelli, 2018). There 
are several forms of hereditary CRC, including familial adenomatous polyposis and 
hereditary non-polyposis colon cancer (HNPCC) (also known as Lynch syndrome) 
(Testa, Pelosi and Castelli, 2018).  
Lynch syndrome is the most common genetic syndrome that can lead to CRC 
and is responsible for up to 6 % of CRC cases (Woenckhaus and Fenic, 2008; Sharifi 




(Knudsen and Vasioukhin, 2010; Koh et al., 2010); a DNA mismatch repair (MMR) 
gene that is involved in the detection and repair of DNA mismatches, many of which 
occur during cell replication (Knudsen and Vasioukhin, 2010). However, familial risk 
of CRC is less than that of the other lifestyle risk factors listed above (Knudsen and 
Vasioukhin, 2010). Other genetic factors that are not related to a familial history of 
the disease can also increase a person’s risk of developing CRC. Mutations of the 
Adenomatous polyposis coli (APC) tumour suppressor gene can occur early on in the 
development of CRC, and occur in over 70 % of all colorectal adenomas (Knudsen 
and Vasioukhin, 2010; Koh et al., 2010).  
As CRC develops, further genetic mutations occur including mutations of 
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) and TP53 (p53) (Kim and 
Shiekhattar, 2016). KRAS is an oncogene that drives progression of the diseases, 
whereas p53 is a tumour suppressor. Mutations in both KRAS and p53 are usually 
accompanied by other genetic aberrations, including chromosomal instability (CIN) 
and CpG island methylation (CIMP) (Li et al., 2011; Cheng et al., 2015). Individuals 
with a germline mutation of DNA MMR genes such as MLH1 have an increased risk 
of developing many types of cancer, including CRC (Pradeepa et al., 2017). 
Preventative factors to reduce a person’s risk of developing CRC include engaging in 
regular physical activity, use of aspirin or hormone replacement therapy, and a diet 
rich in fruit, vegetables, fibre, whole grains, dairy products and fish (Wen et al., 
2018).  
There are three main pathways that lead to CRC. These include the classic 




through CIN mechanisms (Wang et al., 2011). CIN mutations are found in 85% of 
adenoma-carcinoma transitions and include mutations of KRAS and BRAF as well as 
in tumour suppressor genes APC and TP53 (Wang et al., 2011). According to the 
multistep genetic model of colorectal carcinogenesis (Wang et al., 2011), 
inactivation of the tumour suppressor APC occurs first, followed by mutations in the 
KRAS oncogene which usually occur during the adenomatous stage of CRC disease 
progression. Eventually at the later stages of carcinogenesis, deletion of 
chromosome 18q and TP53 inactivation occurs, continuing the transition to 
malignancy (Kingston and Tamkun, 2014). The second pathway of colon 
carcinogenesis is the germline mutation pathway (Kingston and Tamkun, 2014), 
which involves mutation of MMR genes as is seen in Lynch Syndrome (previously 
described). The final pathway of CRC progression is the serrated-sessile-methylation 
pathway (Kingston and Tamkun, 2014). Mutations involved in this third pathway also 
include tumours with KRAS and BRAF mutations and hypermethylation of genes such 
as MGMT, p16 and MLH1 (Smith, Zyoud and Allegrucci, 2019).  
1.1.2.5 Screening and treating colorectal cancer 
The main preventative precaution available for CRC is to screen regularly to catch 
the disease at an earlier, more treatable stage. There are several types of screening 
tests used to diagnose CRC. This includes the FOBT, colonoscopies, and stool DNA 
testing (Kingston and Tamkun, 2014). However, these screening methods lack 
sensitivity and hence there is a need for updated, more vigorous screening methods 
for the detection of CRC (Kingston and Tamkun, 2014). Once detected, colectomy 




and Allegrucci, 2019), although this is dependent on disease stage (Mármol et al., 
2017). In some cases, surgery may be followed by chemotherapy treatment.  
Fluorouracil (5FU) treatment is one chemotherapeutic drug commonly administered 
to CRC patients (Lian, Y; Cai, Z; Gong, 2016). It is an antimetabolite drug (Quagliata et 
al., 2015; Chang et al., 2016; Zhang et al., 2016) that attacks cancerous cells by 
promoting DNA damage, interfering with the metabolism of nucleotides, leading to 
cytotoxicity and apoptosis (Li et al., 2015; Li, Zhao and Wang, 2016; H. Jiang et al., 
2019). This mechanism of cytotoxicity is a result of the incorporation of 
fluoronucleotides into DNA and RNA inhibiting their function (Wang et al., 2011; 
Pradeepa et al., 2017) by targeting the nucleotide synthetic enzyme thymidylate 
synthase (TS) (Peters et al., 2002) during both S and G1 phase of the cell cycle (Li et 
al., 2011; Sun, Hu, et al., 2018). TS is an essential enzyme required for the synthesis 
of DNA and is often a target of chemotherapeutic drugs (Carethers et al., 2004). 5FU 
can be administered on its own, or in conjunction with other chemotherapeutic 
drugs. 
Oxaliplatin (OX) is another commonly administered chemotherapy treatment 
for CRC. It is often used clinically when cancerous cells have become resistant to 5FU 
(Comella et al., 2009), or in combination with 5FU (Ito et al., 2018). It is a platinum-
based chemotherapeutic drug (T. Liu et al., 2018) and its mechanisms of action 
include promoting DNA damage, causing G2/M arrest, and preventing DNA/RNA 
synthesis (Zhuang, Li and Ma, 2019). One way in which oxaliplatin can lead to 
apoptosis in cells is by forming crosslinks (both DNA-DNA and DNA-protein) that can 




Similarly, to the mechanisms of action of 5FU, oxaliplatin can also arrest DNA 
synthesis by inhibiting thymidylate synthase, which prevents the incorporation of 
thymidine in nucleic acid synthesis. This results in arrest during the G2/M phase of 
the cell cycle (Wang et al., 2011; Pradeepa et al., 2017), however some delay in S 
phase has also been observed in cells treated with OX (William-Faltaos et al., 2007). 
Inhibition of RNA synthesis, through disrupting transcription, particularly during 
initiation and elongation, is also one of the mechanisms of action of oxaliplatin 
(Iman et al., 2016; Huang et al., 2017; Ying et al., 2020). It has also been reported 
that after exposure to oxaliplatin, colon cancer cells can emit immunogenic signals 
on their surface before they undergo apoptosis (Ding et al., 2017). This helps trigger 
the production of interferon ƴ by T cells, which can stimulate macrophages, natural 
killer cells and neutrophils, resulting in removal of cancer cells from the body 
(Funayama et al., 2017; Chai et al., 2019; Chang et al., 2019). 
Many of these treatment options are considered aggressive and are 
not always effective, therefore it is important to continue researching and 
developing new therapies to improve overall survival and the quality of life of 
patients with this disease (Cantarino et al., 2016). 
1.2 Prostate Cancer 
1.2.1 The prostate gland 
The prostate is the largest male accessory gland (Chen et al., 2017) and is an 
essential part of the male reproductive system. It is located at the base of the 




major compartments, the epithelium and the stroma. Epithelial cells exert the 
glands secretory functions (Funayama et al., 2017), which are important to male 
fertility (Chai et al., 2019; Chang et al., 2019). The prostate gland is also associated 
with several prostatic diseases, including prostatitis, benign prostatic hyperplasia 
(BPH), and prostate cancer (Berx and van Roy, 2009). 
1.2.2  Prostate cancer 
Prostate cancer (PCa) is the second most prominent cancer in men (Rawla, 2019) 
and is the second most common cause of cancer-related death worldwide (Kumar 
and Lupold, 2016; Gamat and McNeel, 2017). It is thought that PCa arises from 
precancerous legions known as proliferative inflammatory atrophy (PIA) and/or 
prostatic intraepithelial neoplasia (PIN) (Kumar and Lupold, 2016). There have been 
some genetic markers associated with PIA/PIN, including the oncogene HER-2, the 
antiapoptotic protein BCL-2 and the loss of tumour suppressor genes such as CDK1, 
NKX3-1 and GSTP1 (Peek, Mah and Weiner, 2017).  
PCa can develop from PIA/PIN to a low-grade carcinoma which is often 
characterised with increased expression of MYC, SPINK1 and members of the ETS 
family, as well as loss of p27 and FOXP3 (Chang et al., 2016; Qin et al., 2019). Further 
progression of PCa to a high-grade carcinoma is associated with loss of tumour 
suppressors PTEN and p53 (Li et al., 2015). Once PCa has become metastatic, 
tumours have been found to overexpress EZH2 which promotes proliferation, 




shown to regulate androgen-dependent survival signalling and the androgen 
receptor (AR) (Quagliata et al., 2018), as well as loss of Mir-101 (Zhang et al., 2016). 
As PCa is a hormone cancer, the male sex hormone androgen also plays a 
role in its pathogenesis (Grozescu and Popa, 2017). The AR is expressed in all stages 
of prostate carcinogenesis, from primary sites to metastatic tumours (Culig and 
Santer, 2014; Grozescu and Popa, 2017). It is involved in the regulation of 
proliferation, apoptosis, migration, invasion, and differentiation (Culig and Santer, 
2014). PCa tumour growth is known to be dependent on AR signalling (Brooke et al., 
2014) and as a result many therapies target this pathway. 
1.2.2.1 Symptoms and diagnosis of prostate cancer 
PCa is an age associated disease with incidence rates associated with age (Bhatlekar, 
Fields and Boman, 2018; Tatangelo et al., 2018). The mean age of PCa diagnosis is 66 
years (Li et al., 2015; Zhang et al., 2016). Early stages of PCa are hard to diagnose as 
they are usually symptomless (Wang et al., 2011; Pradeepa et al., 2017). It is a slow 
developing cancer and sometimes minimal or no treatment is required (Li et al., 
2011). When symptoms do start to present, these may include an increased urgency 
and frequency to urinate or poor urinary stream and leakage, as well as erectile 
dysfunction (Chang et al., 2016; Qin et al., 2019). These are collectively known as 
lower urinary track symptoms (LUTS) (Shen and Chen, 2011). 
PCa can be diagnosed through several tests: a digital rectal examination 
(DRE), a trans-rectal ultrasound (TRUS), biomarkers and finally as a result of biopsy 




reached if these tests are used in combination (Chang et al., 2016).The Prostate 
Specific Antigen (PSA) is a 34 kDa glycoprotein produced in the prostate (Xie et al., 
2019). It is detectable in the blood and quantification of this antigen aims to detect 
PCa at an early stage, to aid treatment and reduce mortality (Mansour and Senga, 
2017). Serum PSA levels can also indicate the stage of PCa with higher PSA levels 
indicating a later disease stage and can be used to measure therapy response (Dong 
et al., 2017a). Biomarker analysis allows more precise diagnosis of the cancer staging 
and aids with treatment decisions (Falaschi, Abdurashidova and Biamonti, 2010).  
1.2.2.2 Histology and grading of prostate cancer 
The Gleason score is currently the most commonly used system to establish the 
degree of a prostate tumour. A Gleason score is given by adding the grades of the 
two most prevalent neoplastic legions together, taken from biopsy samples, with a 
higher score indicating a more advanced disease state (Duan et al., 2015). The 
Gleason system was originally defined in the 1960s-1970s (Schatoff, Leach and Dow, 
2017) but has now been updated to include five histological grades (Figure 1.2, Table 
1.2), with Grade 1 being the least aggressive and Grade 5 being the most aggressive 



























Figure 1.2 Schematic of the Gleason grading system. 
Schematic of the modified Gleason diagram updated by the World Health 
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Lack gland formation (or with necrosis) with or w/o poorly 
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1.2.2.3 Epidemiology of prostate cancer 
Geographical, racial and ethnic differences have been reported in PCa incidence 
(Han et al., 2018). Worldwide, men of African descent have a higher risk of 
developing PCa and tend to have poorer prognosis and higher mortality rates (Li et 
al., 2015). This has been found to be true for African-American, Caribbean, and Black 
European men, indicating a shared genetic trait could be contributing to an 
increased risk of PCa (Han et al., 2018). Although, part of the disparity in this 
increased risk of PCa and poorer prognosis may  also be the result of differences in 
accessibility to screening programmes and treatment (Boyd et al., 1988; Arango et 
al., 2004). High incidence rates have also been observed in the ‘Western’ world that 
are thought to largely be a result of lifestyle factors (Yokoyama and Cleary, 2008). 
1.2.2.3  Prostate cancer risk factors 
Only a small number of PCa risk factors have been identified as the initial onset of 
the disease is still relatively unknown (Grozescu and Popa, 2017). In most cases, a 
combination of several risk factors likely contributes to PCa development. Ageing is 
positively correlated with developing PCa (Kimura and Egawa, 2018) and is thought 
to be the largest risk factor, with 50 % of men age 50 and 80 % of men ages 80 
presenting with PCa (French et al., 2016). Environmental or lifestyle risk factors that 
have been attributed to PCa include a ‘Western’ diet that is high in saturated fat, red 
meat and dairy products, as well as being obese or having type 2 diabetes (Pradeepa 
et al., 2017). Obesity has also been associated with increased risk of PCa mortality 




exercising regularly, not smoking and maintaining a healthy weight can lower the 
risk of developing PCa (Pernar et al., 2018). 
Having a family history of prostate cancer is a significant genetic risk factor 
for PCa, particularly if a close relative has been diagnosed with the disease (Aarons, 
Shanmugan and Bleier, 2014; Delavari et al., 2014). Having a first-degree relative 
diagnosed with the disease increases PCa risk by 2-3 fold (Giri and Beebe-Dimmer, 
2016). Two types of inherited PCa have been identified: hereditary and familial 
(Grozescu and Popa, 2017). As previously mentioned, men of African descent also 
have an increased risk of developing PCa which could be due to shared genetic traits 
(Rawla, 2019). Genetic mutations may also contribute to PCa development or 
progression (Ríos-Colón et al., 2017). These can include genes involved in DNA 
damage and repair, inflammation, carcinogen metabolism and steroid hormone 
metabolism (French et al., 2016). There has been a rise in reports of some inherited 
gene mutations such as in BRCA1 and BRCA2 that may correlate with PCa metastasis 
and increase the risk of PCa specific death (Guo et al., 2008; Focaccetti et al., 2015). 
1.2.2.4  Screening and treating prostate cancer 
Due to the increased risk of developing PCa if a close relative, such as a father or 
brother has been diagnosed with the disease, there is a strong need for screening 
and early diagnosis in men who fall into this risk category. . Biomarkers can be an 
effective form of screening for disease as they are often non-invasive and relatively 
cheap tests to perform. One of the most specific PCa biomarkers is Prostate Cancer 
Antigen 3 (PCA3), a long non-coding RNA (lncRNA) (William-Faltaos et al., 2007; 




detected in body fluids (Tabaczar et al., 2010; Nader, El Amm and Aragon-Ching, 
2018) making them attractive biomarker targets. PCA3 expression has been found to 
be 60-100 fold higher in more than 95 % PCa tumours compared to nearby non-
cancerous tissue (Misawa, K.-I. Takayama and Inoue, 2017). It is detectable in the 
urine (Misawa, K.-I. Takayama and Inoue, 2017) making screening tests for this gene 
very simple to perform.  
After diagnosis, there are several treatment options for PCa including: radical 
prostatectomy (Triantafillidis, Nasioulas and Kosmidid, 2009), radical radiotherapy 
(Wlodarska, Kostic and Xavier, 2015), chemotherapy, hormone therapy (Wlodarska, 
Kostic and Xavier, 2015) and conservative management (Grozescu and Popa, 2017).  
Radical prostatectomy involves removing the prostate gland and surrounding tissue 
or lymph nodes (Z. Li et al., 2017; Garrett, 2019). With the development of robot-
assisted laparoscopic radical prostatectomy (RALP) systems such as the da Vinci SP 
Surgical System, promising surgical results are being observed (Kolligs, 2016) 
compared to older techniques that were associated with many high-risk side-effects 
including urinary problems and sexual incontinence (Marley and Nan, 2016). 
For non-organ confined PCa, radiotherapy, chemotherapy and hormone 
therapy are common treatment options; both individually and as a combined course 
of action. Docetaxel (DOC) was the first chemotherapy agent to show an overall 
improvement in survival in metastatic CRPC (Zellweger et al., 2018). It is a taxane 
derivative and its mechanisms of action include inhibiting microtubule 
depolymerisation in cancer cells, a process crucial to cell mitosis; DOC specifically 




microtubule depolymerisation, DOC binds to the microtubules, preventing androgen 
receptor nuclear translocation, which is a key regulatory step of the AR (Valderrama-
Treviño et al., 2017). Targeting this nuclear localisation through chemotherapy can 
prevent uncontrolled cell growth (Zellweger et al., 2018). DOC can also initiate 
apoptosis through B-cell lymphoma (Bcl-2)  phosphorylation (Oppelt et al., 2019). 
Bcl-2 is an anti-apoptotic protein and can be up-regulated in cancer (Brenner, Kloor 
and Pox, 2014). In PCa, Bcl-2 is essential for the progression of cells from an 
androgen-dependent state to an androgen-independent state (Kolligs, 2016); 
therefore it is an important target for PCa chemotherapy to induce apoptosis in 
cancerous cells. 
However, as with any chemotherapeutic agent, there is a risk of PCa tumours 
becoming chemoresistant to DOC.  Androgen deprivation therapy (ADT) is often 
used in advanced PCa cases to slow tumour progression and ease symptoms 
(Gandomani et al., 2017). Here, the AR can be targeted via chemical castration 
(reduced androgen production in the testes) and through use of antiandrogens, 
drugs that bind to the AR and hold it in an inactive state (Gandomani et al., 2017). 
ADT is designed to target prostate tumour cells directly, but there are concerns 
about the effects of androgen depletion on the immune system (Kuipers et al., 
2015). Androgen deprivation can result in an increase in naïve T cells, antigen-
specific T cells and IFNƴ production (Kuipers et al., 2015). An infiltration of T-cells 
into the prostate can also occur as a result of androgen deprivation, which could 




in many cases, but eventually tumour cells become resistant to hormone therapy 
and PCa can become castrate resistant (CRPC) (Kolligs, 2016). 
Conservative management is also referred to as active surveillance; it 
involves monitoring the disease and only treating the symptoms that present in a 
patient (Koo et al., 2017). It has become the preferred option for men with a less 
aggressive cancer (Koo et al., 2017) and helps to avoid overtreatment which may 
improve long-term quality of life in patients (Zellweger et al., 2018). Gene therapy is 
a promising treatment option for PCa to increase specificity and reduce side effects 
that are associated with current therapies (Marley and Nan, 2016). Continuing to 
understand the genetics of this disease will increase the possibility of precision 
medicine and tumour-specific treatment as well as assisting with overcoming 
chemoresistance in this disease (Brenner, Kloor and Pox, 2014).  
As therapy resistance is common in PCa, a number of groups are developing 
novel strategies to target the disease that will overcome this barrier. This includes 
cell therapy with mesenchymal stem cells (MSCs) that can deliver therapeutic genes 
to tumours (Tao et al., 2019). An example of a therapeutic gene targets for MSCs in 
PCa includes the death ligand Tumour necrosis factor related apoptosis-inducing 
ligand (TRAIL) that can specifically induce apoptosis in cancerous cells without 
targeting normal, non-cancerous cells (Brenner, Kloor and Pox, 2014). Oncolytic 
virotherapy is an example of using genetically engineered viruses to treat tumour 
cells (Thrymurthy, 2016). Once integrated into a tumour cell, an oncolytic virus can 
replicate and induce tumour cell death; it also has the added benefit of having the 




2019). Many types of naturally occurring viruses can be manipulated for therapeutic 
use, however adenoviruses are among the most studied as they have low levels of 
pathogenicity and are relatively easy to manipulate (Kolligs, 2016). Oncolytic 
adenoviruses have been engineered to target many pathways in PCa tumours 
including deregulated cell cycle and apoptosis pathways induced by chemotherapy 
(Valderrama-Treviño et al., 2017). As a result, several clinical trials have been carried 
out using adenovirus as a method of gene therapy delivery to treat PCa (Kolligs, 
2016; Marley and Nan, 2016). One such adenovirus is Ad-p53, a viral vector 
expressing the tumour suppressor p53, which attempts to counteract the p53 
alternations associated with metastatic PCa (Kuipers et al., 2015). 
1.3 Long non-coding RNAs 
The human genome can be categorised into two regions: coding and non-coding. For 
many years, research efforts had focused on understanding protein-coding genes 
and their regulation. Upon completion of the human genome project in 2003 it was 
discovered that DNA with protein coding potential only accounted for around 2 % of 
the entire genome (Kuipers et al., 2015). The remaining 98 % of the genome is 
comprised of non-coding DNA that had previously been discounted as the ‘noise’ of 
the genome (Brenner, Kloor and Pox, 2014). Since such a large proportion of the 
genome turned out to be this ‘junk’ non-coding DNA, a new field of research was 
born as scientists attempted to understand the relevance of non-coding DNA. In 
recent years, it has become known that non-coding DNA can be further 
characterised into various genetic elements with different roles and regulatory 




transcripts that are transcribed from DNA but do not have the ability to be 
translated into protein (Brenner, Kloor and Pox, 2014). NcRNAs can be classified 
further based on each transcript’s size or function. One such group are long non-
coding RNAs (lncRNAs) which are defined as being greater than 200 nucleotides in 
length with little or no protein coding ability (Brenner, Kloor and Pox, 2014). 
The field of lncRNA biology has grown drastically in the last decade 
(Jasperson and Burt, 2015). Mammalian genomes are now known to encode 
thousands of lncRNAs (Dowty et al., 2013) and there are many more lncRNAs that 
occur in the genome compared to protein-coding messenger RNA (mRNA) (Dowty et 
al., 2013). It is known that lncRNAs have a wide range of functions in the cell (Marley 
and Nan, 2016), and although they do not directly encode proteins, they are key 
regulators of gene expression (Brenner, Kloor and Pox, 2014). Key lncRNA functions 
include: involvement in epigenetic control through chromatin modifications 
(Brenner, Kloor and Pox, 2014); acting as enhancer RNAs (eRNAs) to promote gene 
expression (Brenner, Kloor and Pox, 2014); regulation of the cell cycle, apoptosis 
(Dowty et al., 2013), as well as roles in pattern formation and differentiation during 
embryonic development (Brenner, Kloor and Pox, 2014). However, many of the 
mechanisms by which lncRNAs carry out these functions are still under investigation. 
In general, lncRNAs have a wide range of properties that vary between each 
individual transcript. They can be located in either the nucleus or the cytoplasm of a 
cell and are transcribed by RNA Polymerase II (RNA Pol II) from either the sense or 
anti-sense strand meaning that transcription can occur in any direction (3’ or 5’) 




species (Nguyen and Duong, 2018) so evolve quicker than other protein-coding 
genes. LncRNAs can be preferentially expressed in specific tissues, and the location 
of a particular lncRNA may indicate its functional role (Fearon and Vogelstein, 1990). 
LncRNAs have the ability to function either in cis (close proximity, usually on the 
same chromosome) or in trans (distally transcribed, often from a different 
chromosome) in order to regulate gene expression (Nguyen and Duong, 2018). This 
highlights the wide variety of ways in which lncRNAs regulate gene expression. 
1.3.1 LncRNAs and gene regulation 
Some studies have attempted to group the ways in which lncRNAs influence gene 
regulation into four categories, those acting as decoys, guides, signals, or as 
scaffolds (Testa, Pelosi and Castelli, 2018). Many lncRNAs can be placed into more 
than one of these categories. LncRNAs that are classified as ‘guides’ are able to 
control target genes and influence their expression in an allele-specific manner 
(Testa, Pelosi and Castelli, 2018). They bind to proteins and direct complexes to 
specific genomic targets. This can occur in either a cis or trans manner (Testa, Pelosi 
and Castelli, 2018). HOTTIP is one such lncRNA that regulates gene expression 
through working as a guide. It binds to the WDR5/MLL complex, enabling the 
transcription of nearby HOXA genes through chromosomal looping, hence ‘guiding’ 
the genome to activate gene expression (Qi, Zhou and Du, 2016).  
1.3.2  LncRNAs in disease 
Due to their key roles in the regulation of gene expression and important cellular 




diseases (Hadjipetrou et al., 2017). Aberrant lncRNA expression has been described 
in neurological disorders such as Alzheimer’s disease and Huntington’s disease (Mike 
and Kano, 2015), Cardiovascular disease (Mármol et al., 2017), autoimmune diseases 
(Wolpin and Mayer, 2008), as well as a variety of cancers (Longley, Harkin and 
Johnston, 2003). 
1.3.2.1  LncRNAs in cancer 
In cancer, the dysregulation of lncRNAs can exhibit either oncogenic or tumour 
suppressor like functions (Zhang et al., 2008; Wyatt and Wilson, 2009) that affect 
important processes including oncogenesis, cell growth, cell proliferation, and 
apoptosis (Longley, Harkin and Johnston, 2003). Overexpression of lncRNAs has 
been linked to tumour cell proliferation and metastasis (Peters et al., 2002), leading 
to the progression of cancer. Some lncRNAs are detectable in serum, plasma and 
other bodily fluids such as the urine. Therefore, oncogenic lncRNAs could serve as 
potential prognostic biomarker targets (Guo et al., 2008; Focaccetti et al., 2015). As 
described previously, one such example is PCA3, a lncRNA that has been found to be 
overexpressed in 95% of PCa sites. It was the first urine-based diagnostic test to be 
approved by the Food and Drug Administration (FDA), in the U.S. (Rose, Farrell and 
Schmitz, 2002). This type of test is inexpensive to run, enables many patients to be 
screened quickly, and is non-invasive, something which many other cancer screening 
formats lack.  This highlights the ever-increasing potential for lncRNAs to be used as 





1.4  HOX genes 
HOMEOBOX (HOX) genes are an important set of developmental genes that were 
first discovered in Drosophila (Arango et al., 2004), and since then have been 
reported in every animal genome that has been sequenced so far (Gonçalves-Ribeiro 
et al., 2016; McQuade et al., 2017; García-Alfonso et al., 2019). As a result, HOX 
genes are extremely important when studying animal development. They are an 
extremely conserved set of genes (Almeida et al., 2006) and are involved in gene 
regulation during embryonic development (Wang et al., 2016) and are found on 
every chromosome, organised into clusters. In mammals, there are four Hox 
clusters: Hoxa, Hoxb, Hoxc, and Hoxd that consist of 39 Hox transcription factors and 
multiple transcripts (Wang et al., 2016). Each HOX cluster is arranged from the 3’ to 
5’ end with its HOX genes are named from 1 to 13. (Joo, Park and Chun, 2016). These 
Hox clusters are important for specifying the position of cells and defining how 
crucial structures within the body are formed by regulating gene transcription 
(William-Faltaos et al., 2007). HOX genes located at the 3’ end are expressed early in 
development, while HOX genes expressed from the 5’ end are expressed later in the 
developmental process (Joo, Park and Chun, 2016). They are an extremely conserved 
set of genes (De Kumar and Krumlauf, 2016); again highlighting their importance to 
animal development.  
The expression of Hox and other developmental genes is regulated by the 
MLL/Trithorax (Trx) and Polycomb group (PcG) proteins, which influence the 
activation of genes through trimethylation of histone H3 lysine 4 (H3K4me3) and the 




2004). Trx group proteins regulate the ‘ON’ state of Hox genes, whereas the PcG 
proteins control their ‘OFF’ state (Mármol et al., 2017). Most PcG genes encode the 
subunits of Polycomb repressive complex (PRC)1 and PRC2; both of which are 
involved in transcriptional repression (Zhang et al., 2018). Through cis-regulatory 
elements called Polycomb-response elements (PREs), PRC1 and PRC2 target the 
promoters of Hox genes (Motrich et al., 2018). This is achieved through methylation 
of Histone H3 residues which results in transcriptional repression (Wang et al., 
2018). On the other hand, MLL (human ortholog of Trx) (Hoover and Naz, 2012) 
proteins are responsible for maintaining cell fates during embryonic development 
(Verze, Cai and Lorenzetti, 2016) through positively regulating the Hox genes via the 
active H3K4me3 histone mark (Woenckhaus and Fenic, 2008; Sharifi et al., 2016).  
Hox clusters show transcriptional activity from both coding and non-coding 
regions of the genome during the developmental stages (Knudsen and Vasioukhin, 
2010; Koh et al., 2010). The Hoxa cluster is the most studied (Knudsen and 
Vasioukhin, 2010) and as a result more research has been carried out into its 
surrounding lncRNAs over the other three clusters. LncRNAs are often located in 
close proximity to these Hox clusters (Knudsen and Vasioukhin, 2010). The presence 
of lncRNAs within the HOX clusters suggests a different way in which HOX genes are 
involved in gene regulation (Knudsen and Vasioukhin, 2010; Koh et al., 2010). Recent 
advances in genomic research has uncovered many lncRNA transcripts embedded 
within the Hox clusters and surrounding regions including: Hotair and Hottip 




The expression of Hox and other developmental genes is regulated by the 
MLL/Trithorax (Trx) and Polycomb group (PcG) proteins, which influence the 
activation of genes through trimethylation of histone H3 lysine 4 (H3K4me3) and the 
repression of genes through trimethylation of histone H3 lysine 27 (Rawla, 2019). 
Trx group proteins regulate the ‘ON’ state of Hox genes, whereas the PcG proteins 
control their ‘OFF’ (Pentyala et al., 2016). These two groups of regulatory proteins 
play essential roles maintaining cell fates during embryonic development Two 
lncRNA loci are found on either end of the HOXA cluster; the 3’ end is home to HOXA 
transcript antisense RNA, myeloid-specific 1 (HOTAIRM1), a lncRNA with roles in 
neuronal differentiation as well as being implicated in actute myeloid leukemia 
(Rawla, 2019). On the opposite, 5’ end of the cluster, HOXA transcript at the distal 
tip (HOTTIP) is located, a lncRNA involved in embryonic development (Pentyala et 







Figure 1.3 Schematic of the HOXA cluster and flanking lncRNAs 
Schematic of the human HOXA cluster with HOXA 1-13 genes. The lncRNAs HOTAIRM1 and HOTTIP are 




1.4.1 HOX genes in cancer 
As well as having key roles in development, HOX genes are also involved in 
regulating many cellular process such as apoptosis, receptor signalling, 
differentiation, motility and angiogenesis (Young et al., 2015). Therefore any 
mutations or changes in expression of these genes has the potential to develop and 
progress into many forms of cancer (Grozescu and Popa, 2017). One such HOX gene 
is Homeobox (HOX) A13 (HOXA13), the most distally located of the HOXA genes 
(Grozescu and Popa, 2017). Aberrant HOXA13 expression has been associated with 
some cancers, including gastric (Grozescu and Popa, 2017), pancreatic (Ilic et al., 
2018), liver (Pentyala et al., 2016) and prostate (Litwin and Tan, 2017). HOXA13 
expression has been associated with cancer progression (Grozescu and Popa, 2017; 
Litwin and Tan, 2017) through promoting proliferation and metastasis (Rawla, 2019), 
and interacting with factors that regulate the cell cycle progression (Gordetsky and 
Epstein, 2016; Epstein, 2018). It has also been described as having some 
chemoresistant properties, protecting cancer cells from apoptosis after exposure to 
chemotherapy (Epstein, 2018).  
 
1.4.1.1  HOXA13 in colorectal cancer 
Despite being documented in other cancer types, the role of HOXA13 in CRC has yet 
to be discussed in the literature. HOXA9, closely located to HOXA13 on the HOXA 
cluster, has been reported to be overexpressed in CRC and correlated with lymph 
node metastasis (Grozescu and Popa, 2017; Kimura and Egawa, 2018), suggesting a 




(Rebbeck, 2017; Taitt, 2018), which is a closely related cancer. In GI cancers, HOXA13 
overexpression has been associated with cancer cell invasion, assisting with 
epithelial-to-mesenchymal transition (EMT), and overall contributing to 
tumourigenesis (Rawla, 2019).  
1.4.1.2  HOXA13 in prostate cancer 
The role of HOXA13 in PCa has been studied in more detail than in CRC. HOXA13 
expression is upregulated in PCa, and this has been documented in both cell lines 
and patient tumour samples (Rawla, 2019). High HOXA13 expression has also been 
correlated with poorer overall survival in PCa (Giri and Beebe-Dimmer, 2016). It has 
been found to promote proliferation, migration and invasion, and inhibit apoptosis 




HOXA transcript at the distal tip (HOTTIP) is a lncRNA located at the 5’ end of the 
HOXA cluster (Kimura and Egawa, 2018). It is located near chromosome 7p15.2 
(Grozescu and Popa, 2017) and is transcribed in an antisense direction (Grozescu 
and Popa, 2017). HOTTIP is expressed in both posterior and distal sites in developing 
embryos (Kimura and Egawa, 2018) and in limb bud cells (Grozescu and Popa, 2017). 
It is involved in embryonic development, coordinating the expression of HOXA genes 




nearby 5’ HOXA genes in a cis fashion, including HOXA13, the most proximal HOXA 
gene, located ~330bp upstream of HOTTIP (Pernar et al., 2018).  
This activation of HOXA13 occurs as a result of HOTTIP interacting with DNA 
through chromosomal looping (Pernar et al., 2018). This chromosomal looping 
allows HOTTIP to be brought into close proximity to the chromatin modifying WD 
repeat containing protein 5 (WDR5)/mixed lineage leukaemia 1 (MLL1) complex 
across the HOXA cluster and targets its binding to the WDR5 protein (Grozescu and 
Popa, 2017; Kimura and Egawa, 2018), regulated by the Psip1 protein (Giri and 
Beebe-Dimmer, 2016). HOTTIP expression is associated with an increase in the 
histone modification H3K4me3, which in turn leads to the activation of nearby 5’ 
HOXA genes (Figure 1.4). This tri-methylation marker indicates an active chromatin 
state, ensuring gene expression. MLL is recruited to the promoters of HOX genes to 
maintain their activation sites and subsequent gene expression; HOTTIP is critical for 





Figure 1.4 Schematic of the interactions between the lncRNA HOTTIP and chromatin 
modifying complexes. 
Schematic of the lncRNA HOTTIP (regulated by PSIP1) recruiting the MLL/WDR5 complex to induce 







1.5.1  HOTTIP in cancer 
As their key regulatory roles have become more apparent in many cellular functions, 
lncRNAs have been implicated in the pathogenesis of many diseases including cancer 
(Giri and Beebe-Dimmer, 2016). As a result, lncRNAs such as HOTTIP have become 
attractive therapeutic targets. HOTTIP expression has been found to be up-regulated 
in many human cancers, including: colorectal (Misawa, K. I. Takayama and Inoue, 
2017), pancreatic (Bolha, Ravnik-Glavač and Glavač, 2017), hepatocellular carcinoma 
(HCC) (Misawa, K.-I. Takayama and Inoue, 2017), gastric, lung, prostate, 
osteocarcinoma (Misawa, K.-I. Takayama and Inoue, 2017), and breast (Metcalfe et 
al., 2017). HOTTIP has been described as having roles in metastasis, proliferation, 
migration and invasion, and the expression of this lncRNA  correlates with poor 
patient prognosis (Caffo et al., 1996). HOTTIP expression has also been associated 
with tumour cell chemoresistance (Teo, Rathkopf and Kantoff, 2019). Together, this 
indicates a need to understand the mechanisms of how HOTTIP contributes to 
cancer progression and how it promotes chemotherapy resistance. 
1.5.1.1 HOTTIP in colorectal cancer 
HOTTIP expression is upregulated in CRC, in both cell lines and patient CRC tissue 
samples (Grozescu and Popa, 2017). Previous studies have shown that 
downregulation of HOTTIP in CRC resulted in reduced proliferation and increased 
apoptosis as a result of p21-dependent cell cycle arrest (Metcalfe et al., 2017). Other 
studies have suggested that this also could be due to  HOTTIP interacting with 




has independently been implicated in CRC, through involvement in cellular stress 
response, and SGK1 inhibitors have shown to be promising CRC therapeutic targets 
(Pontes, Huben and Wolf, 1986). A role for HOTTIP in regulating CRC metastasis has 
also been suggested through downregulating the tumour suppressor Dickkopf-1 
(DKK1) (Teo, Rathkopf and Kantoff, 2019), a key gene involved in the Wnt/β-catenin 
signalling pathway (Tabaczar et al., 2010; Nader, El Amm and Aragon-Ching, 2018). 
HOTTIP has also suggested as a potential prognostic biomarker for CRC due its 
involvement in CRC progression and its ability to be detected in blood plasma 
(Nader, El Amm and Aragon-Ching, 2018). Despite being previously described as 
having chemoresistant properties in other cancers (Masoodi et al., 2017), it is yet to 
be determined if this is case for HOTTIP in CRC.  
1.5.1.2  HOTTIP in prostate cancer 
HOTTIP is upregulated in PCa (Nader, El Amm and Aragon-Ching, 2018), where it has 
been described as having roles in cell proliferation, migration and metastasis 
(Placzek et al., 2010). In some instances it has been shown that HOTTIP interacts 
with chromatin modifying complexes to upregulate the expression of nearby HOXA9 
(Lin et al., 2007) and HOXA13 (Evans, 2018). Both HOXA9 and HOXA13 have been 
implicated in prostate development (Brooke et al., 2015), and high expression of 
HOXA13 has been correlated with PCa tumour proliferation (Gamat and McNeel, 
2017). 
A role for HOTTIP in promoting epithelial-mesenchymal transition (EMT) in 




McNeel, 2017), which has a well-documented role in cancer EMT (Mercader et al., 
2001; Gamat and McNeel, 2017). Other studies have shown that HOTTIP depletion 
resulted in cell survival inhibition through reducing the expression of B-cell 
lymphoma 2 (BCL-2) and enhancing the expression of the apoptosis regulator Bcl-2 
associated X (BAX) (Brooke et al., 2015). HOTTIP knockdown has also been 
implicated in causing G0/G1 cell cycle arrest (Grozescu and Popa, 2017), which in 
one study was suggested to be a result of downregulation of the cell cycle regulator 
Cycle D1 (Litwin and Tan, 2017). A role of HOTTIP in contributing to chemoresistance 
in PCa through inhibition of the Wnt/β-catenin pathway has also been described 
(Romero-Otero et al., 2016). However, this has only been documented once 
suggesting that there is scope to explore this mechanism further. 
1.6  PSIP1 
PC4- and SF-interacting protein 1 (PSIP1), also known as lens epithelium-derived 
growth factor (LEDGF) is a chromatin-adapter protein (Altwaijry, Somani and Dufès, 
2018) that interacts with chromatin in order to regulate gene expression (Giri and 
Beebe-Dimmer, 2016). It has been described as an ‘epigenetic reader’ (Mohr et al., 
2019). In humans it is found on chromosome 9 (Mohr et al., 2019) and has two 
protein isoforms: p52 and p75 which interact with the transcription factor PC4, 
where they act as transcriptional coactivators (Cockle and Scott, 2018). 
The N-terminus of PSIP1 contains a PWWP domain which recognises 
methylation sites on histone tails (Cockle and Scott, 2018). The N-terminus also 




relatively charged regions (CR) (Baker et al., 2018). The C-terminus of PSIP1 contains 
an integrase binding domain (IBD) (Adam et al., 2012) (Figure 1.5). Integrase (IN) is 
the enzyme used by viruses such as HIV-1 to integrate host genomes (Tamura et al., 








Figure 1.5 Schematic of PSIP1/p52 and PSIP1/p75 isoforms. 
Schematic of the shorter PSIP1/p52 isoform that results from splice variation, and the longer PSIP1/p75 
isoform. Both isoforms share a PWWP domain and AT-hook like motif, however the PSIP1/p52 isoform 




It has been established in mouse models that Psip1 is involved in transcriptional 
regulation of Hox genes, in particular the Psip1/p75 isoform regulates Hoxa and 
Hoxd expression (Tamura et al., 2018). Psip1/p75 has roles in DNA repair through 
the homologous recombination (HR) pathways to promote the repair of DNA 
double-strand breaks (DSBs) (Alexander et al., 2010). On the other hand, the shorter 
Psip1/p52 isoform which occurs as a result of alternative splicing (Alexander et al., 
2010), acts as a transcriptional coactivator to regulate lncRNA Hottip expression 
through binding to the Mixed Lineage Leukaemia 1 (MLL1) complex (Zhou et al., 
2016). The shorter Psip1/p52 isoform is also involved in alternative splicing through 
interacting with splicing factors such as Serine and Arginine Rich Splicing Factor 1 
(Srsf1) (Zhou et al., 2016).  
1.6.1 The role of PSIP1 in HIV replication 
PSIP1 is associated with the human immunodeficiency virus (HIV-1) (Ignarski et al., 
2019). Replication is an essential process of lentiviruses such as HIV to enable 
integration of their genomes into host cell DNA (Engreitz, Ollikainen and Guttman, 
2016). The IBD of PSIP1 located on the C-terminus of the protein binds to HIV-1 
integrase (IN), promoting transcription and therefore replication of the HIV virus 
(Zhu et al., 2013). Therefore, the longer isoform PSIP1/p75 has been determined as 
contributing to HIV replication (Zhu et al., 2013) as the shorter isoform lacks the IBD 
binding domain. A class of HIV inhibitors termed LEDGINS were developed to block 





1.6.2 PSIP1 in cancer 
PSIP1 has been shown to reduce apoptosis when cells are exposed to stressful 
circumstances, e.g. in patients with inflammatory conditions such as dermatitis (Li et 
al., 2011). The same could be true in a cancer cell, where a reduction in cell death 
can drive progression of the disease through cell proliferation. The presence of PSIP1 
could promote cell survival in the event of further cell stress, such as from 
chemotherapy (Ignarski et al., 2019). In support of this, some studies have shown 
that PSIP1 has the ability to protect cancer cells from cytotoxicity introduced by 
chemotherapeutic drugs (Zhu et al., 2013). When PSIP1 is present, cancer cells 
appear to be protected against treatments that lead to lysosomal membrane 
permeabilisation and eventually cell death (Rinn et al., 2007). Therefore, there is a 
need to understand the molecular workings of this protein in cancer models to 
increase the rate of efficacy of cancer therapies. Singh et al. describes PSIP1 as 
having roles in regulating key genes associated with cell-cycle progression, cell 
migration and invasion (Zhu et al., 2013); all of which contribute to the development 
of cancer. Studies such as this has led to PSIP1 being termed an oncogenic protein. 
Through its ability to interact with chromatin (Zhu et al., 2013), PSIP1 has 
been shown to be important to the development of leukemia via the MLL complex 
(Zhu et al., 2013). MLL is a target of chromosomal rearrangements found in many 
forms of aggressive leukaemia (Khalil et al., 2009) that result after MLL forms a 
complex with MENIN, encoded by Multiple Endocrine Neoplasia I (MEN1), and 
PSIP1/p75 (Wang and Chang, 2011; Flynn and Chang, 2014; Quinn and Chang, 2016). 




(Rinn and Chang, 2012). Inhibition of MLL may lead to new treatment options for 
leukaemia, among other cancers (Wang and Chang, 2011), highlighting the 
importance of understanding the role of PSIP1 in disease progression further. 
1.6.2.1 PSIP1 in colorectal cancer 
As well as its involvement in leukaemia, PSIP1 has been documented in several other 
cancers including breast (Wang and Chang, 2011), ovarian (Hajjari and Salavaty, 
2015) and prostate (Dempsey and Cui, 2016). Overexpression of PSIP1 has been 
documented in CRC (Zhu et al., 2013), however, it is not understood how this 
overexpression is involved in CRC. As previously described, PSIP1/p52 is involved in 
regulating the expression of the lncRNA HOTTIP which has been shown to be 
upregulated in CRC (Dempsey and Cui, 2016). It would be interesting to examine 
whether PSIP1 is also found to be implicated in CRC.  
 
1.7 Aims of this study 
Early diagnosis is important in both CRC and PCa to provide a patient with more 
treatment options and a better prognosis. Therefore, more diagnostic tools that can 
identify early-stage cancer are crucial to improving survival rates. Further, the 
identification of novel targeted therapies will also improve the survival and quality 
of life of patients with these cancers. This study aims to investigate the role of the 
lncRNA HOTTIP (Chapter 3), its nearby HOXA13 gene (Chapter 4) and the regulatory 
transcriptional co-activator PSIP1 protein (Chapter 5) to: 




• Investigate the effect of depletion of HOXA13 in CRC and PCa. 
• Investigate the effect of depletion of PSIP1 in CRC. 
• Decipher the contribution of HOTTIP, HOXA13 and PSIP1 to 
chemoresistance in CRC and PCa. 
It is hypothesised that depletion of HOTTIP, HOXA13 and PSIP1 promote CRC and PCa 
progression and therapy resistance. Downregulation of these factors will therefore 







2 Materials and Methods 
 
2.1 Reagents, buffers and solutions 
2.1.1  Reagents and commercially available kits. 
The details of all reagents and commercially available kits used in this work are 
detailed below (Table 2.1), otherwise stated accordingly in the text. 
 
Table 2.1 List of reagents and commercially available kits used in this study. 
Reagent/Kit Supplier 
Acetate Thermo Fisher 
Acetic Acid Thermo Fisher 
Agarose Thermo Fisher 
Ampicillin Thermo Fisher 
ATP Solution  Thermo Fisher 
Benzonase EMD Millipore 
Blasticidin S Thermo Fisher 
Bovine Serum Albumin Sigma Aldrich 
ClarityTM Western ECL Substrate Bio-Rad 
Crystal Violet Sigma Aldrich 
DCTM protein assay  Bio-Rad 
Dimethyl sulfoxide Sigma Aldrich 
DMEM SLS 
Dimethyl sulfoxide (DMSO) SIGMA 
Docetaxel Sigma Aldrich 
DreamTaq green DNA Polymerase Thermo Fisher 




Ethylenediaminetetraacetic acid (EDTA) Sigma Aldrich 
Ethanol Thermo Fisher 
FastDigest BbsI Thermo Fisher 
Fetal Bovine Serum (FBS) Hyclone 
Fluorouracil (5-FU) Sigma Aldrich 
GeneJET Plasmid Midiprep Kit Thermo Fisher 
Igepal Thermo Fisher 
Kanamycin sulfate Thermo Fisher 
LB Agar Sigma Aldrich 
LB Broth, Miller (Granulated) Thermo Fisher 
Lipofectamine RNAiMAX Transfection Reagent Thermo Fisher 
Lipofectamine 3000 Thermo Fisher 
LunaScriptTM RT SuperMix Kit NEB 
Methanol Thermo Fisher 
Monarch® Plasmid Miniprep Kit NEB 
OptiMEM Gibco 
Oxaliplatin Sigma Aldrich 
PageRuler Plus Prestained Protein Ladder Thermo Fisher 
Penicillin/Streptomycin Gibco 
Phenymethylsulponyl fluoride (PMSF) Sigma Aldrich 
Phosphate buffered saline (PBS) MELFORD 
Polybrene Sigma Aldrich 
Proteinase K Bioline 
Protein inhibitor cocktail  MELFORD 
Propidium iodide Sigma Aldrich 
Puromycin Thermo Fisher 




PVDF Western Blotting Membrane Roche 
RPMI Gibco 
RNase A Thermo Fisher 
RNeasy Mini Kit Qiagen 
SDS Gel Preparation Kit Sigma Aldrich 
SensiFASTTM SYBR No-ROX  Bioline 
Sodium chloride Sigma Aldrich 
Sodium citrate Thermo Fisher 
Sodium deoxycholate Thermo Fisher 
Sodium dodecyl sulfate (SDS) Thermo Fisher 
Superscript II Reverse Transcriptase Thermo Fisher Scientific 
SYBR® Green Master mix Bio-rad 
SYBRTM Safe Thermo Fisher 
10X Tango Buffer Thermo Fisher 
Tetramethylethylenediamine (TEMED) Sigma Aldrich 
Tris Thermo Fisher 
Triton x100 Thermo Fisher 
TRIzol Reagent Thermo Fisher 
Trypsin EDTA Gibco 
Tween 20 Thermo Fisher 
T4 Ligation Buffer 10X NEB 
T4 Polynuleotide Kinase NEB 
T7 DNA Ligase NEB 
QuantiNova Reverse Transcription Kit Qiagen 
1kb DNA Ladder NEB 










2.1.2 Buffers and Solutions  
The details of all buffers and solutions used in this study are provided in the 
following table (Table 2.2). 
Table 2.2 List of Buffers and Solutions used in this study 
Name Description 
3 % BSA Blocking buffer 
3 g BSA 
TBS/T to 100 mL 
Lysis buffer (DNA) 
10 nM Tris-HCl,  pH 7.5 
10 mM EDTA 
10 mM NaCl 
0.5 % SDS 
1 mg/mL proteinase K 
Up to 100 mL ddH20 
Lysis buffer (protein) 
1 mM Tris-HCl 
1 mM EDTA 
1 % Triton X-100 
0.1 % Sodium deoxycholate 
0.1 % SDS 
140 nM NaCl 
Protease inhibitor 
Nicoletti buffer 
0.1 g sodium citrate 
5 mg propidum idodide 
1 mL Triton x100 




4 % PFA 
4 g Parformaldehyde 
dH20 to 100 mL 
Luria Broth (LB)  
20 g LB (Miller, granulated, Thermo Fisher) dissolved in 1 
L of ddH2O. Supplemented if required using antibiotics. 
LB Agar plates 
8.75 g of LB Agar (Sigma-Aldrich) dissolved in 250 mL 
ddH2O, supplemented if required with antibiotics. 
Melted prior to use and poured to make agar plates 
whilst still molten. 
1 x TAE buffer 
40 mM Tris 
20 mM Acetate 
1 mM EDTA 
TBS/T 
6.05 g Tris 
8.76 g NaCl 
0.05 % Tween 20 
dH20 to 1 L 
Transfer buffer (WB) 
22.52 g Glycine 
4.88 g Tris 
400 mL Methanol 
Up to 2 L ddH20 
Propidium iodide staining solution 
1 mL PBS 
20 µl RNAse A (10 mg/mL) 
10 µL propidium iodide (1 mg/mL) 
Wash buffer (WB) 
15.76 g Tris HCl 
87.66 g NaCl 
5 mL Tween-20 







Details of the antibodies used in this study are outlined in Table 2.3. 
Table 2.3 List of antibodies used in this study 
Antibody Supplier Lot no Dilution 
2 Goat anti-rabbit IgG – HRP  Santa Cruz SC-2030 1: 10 000 
PCNA (FL-261/PC10) Santa Cruz SC-7907 1: 10 000 
PSIP1/p75 antibody  Bethyl Laboratories Inc A300-848A 1:5000 
 
 
2.1.4 RT qPCR primers. 
All primers (Table 2.4) were obtained from Sigma-Aldrich, UK. Primers were used at 
a working concentration of 1 µM per reaction. 
Table 2.4 List of RT qPCR primers used in this study 
Primer Sequence (5’ -3’) 
GAPDH F ACCCAGAAGACTGTGGATGG 
R TTCTAGACGGCAGGTCAGGT 
HOTTIP F + INT R F ATGGGTGTTTCTTGGAGCCT  
 
R GTGGACAGGGAAGGGATAGG  
HOTTIP F + R F ATGGGTGTTTCTTGGAGCCT  
R AGGGGAGAAGTTGTGCTGAA  
 
HOTTIP FULL F CCTAAAGCCACGCTTCTTTG 
R TGCAGGCTGGAGATCCTACT 
HOTTIP INT F + R F GGTTCACCCAGGAGTAAGCT 
R AGGGGAGAAGTTGTGCTGAA  





HOXA9 F AAAAGCGGTGCCCCTATACA 
R CGGTCCCTGGTGAGGTACAT 
HOXA11 F CGGCAGCAGAGGAGAAAGA 
R CGGATCTGGTACTTGGTATAGGG 
HOXA13 F GGATATCAGCCACGACGAAT 
R ATTATCTGGGCAAAGCAACG 
L19 F GCAGCCGGCGCAAA 
R GCGGAAGGGTACAGCCAAT  
PSIP/P52 F CATGTTGGCCTTTCAGCATA 
R TCATTTTGGGCTCAAAGCAT 




2.1.5 RNA sequences 
Guide RNA sequences (Table 2.5) and siRNA sequences (Table 2.6) used in this study 
are detailed below. 
Table 2.5 CRISPR gRNA sequences used in this study 
CRISPR gRNA Sequence (5’ -3’) 
HOTTIP CRISPR KO 3P* CACCgcgcaactccatcgaagccga 
 
5P CACCgttaggacacactaaggactg  
PSIP CRISPR KO CACCgctactccaaaagctgccaga 
 






Table 2.6 siRNA sequences. 
siRNA target Sequence (5’ -3’) 
HOXA13 KD 1 GGG AAU ACG CCA CGA AUA A UU 
HOXA13 KD 2 CAG GAG GGU UAA AGA GAA A UU 
HOTTIP KD 1 GCA CUG AAU UGA UGG CUU A UU 
HOTTIP KD 2* CGG CAG GAG CCC AAG GAA A UU 
PSIP1 KD 1 GCA AUG AGG AUG UGA CUA A UU 
PSIP1 KD 2 GAC UAA AGC AGU UGA CAU A UU 
NTC 1 UAA UGU AUU GGA ACG CAU A 
NTC 2 AGG UAG UGU AAU CGC CUU G 
 
* Some blast sequence overlap with HOXA13 
 
2.1.6 Software 
The computer software used in this study is outlined in Table 2.7. 
Table 2.7 Computer Software. 
Computer software Version 
Acurri C6  V3.0 
GraphPad Prism V6 
Image J Fiji 1.52 
MobaXterm V 12.4 
Microsoft Excel Microsoft Office 2016 
NIS-Elements V 4.11.0 
R studio V 3.3.6 





2.1.7 Plasmid vectors 
The details of all plasmid vectors used in this study is outlined in Table 2.8. 
Table 2.8 Plasmid vectors used in this study. 
Plasmid Source 
pSpCas9(BB)-2A-Puro (PX459) Addgene #62988 (Feng Zhang lab) 
PSIP KO P.Madapura/F.McKenna (PX459 backbone) 
HOTTIP KO 3p F.McKenna (PX459 backbone) 




2.2.1 Cell Culture. 
2.2.1.1  Safety and Sterility 
All tissue culture experiments were carried out aseptically in a Class 2 cabinet. All 
laboratory consumables were cleaned with 4 % Virkon disinfectant to destroy 
potential contaminants prior to use. 
2.2.1.2 Cell lines 






Table 2.9 Cell lines used in these studies and corresponding growth media. 
Cell Line Description Media and additional 
supplements 
DU145 Epithelial prostate cancer cell line 
derived from a metastatic site in the 
brain. 
RPMI + 10 % FBS + 5 % P/S 
HCT116  Epithelial colorectal cancer cell line. DMEM + 10 % FBS + 5 % P/S 
HCT116 HOTTIP 
KO 
Epithelial colorectal cancer cell line 
where the lncRNA HOTTIP has been 
deleted via CRISPR-Cas9. 
DMEM + 10 % FBS + 5 % P/S 
HCT116 HOTTIP 
WT 
Epithelial colorectal cancer cell line. 
Control cell line that was subjected to 
transfection reagents but no gene 
editing. 
DMEM + 10 % FBS + 5 % P/S 
HCT116 PSIP1 KO Epithelial colorectal cancer cell line 
where the PSIP1 protein has been 
deleted via CRISPR-Cas9. 
DMEM + 10 % FBS + 5 % P/S 
HCT116 PSIP1 WT Epithelial colorectal cancer cell line. 
Control cell line that was subjected to 
transfection reagents but no gene 
editing. 
DMEM + 10 % FBS + 5 % P/S 
RKO1 Epithelial colorectal cancer cell line. DMEM + 10 % FBS + 5 % P/S 
 
2.2.1.3  Cell culture 
Initially, all cell lines were seeded in pre-warmed growth media (37 ᵒC) in a T25 cell 
culture flask. Cells were passaged for two weeks prior to initiation of experiments. 
Upon reaching confluency, growth media was removed from cells using an aspirator 




added to the cells and the flask was placed in an incubator at 37 ᵒC for 5 min or until 
cells detached from the surface of the flask. After cells had detached from the flask, 
trypsin was neutralised with 2 mL growth media and the cell suspension was 
transferred to a 15 mL falcon. The cell suspension was spun down at 1400 rpm for 5 
min. Meanwhile a T25 tissue culture flask containing 5 mL of pre-warmed 37 ᵒC 
relevant growth media was prepared aseptically. The supernatant was discarded, 
and the cell pellet was re-suspended in 1 mL of the appropriate growth media. Cells 
were then counted and seeded according to the volumes required for each 
experiment. 
2.2.1.4 Cryopreservation of cells 
Cells were detached using Trypsin and pelleted (1400 rpm for 5 min). The 
supernatant was removed, and the pellet was re-suspended in 1 mL of growth 
media. 1 mL of freezing media (400 µL growth media + 400 µL FBS + 200 µL dimethyl 
sulfoxide (DMSO) was added to the cell suspension and the cell suspensions were 
added into cryovials for freezing. Cryovials were placed in polystyrene biofreezing 
boxes to assist with slowing down the freezing process and were kept overnight at -
80 ᵒC before long-term storage in liquid nitrogen at -196 ᵒC. 
2.2.1.5  Thawing and re-culturing of cells 
A cryovial of cells was safely removed from a liquid nitrogen freezer, using the 
appropriate safety precautions. After the vial was removed, it was immediately 
placed inside a water bath heated to 37 ᵒC for 5 min until the cells had thawed. 




media was prepared aseptically. Once the vial of cells had thawed it was spun down 
at 1400 rpm for 5 min. The supernatant was removed and pelleted cells were re-
suspended in 1 mL of the appropriate growth media. The whole re-suspension was 
added to the T25 tissue culture flask and once cells had settled, the flask was 
checked under a microscope to assess the condition of the cells and to confirm the 
absence of microbial contamination.  
2.2.2  Using Clustered regularly interspaced short palindromic repeats (CRSIPR) Cas9 
to create knock out stable cell lines 
2.2.2.1  Guide RNA design 
Guide RNAs (gRNAs) were designed using the UCSC genome browser 
(https://genome.ucsc.edu/) and the Zhang lab (MIT) online CRISPR design tool 
(http://crispr.mit.edu/). 20 bp gRNAs were designed in the region of interest.  
2.2.2.2  Cloning of gRNAs into vectors 
gRNA oligos were phosphorylated and annealed at 37 ᵒC for 30 min, 95 ᵒC for 5 min 
and ramped down to 25 ᵒC in the following reaction (Table 2.10). 
Table 2.10 Phosphorylation/annealing reaction. 
Phosphorylation/annealing reaction 
100 µM oligo1 
100 µM oligo 2 
1 µl 10X T4 Ligation Buffer 
6.5 µl dH20 





The annealed oligo was diluted 1:500 with dH20 and the following digestion-ligation 
reaction was set up (Table 2.11). 
Table 2.11 Digestion-ligation reaction. 
Digestion-ligation reaction 
100 ng backbone vector  
2 µl diluted phosphorylated and annealed duplex from previous step 
2 µl 10X Tango buffer 
1 µl 1M DTT 
1 µl 10mM ATP 
1 µl 10U/µL FastDigest BbsI 
0.5 µl T7 ligase 
dH20 up to 20 µl 
 
The ligation reaction was incubated in a thermocycler under the following conditions 
(Table 2.12). 
Table 2.12 Ligation reaction temperature conditions. 
 
Once ligated, the vectors were transformed into competent cells. 
2.2.2.3 Transformation of vectors 
After gRNAs had been successfully cloned into vectors, they were transformed into 
Escherichia coli (E. coli) competent cells (DH5α or XL1-Blue strain). Competent cells 
Ligation reaction 
37 ᵒC 5 min  
Repeat for 6 cycles 23 ᵒC 5 min 




were thawed on ice for 30 min before use. 50 ng of plasmid DNA was incubated with 
50 µl of competent cells on ice for a further 30 min. Cells were heat-shocked at 42 ⁰C 
for 45 secs and then placed on ice for a further 2 min. 500 µl of pre-warmed LB 
broth was added to the cells and the sample was incubated whilst shaking at 37 ⁰C 
for 60 min. Agar plates had been previously prepared with the appropriate antibiotic 
for selection added. 100 µl of sample was spread aseptically onto the agar plate 
using a sterile spreader. Plates were incubated overnight at 37 ⁰C and the next day 
bacterial colonies were picked for plasmid isolation. 
2.2.3 Isolation of plasmids 
Plasmids were isolated from bacterial cultures using the Monarch® Plasmid 
Miniprep Kit (NEB) or the GeneJET Plasmid Midiprep Kit (Thermo Fisher) depending 
on the desired end concentration required. The concentration and purity of each 
plasmid was quantified using a nanodrop before continuation. 
2.2.3.1 Transfection 
Cells were grown to ~80 % confluency and seeded into 6-well plates with 800 000 
cells per well. 2 µg of gRNA plasmid was transfected into cells using the 
Lipofectamine® 3000 (Thermo Fisher) reagents following the manufacturer’s 
protocol. A separate control well was also set up that included all transfection 
reagents except the gRNA plasmid (mock transfection control). 2 mL of growth 
media containing 2.5 µg/µl puromycin was added to each well of cells 24 h and 48 h 




transfected cells were seeded into 10 cm dishes by counting with a haemocytometer 
and cultured until colonies formed. 
2.2.3.2 Colony picking 
Cells were cultured for 8-10 days or until clear colonies of cells had formed. A 96-
well plate was prepared with 35 µl room temperature trypsin per well, using a 
multichannel pipette. The plate was kept on ice throughout the duration of colony 
picking. Media was removed from the 10 cm dish of colonies using an aspirator, and 
then washed once with pre-warmed PBS. The bottom of the plate was covered with 
~7 ml PBS. Using a microscope, colonies were picked from the plate using a P20 set 
to 4 µl using filter tips. The tip was used to scrape around the colony to ensure it is 
fully detached from the plate; then the detached colony was collected in the tip. 
Each colony was transferred into 35 µl of trypsin and pipetted up and down to break 
up the colony. After picking a sufficient number of colonies the 96-well plate was 
placed in a 37 ᵒC incubator for 10 min to allow the trypsin to break up the colony 
into single cells. 200 µl of appropriate growth media was added to each trypsinised 
colony and pipetted up and down to break up the colony further using a 
multichannel pipette. The cells were then cultured in the 96-well plate refreshing 





2.2.4 Validation of positive clones 
2.2.4.1  Genomic DNA extraction 
Upon confluency of cells, media was removed and wells were washed 2x with 100 µl 
of PBS. The edges of the plates were sealed with parafilm and frozen at -80 ᵒC 
overnight to help with cellular lysis. The next day plates were left to thaw on the 
bench for 5 min. 50 µl of DNA lysis buffer was added to each well using a 
multichannel pipette. The edges of the plate were then sealed with parafilm and it 
was placed in a humidified chamber and incubated overnight at 55 ᵒC. Plates were 
removed from the incubator and spun down at 1000 rpm for 5 min. 150 µl of 5 M 
NaCl was added to 10 mL of cold ethanol (EtOH) and 100 µl of this solution was 
added to each well. The plate was tapped gently to mix and left at room 
temperature for 30 min. The plate was spun at 1500 rpm for 5 min and the 
NaCl/EtOH solution was removed by inverting the plate allowing the solution to 
drain. The plate was then blotted gently on paper towels to remove any excess 
ethanol. The wells were then washed 3x with 150 µl of freshly prepared 70 % EtOH, 
blotting the plate gently on paper towels in between each wash. The plate was air 
dried at RT for ~30 min and the remaining DNA was resuspended in 50 µl dH20. 
2.2.4.2  Validation of HOTTIP KO clones via PCR 
Positive clones with a deletion of HOTTIP were identified via PCR. The following PCR 





Table 2.13 PCR reaction reagents. 
Reagent Quantity 
Primers (4µM) 2 µl 
DNA (50 ng) 2 µl 
DreamTaq 3x master mix 5 µl 
dH20 1 µl 
Total Volume 10 µl 
 
The reaction was incubated in a thermal cycler under the following conditions (Table 
2.14). 
Table 2.14 Thermal cycler conditions for DreamTaq PCR. 
Number of cycles Step duration Temperature (ᵒC) 
1 3 min 95 
35 20 sec 95 
30 sec 58 
30 sec 72 
1 5 min 72 
Hold 4 
 
The resulting mixture was separated on a 1.5 % agarose gel at 80 V for 40 min. The 
gel was imaged on a BioRad EZ Gel Doc system. 
2.2.4.3 Validation of PSIP KO clones via Western blotting 
2.2.4.3.1.1 Protein extraction 
The following steps were carried out on ice and all buffers were pre-chilled to 4 ᵒC. 
Clones were grown until confluency was achieved in 6-well plates. Media was 




to each well and the plate was incubated on ice for 30 min with occasional mixing. 
Samples were transferred to 1.5 mL tubes and placed in -20 ᵒC for storage. Prior to 
western blotting, samples were thawed on ice then spun at 13000 rpm for 10 min at 
4 ᵒC.  
2.2.4.4 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
2.2.4.4.1.1 Gel preparation 
Gels consisted of two layers; the resolving gel and the stacking gel and both were 
prepared using the SDS Gel Preparation Kit (Sigma Aldrich, 08091). 1.5 mm glass 
plates were assembled in a casting stand. The resolving gel was added via pipetting, 
leaving a 2 cm space at the top of the plate, and left to polymerize for 20 min. 1 mL 
of dH20 was pipetted onto the top of the gel surface to ensure the gel was level and 
to remove any bubbles. Following polymerization, the dH20 was removed and the 
stacking gel and 1.5 mm comb were applied to the cast. The gel was left for a further 
30 min to ensure full polymerization of the stacking gel. The fully polymerized gel 
was then covered with a damp paper towel and stored at 4 ᵒC for at least 2 h before 
use. The gels were stored at 4 ᵒC for no longer than two weeks. 
2.2.4.4.1.2  Preparation of protein samples and gel electrophoresis 
Protein samples were transferred from storage (-20 ᵒC) and defrosted on ice. Once 
thawed, the protein samples were spun briefly and mixed in a 1:1 ratio with sample 
incubation buffer (SDS gel preparation kit, Sigma Aldrich) making 20 µl total volume. 
Samples were incubated for 5 min at 95 ᵒC allowing them to denature, prior to being 
loaded into the wells of the gel. 2 µl of the PageRulerTM protein ladder (Thermo 




band. The protein samples were then separated on the gel at 200 V until the dye 
front reached the base of the resolving gel (approximately 120 min). 
2.2.4.4.1.3  Membrane transfer 
Prior to the start of transfer, the membrane was soaked in methanol for 5 min. The 
PVDF membrane (Roche), blotting paper and the SDS gel were soaked in transfer 
buffer for a further 5 min to equilibrate. The transfer was carried out using the Bio-
Rad Trans-Blot machine at 0.7 A, 25 V for 30 min. After the transfer had taken place, 
the gel was discarded, and the membrane was collected. 
2.2.4.4.1.4 Membrane blocking and antibody incubations 
Following transfer, the membranes were carefully removed from the transfer 
cassette and incubated in blocking buffer (3 % BSA/TBST) overnight at 4 ⁰C with 
gentle agitation to reduce non-specific binding. The next day, blocking buffer was 
removed and membranes were incubated with primary antibody (PSIP1/p75 
antibody (A300-848A) and PCNA (FL-261/PC10)), diluted in 1:5000 in 1 % BSA/TBST 
for 2 h at RT with gentle agitation. Membranes were then washed with TBST for 3x5 
min at RT with agitation and incubated for 1 h with Goat anti-rabbit IgG – HRP (Santa 
Cruz, lot no. A0615, SC-2030) secondary antibody with gentle agitation at room 
temperature. Before protein detection, the membranes were once again washed 
3x5 min with TBST with strong agitation at room temperature.  
2.2.4.4.1.5 Protein detection 
In order to detect protein presence, the ClarityTM Western ECL Blotting buffers (Bio-




Membranes were imaged using the FUSION -FX7 (VILBER LOURMAT) advanced 
analysis camera system.  
2.2.5 RNA expression analysis 
2.2.5.1 RNA extraction 
Total RNA was extracted from each cell line using the Qiagen RNeasy mini kit 
(Qiagen, UK). 
2.2.5.2  Reverse transcription 
In order to reverse transcribe RNA to cDNA, the SuperScript II Reverse Transcriptase 
(Invitrogen), QuantiNova Reverse Transcription Kit (Qiagen, UK), or LunaScript® RT 
SuperMix kit (NEB) was used as per the manufacturers protocol. Resulting cDNA was 
diluted 1:10 in dH20 before proceeding with qPCR. 
2.2.5.3  Quantitative Real-Time PCR (qPCR) 
Mastermixes containing SYBR green, primer concentration and dH20 were prepared 
for all reactions to ensure equal distribution of components between wells. After 
mastermixes were prepared, they were gently mixed and spun. 2 µl of cDNA was 
added to each well in a 96-well plate that was placed in a cool block. 8 µl of 
mastermix was then added to the well. All reactions were performed in triplicate. 
After the plate was loaded, it was sealed with adhesive film and centrifuged at 1000 
rpm for 1 min. The CFX connectTM Real-Time PCR Detection System (Bio-Rad) was 




Table 2.15 qPCR reaction conditions. 
Number of cycles Step duration Temperature (ᵒC) 
1 5 min 95 
39 10 sec 95 
30 sec 60 
1 1 min 95 
- 1 min 55 
10 sec at each 0.5 ˚C increment between 
55 ˚C and 95 ˚C 
 
2.2.5.4  Data analysis 
Samples were loaded in triplicate for each gene to be analysed by qPCR. Any 
anomalies (replicate wells that did not fall into 1 cycle of other replicates) were 
excluded from future analysis. The delta-delta Ct (2-ΔΔCt) of each sample was 
calculated and samples were plotted on a graph based on fold change. Samples were 
normalised to a housekeeping gene (GAPDH, L19). 
2.2.6 siRNA knockdown 
2.2.6.1  siRNA design 
siRNA duplexes were designed using the Dharmacon siDESIGN Center 
(https://dharmacon.horizondiscovery.com/design-center/) against each target gene, 




2.2.6.2  siRNA transfection 
Cells were transfected 24 h after seeding with 10 nM of siRNA diluted in Opti-MEM 
medium and mixed with Lipofectamine RNAiMAX transfection reagent. The siRNA-
lipid complex solutions were incubated for 5min prior to adding to cells and the 
cultures were incubated for 48-72 h.  
2.2.6.3  siRNA knockdown validation 
2.2.6.3.1.1  RNA expression analysis 
To ensure successful knockdown of each target gene, cells transfected with siRNAs 
were validated by extracting RNA from samples. Media was removed from cells and 
500 µL TRIzol reagent was added to each well (12-well plate) and the subsequent 
solution was transferred to a 1.5 mL microcentrifuge tube. 100 µL of chloroform was 
added and each sample was gently shaken and then incubated at room temperature 
for 3 min. Samples were centrifuged at 12,000 x g for 15 min at 4 ⁰C. After spinning, 
200 µL of the clear top phase was transferred to a fresh microcentrifuge tube. 250 
µL of cold isopropanol was added to each tube, mixed, and samples were incubated 
for 10 min at room temperature. Samples were centrifuged at 12,000 x g for 10 min 
at 4 ⁰C. The supernatant was removed and pellets were washed twice with 75 % 
EtOH. After removing excess EtOH with a pipette tip, samples were left to air dry for 
10 min at room temperature before being resuspended in 20 µL dH20. Samples were 




2.2.6.3.1.2 Validation of protein knockdown via siRNA 
To validate PSIP1 knockdown, protein lysate was extracted and samples were 
checked for sufficient knockdown via Western blotting as per section 2.2.4.3 
2.2.7  Cell assays 
2.2.7.1 Cell proliferation growth assay 
4000 cells were seeded in triplicate in a 96-well plate with 100 µl of growth media 
and incubated for the desired timepoints. Cells were fixed with 100 µl 4 % 
Paraformaldehyde (PFA) for 1 h at each time point. The fixative was removed, cells 
were washed twice with PBS and plates were left to dry at RT. Cells were stained 
with 50 µl 0.04 % crystal violet per well. After a 1 h incubation at RT, the stain was 
removed, and cells were washed 3x with dH20. Plates were left to dry and then 10 % 
acetic acid was added to each well and plates were placed on a rocker for 1 h at RT. 
Absorbance levels were then measured at OD490 with a CalrioStar multiwall plate 
reader (BMG Labtech). 
2.2.7.2 Scratch/wound healing assay 
Cells were seeded into 96-well plates so that they reached 100 % confluency after 24 
h. At this point, scratches were made in each well with a 20 µl sterile tip. Media and 
any detached cells were then removed with an aspirator and 100 µL fresh media was 
slowly added to each well. Images of the scratched wells were obtained at intervals 
between 0 and 24 h. The subsequent migration of cells into the ‘scratched’ areas 





2.2.7.3 Colony formation assay 
1000 cells were seeded into a 6-well plate. Cells were cultured for ~2 weeks with 
regular media changes until colonies formed. Cells were fixed with 4 % PFA and 
stained with 0.04 % crystal violet. Colony numbers were analysed using ImageJ 
software (https://imagej.nih.gov/ij/). 
2.2.7.4 Cell tracking assay 
1000 cells per well were seeded in a 96-well plate 24 h prior to transfection or 
treatment. 100 µl of PBS was added to the outer wells of the plate to prevent 
evaporation. A Wide-Field microscope (Eclipse Ti, Nikon) with a motorized stage and 
humidified chamber (Model:H301, OkoLab, Italy) set at 37 ᵒC with 5 % CO2 was used 
to acquire images 24 h after treatment/seeding. A 10X 0.3 N.A objective lens was 
used. Two-dimensional (2D) time series frames were captured with an Andor 
camera (Model: Luca-R-DL-626, Andor Techology, UK) using NIS-Elements software 
every 20 min for 24 h. 
2.2.7.5 Flow cytometric analysis of apoptotic cells (DNA hypodiploidy staining). 
Cells were seeded in a 6-well plate and subsequently treated and cultured for 3 
days. Culture media was removed and transferred to 1.5 mL tubes. Samples were 
washed with PBS and this was also transferred to the same tube. 500 µl of trypsin 
was added to cells and incubated for a few min to allow cell dissociation. 500 µl of 
the collected media and PBS mixture was added to cells and pipetted gently up and 




for 3 min at 5000 rpm and the supernatant was removed. Pellets were suspended in 
100 µl of Nicoletti buffer and tubes were immediately vortexed to avoid cell 
clumping. The percentage of apoptotic cells was quantified using an Accuri C6 flow 
cytometer. 1000 cells in total were measured per sample. 
2.2.7.6  Cell cycle analysis 
Cells were seeded in 6-well plates and grown until 80 % confluent. Cells were 
harvested, washed twice with PBS and fixed by dropwise addition of 500 µl 70 % 
ethanol with a gentle vortexing for 30 min. After fixation, cells were washed twice 
with PBS and pelleted (3000 rpm, 5 min) each time to remove excess ethanol. Cells 
were resuspended in 500 µl PI staining solution which includes a ribonuclease 
element (RNAse A) to ensure only DNA was stained. The number of cells in each 
stage of the cell cycle were quantified using an Acurri C6 flow cytometer. 10 000 
cells in total were measured per sample. 
2.2.7.7  Cell treatment with chemotherapeutic drugs 
The chemotherapeutic drugs fluorouracil, oxaliplatin, and docetaxel were used to 
test the sensitivity of colorectal and prostate cancer cells to chemotherapeutic drugs 
when HOTTIP, HOXA13, and PSIP1 expression is reduced. A dose response curve was 
carried out to determine the optimal concentration of drug to use for each cell line. 
Drugs were added to cells in 96-well plates and cells were allowed to grow for three 




2.2.8  RNA preparation for sequencing analysis 
2.2.8.1 RNA preparation 
Total RNA was extracted from knock out and control cell lines using the Qiagen 
RNeasy Mini Kit (74104). cDNA was synthesised and qPCR carried out as described in 
2.2.5.2 and 2.2.5.3 to validate the gene expression levels of knock out cell lines. 
2.2.8.2  RNA quality check 
The quality of RNA was checked by running samples on a 1.2 % agarose/TBE RNA gel. 
RNA samples were diluted 1:1 with loading dye and denatured by boiling for 10 min 
at 70 ᵒC before immediately being placed on ice for a further 2 min. Samples were ran 
on an agarose gel by electrophoresis at 80 V for 60 min. The RNA integrity number 
(RIN) of each sample was quantified by Qubit RNA IQ assay (Thermo Scientific) prior 
to diluting samples to the sequencing company’s (Novagene, Cambridge, UK) 
requirements.  
2.2.9 Bioinformatics 
RNA-Seq data analysis was completed using the linux/bash shell platform, Python, R, 
SeqMonk (Babraham Institute), and Gorilla gene ontology database (Bolha, Ravnik-
Glavač and Glavač, 2017). The following packages were used: ‘‘TopHat2’ to align 
RNA-Seq reads to the human genome (Yang et al., 2017), ‘HTSeq’ to count how 
many reads map to each gene (Hajjari and Salavaty, 2015) and ‘DESeq2’ to calculate 
the differential expression of RNA-Seq data (Hajjari and Salavaty, 2015). The data 




2.2.10  Statistical analysis 
All statistical analysis was carried out using Graphpad prism 8, Rstudio or SeqMonk. 
A summary table of the statistical test used for each experiment is included below 
(Table 2.16). All experiments were the standard error of the mean (S.E.M) or 
standard deviation (S.D) of 3 biological repeats. 
Table 2.16 Statistical analysis summary table 
Assay Statistical test Description 
Apoptosis assay Two way ANOVA - 
Cell cycle assay Two way ANOVA - 
Cell tracking assay Kruskal-Wallis siRNA vs NTC 
Cell tracking assay Mann-Whitney WT vs KO 
Colony formation assay Unpaired t test  WT vs KD/KO 
Colony formation assay Two way ANOVA Treatment vs no treatment 
Dose response  Two way ANOVA - 
Growth assay Two way ANOVA - 
qPCR Unpaired t-test WT vs KD/KO 
qPCR Two way ANOVA Multiple gene comparison 






3 Investigating the role of HOTTIP in the progression of cancer. 
 
3.1 Introduction 
HOXA transcript at the distal tip (HOTTIP) is a long non-coding RNA (lncRNA) located 
at the 5’ end of the HOXA cluster and is involved in the regulation of nearby HOXA 
genes, in particular HOXA13, which is located in the closest proximity to HOTTIP (Qi, 
Zhou and Du, 2016). HOTTIP interacts with DNA through chromosomal looping, 
which results in these nearby HOXA genes being regulated in a cis fashion (Qi, Zhou 
and Du, 2016). HOTTIP binds to the WDR5 adapter protein enabling it to target 
WDR5/MLL complexes across the 5’ end of the HOXA cluster, resulting in increased 
H3K4me3 levels which in turn maintains active expression of 5’ HOXA genes (Bridges 
and Morgan, 1923). 
HOTTIP expression is up-regulated in many cancers, including colorectal 
(Lappin et al., 2006), pancreatic (Holland, 2013), hepatocellular carcinoma (HCC) 
(Quagliata et al., 2015), breast (Yang et al., 2017), gastric, lung, osteosarcoma and 
prostate cancer (Joo, Park and Chun, 2016). HOTTIP has been implicated in the 
development of some of these cancers alongside the nearby HOXA13 gene (e.g. 
HCC, prostate, gastric), and together they have been associated with metastasis, 
increased cell proliferation and poor prognosis (Quagliata et al., 2015; Chang et al., 
2016; Zhang et al., 2016). A role for HOTTIP in promoting chemoresistance in cancer 
has also started to emerge (Joo, Park and Chun, 2016). However, this has only been 
documented once in prostate cancer (PCa) (De Kumar and Krumlauf, 2016) and no 
studies investigating the role of HOTTIP in colorectal cancer (CRC) chemosensitivity 




This chapter will outline the role of HOTTIP in the progression of CRC and PCa 
cancer and investigate whether HOTTIP has a role in chemosensitivity. Global gene 
expression will also be explored following HOTTIP knock-out in HCT116 cells to 
determine the role of this lncRNA in the CRC transcriptome.  
3.2 Validating siRNA mediated HOTTIP depletion and stable CRISPR-Cas9 
HOTTIP knock out in cancer cell lines. 
3.2.1 siRNA mediated depletion of HOTTIP   
In order to determine the role of HOTTIP in CRC and PCa, siRNAs were employed to 
knockdown (KD) HOTTIP levels in three cell lines: HCT116 (Wang et al., 2011), RKO1 
(Wang et al., 2011) (CRC) and DU145 (Kingston and Tamkun, 2014) (PCa). Two 
siRNAs (termed HOTTIP KD 1 and HOTTIP KD 2) targeted to transiently knockdown 
the expression of HOTTIP have been used throughout this study. These siRNA were 
compared to a non-targeting (NTC) siRNA control to reduce false-positive results or 
any changes occurring due to off-target effects. 
Firstly, to confirm successful HOTTIP depletion in each cell line, cells were 
seeded in 6-well plates and transfected with either HOTTIP targeting or NTC siRNA. 
After 72 h, RNA was extracted and reverse transcribed to synthesise cDNA prior to 
qPCR analysis. Gene expression levels were quantified and data normalised to the 
ribosomal protein gene L19. The effect of siRNA mediated HOTTIP depletion upon 
nearby HOXA genes (HOXA13, HOXA11) was also quantified, due to the role of 




A reduction in HOTTIP expression was observed in HOTTIP depleted HCT116 
cells compared to NTC indicating successful HOTTIP KD (Figure 3.1A), as well as a 
reduction in HOXA13 and HOXA11 expression. A reduction in HOTTIP and HOXA13 
expression was also observed in HOTTIP depleted RKO1 cells, however this was not 
found to be significant (Figure 3.1B).  
In HOTTIP depleted DU145 cells, both HOTTIP and HOXA13 expression were 
reduced (Figure 3.1C), although this was not significant. siRNA mediated knockdown 
of HOTTIP in these cell lines followed the pattern stated in the literature where 
HOXA13 expression is also reduced upon HOTTIP is depletion (Smith, Zyoud and 
Allegrucci, 2019). Therefore, these data can confirm successful siRNA mediated 
depletion in these cell lines. Successful siRNA depletion was regularly confirmed 







Figure 3.1 siRNA mediated HOTTIP depletion gene expression 
(A) HCT116, (B) RKO1 and (C) DU145 cells were transfected with HOTTIP targeting or NTC siRNA for 
72 h. RNA was subsequently extracted and cDNA synthesised. Gene expression levels of target genes 
(HOTTIP, HOXA13, HOXA11) were quantified and compared to NTC via qPCR. Data are mean (± S.E.M) 
fold change of relative expression of 3 biological replicates (N=3), analysed by qPCR and normalized 





3.2.2  Creating stable HOTTIP knock out lines using CRISPR-Cas9. 
To validate the findings from the siRNA KD studies, stable CRISPR-Cas9 HOTTIP knock 
out (KO) and wild type (WT) control HCT116 cell lines were created (as per Chapter 2, 
section 2.2.2). Two guide RNAs (gRNAs) were designed to target each end of the 
HOTTIP transcript (5’ and 3’). This resulted in a deletion at each end (Figure 3.2A) and 
a truncated, non-functional version of the HOTTIP transcript. The 5’ gRNA was 
designed, slightly downstream of the transcription start site (TSS), to avoid removing 
any transcriptional machinery that could be acting on nearby genes.  
After CRISPR-Cas9 selection, DNA was extracted from cells and a PCR screen 
was performed to identify WT (empty plasmid backbone) and HOTTIP KO clones. 
Three primer sets were designed to screen for positive HOTTIP KO CRISPR clones 
(Figure 3.2A). A total of 48 possible clones were screened via PCR for the desired 
HOTTIP KO genotype. After successful PCR screening, positive clones (1 x WT and 3 X 
HOTTIP KO) were sent for Sanger sequencing analysis (Figure 3.2B). One WT and one 
HOTTIP KO clone (Figure 3.2C) were selected for further work.  
To confirm HOTTIP depletion at the RNA level, RNA was extracted from the 
WT and KO clones and reverse transcribed to synthesise cDNA. Gene expression 
levels were quantified via qPCR and data normalised to the ribosomal protein gene 
L19. A highly significant loss of HOTTIP (Figure 3.2D) was observed indicating loss of 
the HOTTIP transcript on the gene expression level. As well as loss of HOTTIP 
expression, the nearby HOXA13 gene was also significantly down regulated. HOXA1 
expression is unaffected when HOTTIP expression is KO, which may be explained by 




with previous studies confirming that HOTTIP only regulates expression of nearby 
HOX genes in cis (Kingston and Tamkun, 2014). Overall, these data confirm 
successful CRISPR-Cas9 mediated HOTTIP KO in HCT116 cells. These cell lines will be 
used in conjunction with siRNA mediated HOTTIP depletion to further understand 






Figure 3.2 CRISPR-Cas9 mediated HOTTIP KO validation 
(A) Schematic of 5’ and 3’ gRNA design targeted to delete HOTTIP DNA. Three primer pairs used to 
validate CRISPR KO clones were designed around the gRNA cut sites. Primer 1 (175 bp amplification) 
represents a KO clone, Primer 2 (346 bp amplification) represents a WT/HET clone. Primer 3 (283 bp 
amplification) represents a WT/HET clone. (B) Sequence data of a positive HOTTIP KO HCT116 clone that 
was analysed via Sanger sequencing. (C) DNA was extracted from WT and HOTTIP KO HCT116 clones and 
genotyped by PCR with three primer sets, primer 1 (175 bp = KO clone), primer 2 (346 bp = WT/HET 
clone), primer 3 (283 bp = WT/HET clone). (D) RNA was extracted from positive WT and HOTTIP KO 
HCT116 clones and cDNA subsequently synthesised. HOTTIP, HOXA13 and HOXA1 gene expression levels 
in both clones were analysed via qPCR. Data are mean (± S.E.M) expression of 3 biological replicates (N=3), 
analysed by qPCR and normalised to L19. Two-way ANOVA with Dunnett’s multiple comparison test was 





3.3 Investigating the role of HOTTIP deletion on the movement and migration 
of CRC and PCa cells. 
Previous studies have described HOTTIP having roles in cell proliferation, migration 
and invasion in cancer (Kingston and Tamkun, 2014). Through HOTTIP 
depletion/deletion studies, this work will investigate this further in CRC and PCa cell 
lines and attempt to add to the knowledge of HOTTIP’s potential role as promoting 
oncogenesis. 
 
3.3.1 Reduction of HOTTIP leads to a reduction in CRC and PCa single cell motility. 
Single cell tracking analysis was used to analyse average cell speeds in HOTTIP 
depleted CRC and PCa cells. Prior to seeding, CYTO-ID dye (Enzo life sciences) was 
used to label cells, allowing fluorescence detection. Dyed cells were seeded sparsely 
in 96-well plates to enable individual analysis of a single cell to be possible. A Nikon 
Widefield microscope was used to capture images of each well every 20 minutes 
over a 24 h period. Cells were placed in a humidified CO2 chamber to retain their 
optimum culturing conditions during this time. Average cell speeds were calculated 
using the Trackmate plugin on ImageJ Fiji (Milne et al., 2002; Smith, Zyoud and 
Allegrucci, 2019). 
 
Firstly, the average speed of siRNA mediated HOTTIP depleted CRC and PCa 
cells were tested. HCT116 cells transfected with HOTTIP KD 1 siRNA exhibited a 
slightly slower average cell speed and a smaller range of average speeds, although, 
these observations were not found to be significant (Figure 3.3A). An increase in 




well as a larger range of average speeds. However, this was also not found to be 
significant (Figure 3.3A). HOTTIP depleted RKO1 cells exhibited a reduction in the 
range of average cell speeds, however, the mean average cell speed was similar to 
that of NTC and was non-significant (Figure 3.3B). HOTTIP depleted DU145 cells 
exhibited a slightly higher average cell speed than control; again, this was also not 
significant (Figure 3.3C). A reduction in average cell speed was observed in CRISPR-
Cas9 mediated HOTTIP KO cells compared to WT (Figure 3.4); this was also not found 
to be statistically significant. Together, these data do not indicate a role of HOTTIP in 





Figure 3.3 Single cell tracking analysis of siRNA mediated HOTTIP depleted cancer cells. 
(A) HCT116, (B) RKO1 and (C) DU145 cells were transfected with HOTTIP targeting or NTC siRNA for 72 h. 
After being sparsely being seeded in 96-well plates, cells were placed in a humidified CO2 chamber 
attached to a Nikon Widefield microscope where images were taken every 20 min for 24 h. Individual 
cells were tracked and average speeds were calculated using ImageJ Fiji. Data are mean (± S.E.M) 
expression of 3 biological replicates (N=3). Kruskal-Wallis test with Dunn’s post-hoc test was used to 










Figure 3.4 Single cell tracking of CRISPR-Cas9 HOTTIP KO HCT116 cells. 
CRISPR-Cas9 mediated HOTTIP KO and WT HCT116 cells were seeded sparsely in 96-well plates and placed 
in a humidified CO2 chamber attached to a Nikon Widefield microscope where images were taken every 
20 min for 24 h. Individual cells were tracked and average speeds were calculated using ImageJ Fiji. Data 






3.3.2 HOTTIP depletion results in reduced migration of CRC and PCa cells. 
To measure the migration rates of HOTTIP depleted cancer cells, wound healing 
assays were implemented. Cells were seeded in 6-well plates so they reached 100 % 
confluency within 24 h. A ‘wound’ was created in each well using a P20 pipette tip. A 
Nikon Widefield microscope was used to take pictures of each well every 20 minutes 
over a 24 h period. Cells were placed in a humidified CO2 chamber to retain their 
optimum culturing conditions during this time. The percentage of cell coverage at 
each time point was analysed using Image J software (De Kumar and Krumlauf, 
2016). 
A reduction in cell migration was observed in HOTTIP depleted HCT116 and 
DU145 cells (Figure 3.5A/C), however, this was not significant for either cell line. 
RKO1 cells transfected with HOTTIP KD 1 exhibited an increase in migration, whereas 
RKO1 cells transfected with HOTTIP KD 2 resulted in a decrease in migration (P=0.07) 
(Figure 3.5B). Migration was also reduced in CRISPR-Cas9 HOTTIP KO compared to 
WT HCT116 cells, but again, this failed to reach diagnosis (P=0.08) (Figure 3.6). As no 
significant reduction in cell migration was observed, it cannot be confirmed that 






Figure 3.5 Cell migration rates of HOTTIP depleted cancer cells. 
Wound healing assays were carried out to measure the migration rates of siRNA mediated HOTTIP depleted 
cancer cells. ‘Wounds’ were tracked over 24 h and HOTTIP depleted cell migration was calculated relative to 
NTC. Cell migration of HOTTIP depleted (A) HCT116 (B) RKO1 (C) DU145 cells. Data are mean (± S.E.M) of 3 
biological replicates (N=3). One-way ANOVA with Dunnett’s multiple comparison was used to test statistical 
significance. Representative images of WT and HOTTIP KD ‘wounds’ at 0 h, 12 h, and 22 h after initial 
scratching of confluent (D) HCT116 (E) RKO1 (F) DU145 cells taken using a Nikon Widefield microscope and 






Figure 3.6 Cell migration rates of CRISPR-Cas9 mediated HOTTIP KO HCT116 cells. 
Wound healing assays were carried out to measure the migration rates of CRISPR-Cas9 mediated HOTTIP 
KO HCT116 cells. (A) ‘Wounds’ were tracked over 24 h and HOTTIP KO cell migration was calculated 
relative to WT. Data are mean (± S.E.M) of 3 biological replicates (N=3). Unpaired t-test with Welch’s 
correction was used to quantify statistical significance. (B) Representative images of WT and HOTTIP KO 
‘wounds’ at 0 h, 12 h and 24 h after initial scratching of confluent cells taken using a Nikon Widefield 





3.3.3  Investigating the effect of HOTTIP on cell viability and proliferation in HCT116 
cells. 
Colony formation assays were used to investigate the effect of HOTTIP on cancer cell 
growth; this assay allows measurement of cell viability and the ability of cells in a 
population to continually divide (De Kumar and Krumlauf, 2016). CRISPR-Cas9 
mediated HOTTIP KO and WT HCT116 cells were seeded sparsely into 12-well plates 
and grown for ~10 days to allow single cells to form colonies. The number of 
colonies formed was quantified using ImageJ Fiji software (Schindelin et al., 2012). 
No significant difference in the number of colonies was observed in HOTTIP KO cells 
compared to WT (Figure 3.7), indicating that HOTTIP does not have a role in 
maintaining HCT116 cell viability and proliferation. 
The proliferation rates of CRISPR-Cas9 HOTTIP KO and WT HCT116 cells were 
then compared. Cells were seeded in 96-well plates and grown over a time series for 
8 days. After each time point, cells were fixed and stained with crystal violet prior to 
colorimetric measurement (OD 490 nm) and growth rates were calculated relative to 
day 0 (no growth). A reduction in proliferation was observed in HOTTIP KO cells 
compared to WT (P=0.06) (Figure 3.8), suggesting HOTTIP may promote proliferation 









Figure 3.7 Colony formation ability in CRISPR-Cas9 mediated HOTTIP KO HCT116 cells 
compared to WT. 
CRISPR-Cas9 mediated HOTTIP KO and WT HCT116 cells were seeded and allowed to form colonies for 
~10 days. (A) Relative colony number of HOTTIP KO cells compared to WT. Data are mean (± S.E.M) of 3 
biological replicates (N=3) relative to control WT cells. Unpaired t-test with Welch’s correction was used 
to quantify the statistical significance. (B) Representative wells of colonies stained with crystal violet after 





Figure 3.8 HOTTIP KO proliferation assay 
CRISPR-Cas9 mediated HOTTIP KO and WT HCT116 cells were seeded in 96-well plates and growth 
rates were measured over an 8-day time series. Growth rates were calculated relative to day 0 (no 
growth). Data are mean (± S.E.M) of 3 biological replicates (N=3). A paired t-test was used to calculate 






3.3.4  HOTTIP has no significant effect on apoptosis in cancer cells. 
Flow cytometry was used to assess whether HOTTIP depletion alters the levels of 
apoptosis in HCT116, RKO1 and DU145 cells. Again, siRNAs were used to knockdown 
HOTTIP expression. 72 h after transfection, all cells and media were collected and 
pelleted. Pelleted cells were re-suspended in Nicoletti buffer (De Kumar and Krumlauf, 
2016) containing propidium iodide (PI), used to stain apoptotic cells. During the 
process of apoptosis DNA becomes fragmented. As a result, rates of apoptosis can be 
measured by the identification of hypodiploid cells using a DNA stain such as PI.  
Cellular PI intensity was quantified using flow cytometry and rates of apoptosis were 
compared to NTC siRNA controls. 
In HOTTIP depleted HCT116 cells, a decrease in apoptosis was observed 
compared to NTC (Figure 3.9A). HOTTIP depleted RKO1 and DU145 cells exhibited an 
increase in apoptosis (Figure 3.9B/C). In all cases, this was not found to be significant. 
The apoptosis rates of CRIPSR-Cas9 HOTTIP KO HCT116 cells were then examined, and 
whilst they were found to increase compared to WT, this was again a non-significant 
result (Figure 3.10). Overall, depletion of HOTTIP in these cell lines does not appear to 








Figure 3.9 Investigating the apoptosis rates of siRNA mediated HOTTIP depleted cancer cells. 
After transfection for 72 h with siRNA targeting HOTTIP or NTC, all cells and media were collected and 
pelleted. Pellets were re-suspended in Nicoletti buffer and percentage apoptosis of HOTTIP depleted (A) 
HCT116, (B) RKO1 and (C) DU145 cells were analysed for DNA hypodiploidy via flow cytometry. (D) 
Representative flow cytometry plots of HOTTIP depleted and NTC HCT116, RKO1 and DU145 cells, average 
Sub-G1 percentages highlighted in red. Data are mean (±S.E.M) of 3 biological replicates (N=3). Two-way 





Figure 3.10 Investigating the apoptosis rates of CRISPR-Cas9 mediated HOTTIP KO HCT116 
cells. 
CRISPR-Cas9 mediated HOTTIP KO and WT cells were cultured in 6-well plates prior to all cells and 
media being collected and pelleted. Pellets were re-suspended in Nicoletti buffer and percentage 
apoptosis was analysed for DNA hypodiploidy via flow cytometry. (A) Percentage apoptosis of CRISPR-
Cas9 mediated HOTTIP knockout HCT116 cells. (B) Representative flow cytometry plots of HOTTIP KO 
and WT HCT116 cells, average Sub-G1 percentages highlighted in red. Data are mean (±S.E.M) of 3 
biological replicates (N=3). Two-way ANOVA with Sidak’s multiple comparisons test was used to 






3.3.5 HOTTIP does not drive cell cycle progression in cancer cells. 
HOTTIP has previously been described to promote cell cycle progression in 
leukaemia (Rinn et al., 2007; Wang et al., 2011). Flow cytometry was used to 
investigate if this is also seen in HCT116, RKO1 and DU145 cells. Cell cycle assays 
assess cellular DNA content and indicate what percentage of cells in a sample are in 
each stage of the cell cycle (Wang et al., 2011). Cells were transfected with HOTTIP 
KD or NTC siRNA for 72 h, after which point all cells and media were pelleted and 
fixed so the cell cycle stage of each cell could be analysed. The fixative was removed, 
and samples were re-suspended in a stain containing PI. A flow cytometer was used 
to measure the percentage of cells in each stage of the cell cycle (G1 vs S vs G2/M) 
to see if there is a change in this distribution when HOTTIP is depleted in HCT116, 
RKO1 and DU145 cells. The percentage of cells in each phase of the cell cycle was 
analysed and HOTTIP depleted cells were compared to NTC.  
HOTTIP depleted HCT116 cells resulted in an increase in S phase and a 
decrease in G2/M and G1 phase compared to NTC (Figure 3.11A). An increase in 
G2/M and S phase was observed in HOTTIP depleted RKO1 cells, however, no 
difference in G1 phase was observed (Figure 3.11B).  In DU145 cells, HOTTIP 
depletion led to an increase in G2/M and a decrease in G1 phase, nevertheless, no 
change in S phase was observed (Figure 3.11C). None of these data were found to be 
significant. In CRISPR-Cas9 HOTTIP KO HCT116 cells, an increase in G1 phase and a 
decrease in G2/M and S phase was observed (Figure 3.12), again this was not found 
to be significant. Overall, these data suggest that HOTTIP does not influence cell 





Figure 3.11 Cell cycle analysis of siRNA mediated HOTTIP depletion in cancer. 
siRNA mediated HOTTIP depleted and NTC cells were analysed via flow cytometry to measure the 
percentage of (A) HCT116 (B) RKO1 (C) DU145 cells in each stage of the cell cycle. Data are mean (± 
S.E.M) of 3 biological replicates (N=3). Two-way ANOVA with Dunnett’s multiple comparisons test 
was used to quantify statistical significance. (D) Representative flow cytometry plots of HOTTIP 






Figure 3.12 Cell cycle analysis of CRISPR-Cas9 mediated HOTTIP knockout in HCT116. 
(A) Cell cycle analysis was carried out on CRISPR-Cas9 mediated HOTTIP KO and WT HCT116 cells 
using flow cytometry. Data are mean (± S.E.M) of 3 biological replicates (N=3). Two-way ANOVA with 
Tukey’s multiple comparisons test was used to quantify statistical significance. (B) Representative 





3.4 HOTTIP protects colorectal and prostate cancer cells against 
chemotherapeutic drugs. 
Previous studies have suggested a role of HOTTIP in protecting cancer cells (small 
cell lung cancer and pancreatic cancer) from death when exposed to chemotherapy 
(Wang et al., 2011). Two commonly used colorectal cancer chemotherapeutic drugs; 
Fluorouracil (5FU) (Li et al., 2018) and Oxaliplatin (OX) (Wang et al., 2011), and a 
prostate cancer drug; Docetaxel (DOC) (Ito et al., 2018) were selected to investigate 
whether HOTTIP expression protects CRC and PCa cells against chemotherapy 
toxicity. 
 
3.4.1 HOTTIP depletion results in sensitivity of cells towards chemotherapy in cancer. 
Initially, the dose response of siRNA mediated HOTTIP depletion and CRISPR HOTTIP 
KO cells to chemotherapeutic drugs was tested in order to investigate whether 
HOTTIP has a role in promoting chemoresistance in cancer cells. Cells were seeded in 
96-well plates and treated with a dose range of either 5FU, OX or DOC for 72 h prior 
to being fixed and stained with crystal violet for colorimetric measurement (OD 490 
nm). The optical density was calculated relative to no drug treatment (0 µM). 
Proliferation rates were calculated for both control and HOTTIP depleted cells 
treated with each drug. 
Both 5FU and OX were found to inhibit HCT116 and RKO1 NTC growth across 
all concentrations tested. A reduction in cell growth was observed in HOTTIP 




µM), indicating increased sensitivity to 5FU compared to NTC at these doses (Figure 
3.13A). When treated with OX, HCT116 cells transfected with HOTTIP KD 1 exhibited 
greater sensitivity to the drug than both HOTTIP KD 2 and NTC (Figure 3.13B). 
However, this was not significant for either drug. A significant sensitivity in RKO1 
cells transfected with HOTTIP KD 1 and treated with 0.1 µM 5FU was observed 
(Figure 3.14A). No sensitivity to OX was observed in HOTTIP depleted RKO1 cells 
(Figure 3.14B). Unexpectedly, no sensitivity to DOC was observed in DU145 NTC 
cells. However, there was increased sensitivity to DOC observed in HOTTIP depleted 
DU145 cells (Figure 3.15), although this was not a significant effect. 
An increase in sensitivity of CRISPR-Cas9 HOTTIP KO HCT116 cells to 5FU was 
observed at the 0.1 and 1 µM concentrations (Figure 3.16A). However, a rise in 
HOTTIP KO cell growth was evident when both KO and WT cells were treated with 10 
µM 5FU. An increase in sensitivity was also observed in HOTTIP KO HCT116 cells 
when treated with OX at the 10, 100 and 1000 µM doses (Figure 3.16B). Overall, 
siRNA mediated depletion of HOTTIP in HCT116 or DU145 did not result in significant 
increase in sensitivity of the cells to chemotherapy. The exception was HOTTIP 
depleted RKO1 cells, where significant sensitivity was observed when treated with 
0.1 µM 5FU. When HOTTIP was permanently deleted in CRISPR-Cas9 KO HCT116 
cells, significant sensitivity of the cells was observed when treated with either 5FU or 






Figure 3.13 Dose response of siRNA mediated HOTTIP depleted HCT116 cells to 
chemotherapeutic drugs. 
HCT116 cells were transfected with HOTTIP targeting and NTC siRNA for 72 h. Cells were then seeded 
in 96-well plates and subsequently treated with a dose response of (A) 5FU (0, 0.1, 1, 10, 100 µM) or 
(B) OX (0, 1, 10, 100, 1000 µM) for a further 72 h. The dose response of siRNA mediated HOTTIP 
depleted HCT116 cells to chemotherapeutic drugs was examined and compared to NTC. All data are 
mean (± S.E.M) of 3 biological replicates (N=3). Two-way ANOVA with Dunnett’s multiple comparisons 






Figure 3.14 Dose response of siRNA mediated HOTTIP depleted RKO1 cells to 
chemotherapeutic drugs. 
RKO1 cells were transfected with HOTTIP targeting and NTC siRNA for 72 h. Cells were then seeded in 
96-well plates and subsequently treated with a dose response of (A) 5FU (0, 0.1, 1, 10, 100 µM) or (B) 
OX (0, 1, 10, 100, 1000 µM) for a further 72 h. The dose response of siRNA mediated HOTTIP depleted 
RKO1 cells to chemotherapeutic drugs was examined and compared to NTC. All data are mean (± 
S.E.M) of 3 biological replicates (N=3). Two-way ANOVA with Dunnett’s multiple comparisons test 







Figure 3.15 Dose response of siRNA mediated HOTTIP depleted DU145 cells to 
chemotherapeutic drugs. 
DU145 cells were transfected with HOTTIP targeting and NTC siRNA for 72 h. Cells were then seeded 
in 96-well plates and subsequently treated with a dose response of DOC (0, 0.1, 1, 10, 100 µM) for a 
further 72 h. The dose response of siRNA mediated HOTTIP depleted HCT116 cells to 
chemotherapeutic drugs was examined and compared to NTC. All data are mean (± S.E.M) of 3 
biological replicates (N=3). Two-way ANOVA with Dunnett’s multiple comparisons test was used to 






Figure 3.16 Dose response of CRISPR-Cas9 mediated HOTTIP KO HCT116 cells to chemotherapeutic 
drugs. 
CRISPR-Cas9 mediated HOTTIP KO and WT HCT116 cells were seeded in 96-well plates and 
subsequently treated with a dose response of (A) 5FU (0, 0.1, 1, 10, 100 µM) or (B) OX (0, 1, 10, 100, 
1000 µM) for 72 h. The dose response of HOTTIP KO HCT116 cells to chemotherapeutic drugs was 
examined and compared to WT. All data are mean (± S.E.M) of 3 biological replicates (N=3). Two-way 






3.4.2 Reduction in HOTTIP leads to an increase in cell death when CRC cells are 
treated with chemotherapeutic drugs. 
After investigating sensitivity to chemotherapy in cancer cells with reduced HOTTIP 
expression, the rates of cell death (apoptosis) after exposure to 10 µM 5FU, 10 µM OX 
or 1 µM DOC was tested. Cells were treated with chemotherapeutic drugs and 
incubated for different time points: 24 h, 48 h, 72 h. A no drug comparison was also 
included for each cell line. Flow cytometry was used to quantify the percentage of 
cells undergoing apoptosis as described above (Section 3.3.4). HOTTIP depleted cells 
were compared to NTC and no drug controls. 
After 72 h siRNA knockdown, HOTTIP depleted HCT116 cells exhibited a 
reduction in the percentage of cells undergoing apoptosis. With the addition of 
chemotherapy treatment, a significant increase in apoptosis was observed in HOTTIP 
depleted HCT116 cells treated with both 5FU (Figure 3.17A) and OX (Figure 3.17B). 
An increase in the percentage of RKO1 cells undergoing apoptosis was seen upon 
siRNA mediated HOTTIP depletion. This pattern was also observed when RKO1 cells 
were treated with 5FU (Figure 3.18A) or OX (Figure 3.18B). HOTTIP depleted DU145 
cells showed an increase in apoptosis compared to NTC (Figure 3.19A), and this was 
sustained with the addition of DOC treatment.  
Stable HOTTIP KO HCT116 cells exhibited a slight increase in the percentage 
of cells undergoing apoptosis compared to WT HCT116 cells (Figure 3.20). With the 
addition of 5FU treatment, no significant difference in apoptosis was observed for 




exhibited a significant increase in apoptosis at the 24 and 48 h time points (Figure 
3.20B). Together, these data suggest a chemosensitive role for HOTTIP in HCT116 








Figure 3.17 Apoptosis of HOTTIP depleted HCT116 cells to chemotherapeutic drugs. 
HCT116 cells were transfected with HOTTIP targeting or NTC siRNA for 72 h and subsequently treated 
with chemotherapeutic drugs for DNA hypodiploidy analysis using a flow cytometer at 24 h, 48 h and 
72 h after initial treatment. No drug controls were also included. Data are mean (± S.E.M) of 3 
biological replicates (N=3). Two-way ANOVA via Dunnett’s comparison test was used to quantify the 
statistical significance (**P<0.01, ***P<0.001. ****P<0.0001). HOTTIP depleted HCT116 cells were 
treated with 10 µM (A) 5FU or (B) 10 µM OX for up to 72 h. Representative flow cytometry plots of 
HOTTIP depleted and NTC HCT116 cells treated with (C) 10 µM 5FU or (D) 10 µM OX, average Sub-G1 






Figure 3.18 Apoptosis of HOTTIP depleted RKO1 cells to chemotherapeutic drugs. 
RKO1 cells were transfected with HOTTIP targeting or NTC siRNA for 72 h and subsequently treated 
with chemotherapeutic drugs for DNA hypodiploidy analysis assay using a flow cytometer at 24 h, 48 
h and 72 h after initial treatment. No drug controls were also included. Data are mean (± S.E.M) of 3 
biological replicates (N=3). Two-way ANOVA via Dunnett’s comparison test was used to quantify the 
statistical significance. (A) HOTTIP depleted RKO1 cells were treated with (A) 10 µM 5FU or (B) OX for 
up to 72 h. Representative flow cytometry plots of HOTTIP depleted and NTC RKO1 cells treated with 






Figure 3.19 Apoptosis of HOTTIP depleted DU145 cells to chemotherapeutic drugs. 
DU145 cells were transfected with HOTTIP targeting or NTC siRNA for 72 h and subsequently treated 
with chemotherapeutic drugs for DNA hypodiploidy analysis using a flow cytometer at 24 h, 48 h and 
72 h after initial treatment. No drug controls were also included. Data are mean (± S.E.M) of 3 
biological replicates (N=3). Two-way ANOVA via Dunnett’s comparison test was used to quantify the 
statistical significance (*P<0.05, **P<0.01, ***P<0.001. ****P<0.0001). (A) HOTTIP depleted cells 
were treated with 1 µM DOC for up to 72 h. (B) Representative flow cytometry plots of HOTTIP 






Figure 3.20 Apoptosis of CRISPR-Cas9 mediated HOTTIP KO cells to chemotherapeutic drugs. 
CRISPR-Cas9 mediated HOTTIP KO and WT cells were treated with chemotherapeutic drugs for DNA 
hypodiploidy analysis using a flow cytometer at 24 h, 48 h and 72 h after initial treatment. No drug 
controls were also included. Data are mean (± S.E.M) of 3 biological replicates (N=3). Two-way 
ANOVA with Sidak’s multiple comparisons test was used to quantify statistical significance (*P>0.05, 
****P<0.0001). Stable HOTTIP KO and WT HCT116 cells treated with (A) 10 µM 5FU or (C) OX. 
Representative flow cytometry plots of stable HOTTIP KO and WT HCT116 cells treated with (B) 5FU 





3.4.3 Reduction in HOTTIP expression reduces HCT116 colony forming ability when 
exposed to chemotherapeutic drugs. 
 
Colony formation assays were used to further investigate the effect of HOTTIP on 
cancer cell survival when exposed to chemotherapeutic drugs. CRISPR-Cas9 HOTTIP 
KO and WT stable cells were seeded sparsely in 12-well plates. After 3-4 days, cells 
were treated with 10 µM 5FU or 10 µM OX. A no drug control was also included to 
measure the colony growth without the addition of chemotherapy treatment. There 
was no significant difference in the number of colonies present in the HOTTIP KO 
and WT HCT116 cells prior to the introduction of chemotherapy. When treated with 
5FU or OX, a significant reduction in colonies was observed in HOTTIP KO compared 
to WT (Figure 3.21).  
The proliferation rate of CRISPR-Cas9 HOTTIP KO HCT116 cells when treated 
with 10 µM 5FU or 10 µM OX were investigated over a 4-day time series. 
Proliferation rates were calculated relative to day 0. Prior to the addition of 
chemotherapy, reduced proliferation of CRISPR-Cas9 mediated stable HOTTIP KO 
HCT116 cells was observed compared to WT (P=0.06) (Figure 3.22A). Reduced 
proliferation was also observed in HOTTIP KO cells treated with 5FU; this was found 
to be significant at for HOTTIP KO compared to WT at day 4 (Figure 3.22B). When 
treated with OX, HOTTIP KO cells also exhibited reduced growth; however, this was 
not a significant result (Figure 3.22C). This loss in proliferation may be a result of 
HOTTIP KO rather than the introduction of OX as there is a similar pattern observed 




treated with OX. Together, these data may further indicate sensitivity of HOTTIP KO 
cells to chemotherapy, particularly 5FU as reduced growth is observed in HOTTIP KO 






Figure 3.21 CRISPR-Cas9 mediated HOTTIP KO cells exhibit significant loss of colony formation 
ability in HCT116 cells. 
(A) Relative colony number of CRISPR-Cas9 mediated HOTTIP KO and WT HCT116 cells were compared 
with no drug, treatment with 10 µM 5FU or 10 µM OX. Data are mean (± S.E.M) of 3 biological replicates 
(N=3) relative to control WT cells. Two-way ANOVA with Sidak’s multiple comparisons test was used to 
quantify statistical significance (** P<0.01). (B) Representative wells of colonies formed and stained with 






Figure 3.22 Proliferation of CRISPR-Cas9 mediated HOTTIP KO and WT HCT116 cells when 
treated with chemotherapeutic drugs.  
CRISPR-Cas9 mediated HOTTIP knockout and WT HCT116 cells were grown over a 4-day time course 
in the presence of (A) no drug, (B) 10 µM 5FU and (C) 10 µM OX. Cells were fixed with 4% PFA and 
stained with crystal violet prior to colorimetric assay measurement (OD 490 nm). Growth rates were 
calculated relative to day 0 (no growth or drug treatment). No significant change in growth rate was 
observed. Data are mean (± S.E.M) of 3 biological replicates (N=3). Two-way ANOVA with Sidak’s 






3.4.4 Chemotherapeutic drugs do not induce cell cycle arrest when HOTTIP is 
depleted in CRC and PCa cells. 
After sensitivity to chemotherapy was observed in HOTTIP depleted cells, it was 
decided to investigate whether 5FU, OX or DOC treatment influences changes in the 
cell cycle upon HOTTIP depletion. siRNA mediated HOTTIP KD or CRISPR-Cas9 HOTTIP 
KO cells and their respective controls were treated with 10 µM 5FU, 10 µM OX or 1 
µM DOC for 72 h. No drug controls were also included in this analysis. A flow 
cytometer was used to measure the percentage of cells in each stage of the cell cycle 
as outlined previously (Section 3.3.5). 
Upon siRNA mediated HOTTIP depletion, HCT116 cells exhibited an increase in 
G1 and S phase, as well as a reduction in the percentage of cells undergoing G2/M 
phase (Figure 3.23A). After treatment with 5FU, no changes in the cell cycle were 
observed for HCT116 cells transfected with HOTTIP 1 siRNA. However, when 
transfected with HOTTIP 2 siRNA HCT116 cells exhibited a slight increase in G1 phase 
(Figure 3.23B) compared to NTC (Figure 3.23A). HOTTIP depleted HCT116 cells treated 
with OX resulted in a higher percentage of cells in G1 phase, and a reduction of cells 
in G1 and G2/M phase compared to NTC (Figure 3.23C). 
RKO1 cells exhibited an increase in cells in G2/M and S phase after siRNA 
mediated depletion (Figure 3.24A). When treated with 5FU, no change was observed 
for RKO1 cells transfected with HOTTIP KD 1. However, an increase in the 
percentage of cells undergoing G2/M and S phase, as well as a reduction in G1 phase 




When treated with OX, HOTTIP depleted RKO1 cells underwent an increase in the 
percentage of cells in G2/M and S phase, as well as a reduction in cells undergoing 
G1 phase (Figure 3.24C).  
After siRNA mediated HOTTIP depletion, DU145 cells showed no change in 
cells in S phase; although, an increase in G2/M and decrease in G1 phase was 
observed (Figure 3.25A). When treated with DOC, there were no differences in cell 
cycle stages seen between NTC and DU145 cells transfected with siRNA HOTTIP KD 
1, with the exception of S phase, where a decrease in the number of cells at this 
stage of the cell cycle was observed. However, a decrease in the percentage of cells 
in S and G1 phase and an increase in the percentage of cells in G2/M was observed 
in DU145 cells transfected with HOTTIP KD 2, also treated with DOC (Figure 3.25B). 
Despite these observations, none of the above data for either cell line was found to 
be significant. 
The cell cycle of stable CRISPR-Cas9 HOTTIP KO and WT cells treated with 10 
µM 5FU or 10 µM Ox was investigated next. A time series was established for each 
drug treatment: 0 h (no drug control), 24 h, 48 h and 72 h to investigate if any shifts 
in the cell cycle were occurring before the 72 h time point used in the siRNA 
experiments. Prior to the addition of chemotherapy, an increase in cells in G1 phase, 
and a decrease in G2/M and S phase was observed for HOTTIP KO HCT116 cells. 
When treated with 5FU for 24 h, the same pattern was observed, with the exception 
of increased HOTTIP KO cells undergoing G2/M phase compared to WT. After longer 




between HOTTIP KO and WT cells seen (Figure 3.26A), suggesting 5FU was equally 
affecting the cell regardless of level of HOTTIP expression. 
When treated with OX, an increase in the percentage of cells in G2/M and G1 
phase was observed in HOTTIP KO cells over the time course. Similarly, a reduction 
in HOTTIP KO cells undergoing S phase was also seen at each time point (Figure 
3.26B). However, in both instances, any changes in cell cycle stages, as a result of 







Figure 3.23 Cell cycle analysis of siRNA mediated HOTTIP depletion in HCT116 cells. 
Cell cycle analysis of (A) siRNA mediated HOTTIP depleted and NTC HCT116 cells treated with (B) 10 
µM 5FU or (C) 10 µM OX for 72 h. A no drug control was also included. Data are mean (± S.E.M) of 3 
biological replicates (N=3). Two-way ANOVA with Dunnett’s multiple comparisons test was used to 
quantify statistical significance. (D) Representative flow cytometry plots of siRNA mediated HOTTIP 







Figure 3.24 Cell cycle analysis of siRNA mediated HOTTIP depletion in RKO1 cells. 
Cell cycle analysis of (A) siRNA mediated HOTTIP depleted and NTC RKO1 cells treated with (B) 10 µM 
5FU or (C) 10 µM OX for 72 h. A no drug control was also included. Data are mean (± S.E.M) of 3 
biological replicates (N=3). Two-way ANOVA with Dunnett’s multiple comparisons test was used to 
quantify statistical significance. (D) Representative flow cytometry plots of siRNA mediated HOTTIP 






Figure 3.25 Cell cycle analysis of siRNA mediated HOTTIP depletion in DU145 cells. 
Cell cycle analysis of (A) siRNA mediated HOTTIP depleted and NTC DU145 cells treated with (B) 1 µM 
DOC for 72 h. A no drug control was also included. Data are mean (± S.E.M) of 3 biological replicates 
(N=3). Two-way ANOVA with Dunnett’s multiple comparisons test was used to quantify statistical 
significance. (C) Representative flow cytometry plots of siRNA mediated HOTTIP depleted and NT cells 








Figure 3.26 Cell cycle analysis of CRISPR-Cas9 mediated HOTTIP knockout in HCT116 cells 
treated with chemotherapeutic drugs. 
CRISPR-Cas9 mediated HOTTIP KO and WT HCT116 cells were treated with (A) 10 µM 5FU or (B) 10 
µM OX for 24 h, 48 h, 72 h and the percentage of cells in each stage of the cell cycle was analysed via 
flow cytometry. A no drug control was also included (0h). Data are mean (± S.E.M) of 3 biological 
replicates (N=3). Two-way ANOVA with Tukey’s multiple comparisons test was used to quantify 
statistical significance. Representative flow cytometry plots of HOTTIP KO and WT cells treated with 





3.5 RNA-Seq analysis of stable HOTTIP KO cell lines 
After the above functional assays investigating the role of HOTTIP in CRC and PCa 
were carried out, it was decided to look at the transcriptome when HOTTIP is 
deleted in HCT116 cells in more detail. The CRISPR-Cas9 HOTTIP KO and WT HCT116 
cell lines were used once again for this work. RNA extracted from HOTTIP KO and WT 
cells was sent for RNA-Sequencing (RNA-Seq) (Novogene, UK), where all further 
library preparations for sequencing were completed. FASTA files of each genotype 
(triplicate independent repeats) were returned for analysis. Firstly, FASTQC analysis 
was carried out to ensure each raw sequence data file had good quality reads. The 
raw data files were subsequently mapped to the genome (hg38), reads were 
counted and differential expression of genes in each sample calculated using 
statistical analysis packages: TopHat2 (Kim et al., 2013), HTSeq (Wen et al., 2018) 
and DESeq2 (Chang et al., 2016; Qin et al., 2019). Genomic tracks of WT and HOTTIP 
KO samples were compared at the HOXA cluster (Figure 3.27).  A clear deletion of 
the HOTTIP transcript in the KO lines was identified. In agreement with previous 
results, (Section 3.2.2), a reduction in HOXA13 was also seen in HOTTIP KO 
compared to WT. Interestingly, an increase in HOXA3 was observed in the KO lines 
compared to WT. 
After HOTTIP deletion was confirmed, the differential expression of HOTTIP 
KO and WT genes was explored. Differentially expressed genes were filtered to 
include only those with P<0.01 and Log2Fold Change (Log2FC) >0.5 values. A 
heatmap of all filtered genes was produced (Figure 3.28) to compare gene 




upregulated (Supplementary Table 8.1) and 494 downregulated (Supplementary 








Figure 3.27 Seqmonk visualisation of WT and HOTTIP KO genome tracks at the HOXA cluster 
generated from RNA-Seq analysis. 
The transcriptome of WT and HOTTIP KO HCT116 cells was analysed in triplicate by RNA-Seq. Differential 
expression of genes was analysed through using the statistical packages ‘TopHat2’, ‘HTSeq’ and ‘DESeq2’. 
After analysis, BAM files were loaded in to the SeqMonk programme (Babraham Institute) to visualise the 
mapped sequence data. Genomic tracks of HOTTIP KO and WT replicates were compared at the HOXA 






Figure 3.28 Heat map of differentially expressed genes identified through HOTTIP KO 
HCT116 RNA-Seq analysis. 
The transcriptome of WT and HOTTIP KO HCT116 cells was analysed by RNA-Seq. Differential 
expression of genes was analysed through using the statistical packages ‘TopHat2’, ‘HTSeq’ and 
‘DESeq2’. After analysis, BAM files were loaded in to the SeqMonk programme (Babraham Institute) 
to visualise and analyse the mapped sequenced data further. Data was filtered by only accepting 
genes P<0.01 and a Log2FC >0.5 (925 genes total). A heat map indicating differential expression of 
genes in WT and HOTTIP KO replicates was produced and colour coded depending on differential 
expression value. Y-axis labels are a subset of all 925 differentially expressed genes although all genes 





To explore differential expression further, all significant HOX genes from the filtered 
data were plotted. Again, this was compared across all replicates of the HOTTIP KO 
and WT samples (Figure 3.29). HOTTIP, HOXA13 and HOXD8 were all found to be 
downregulated in HOTTIP KO samples. All other HOX genes were upregulated upon 
HOTTIP deletion. Interestingly, many HOXB genes (HOXB3, HOXB4, HOXB6, HOXB8, 
HOXB9) were subject to this upregulation. Many HOXB genes have been associated 
with cancer; in particular HOXB8 has been described as being oncogenic and 
promoting CRC invasiveness (Li et al., 2015).  
HOTTIP is known to directly regulate 5’ HOXA genes (HOXA13, HOXA11, 
HOXA10 and HOXA9), as HOTTIP is located on the 5’ end of the HOXA cluster 
(Quagliata et al., 2018) and acts in cis to regulate expression of nearby genes (Zhang 
et al., 2016). Altered HOXB expression could be due to an indirect effect of HOXA13 
downregulation, as HOX transcription factors (TFs) are known to regulate expression 
of each other (Quagliata et al., 2018). HOXA3 expression is highly upregulated in 
HOTTIP KO samples compared to WT, which follows what was observed when 
genomic tracks were previously compared (Figure 3.27). Although not found in close 
proximity to HOTTIP, the lncRNA HOXA cluster antisense RNA 2 (HOXA-AS2) was also 
found to be upregulated in HOTTIP KO samples and is located between HOXA3 and 
HOXA4 in the HOXA cluster (Qin et al., 2019). The upregulation of HOXA3 observed 
could be a direct effect of HOXA-AS2 upregulation rather than HOTTIP KO.   
All differentially expressed genes were then visualised using a scatter plot to 
further determine which genes were upregulated in either HOTTIP KO or WT 




expression was observed for HOTTIP, HOXA13 and HOXD8 in WT samples and higher 
expression of all remaining significant HOX genes was observed in HOTTIP KO 






Figure 3.29 Heat map of differentially expressed HOX genes identified through HOTTIP KO 
HCT116 RNA-Seq analysis. 
The transcriptome of WT and HOTTIP KO HCT116 cells was analysed by RNA-Seq. Differential expression 
(RPKM) of genes was analysed through using the statistical packages ‘TopHat2’, ‘HTSeq’ and ‘DESeq2’. 
After analysis, BAM files were loaded in to the SeqMonk programme (Babraham Institute) to visualise and 
analyse the mapped sequenced data further. Data was filtered by only accepting genes P<0.01 and a 
Log2FC >0.5 (925 genes total). A heat map of target genes only (N=10) indicating differential expression of 
HOTTIP and HOX genes in WT and HOTTIP KO replicates was produced and colour coded depending on 





Figure 3.30 Differential expression of genes identified through analysis of the WT and 
HOTTIP KO HCT116 cell transcriptomes. 
The transcriptome of WT and HOTTIP KO HCT116 cells was analysed by RNA-Seq. Differential 
expression of genes was analysed through using the statistical packages ‘TopHat2’, ‘HTSeq’ and 
‘DESeq2’. Data was filtered by only accepting genes P<0.01 and a Log2FC >0.5 (925 genes total). A 
scatter plot was drawn indicating differential expression of genes and whether the expression was 







It was then decided to further investigate the potential importance of these 
differentially expressed HOX genes in CRC. Kaplan-Meier (K-M) survival plots were 
generated using an online database (kmplot.com) (Falaschi, Abdurashidova and 
Biamonti, 2010) to examine if their expression levels correlate with patient survival 
(Figure 3.31). Rectal adenocarcinoma RNA-Seq data from 165 patients was chosen 
for this analysis as it falls into the CRC classification. Higher levels of HOXA3 
(P=0.036) and HOXB4 (P=0.015) were significantly correlated with poorer survival in 
rectal adenocarcinoma, whereas higher HOXA13 (P=0.066) and HOXB9 (P=0.078) 
expression were correlated with better patient survival. Both HOXA3 and HOXB4 
were upregulated when HOTTIP was deleted in HCT116 cells; indicating HOTTIP may 
have tumour suppressive properties in preventing overexpression of HOXA (or its 
regulatory lncRNA HOXA-AS2) and HOXB4 in CRC. 
After exploring HOX gene expression, all significant differentially expressed 
genes were investigated further by performing gene ontology (GO) analysis. The 
GOrilla online tool (Han et al., 2018; Shi et al., 2018) was used to analyse all genes 
and determine what biological pathways or processes they may be involved in. A 
total of 987 genes out of 1291 were associated with a GO term. From this list, 32 
genes (Supplementary Figure 3) associated with the most significant biological 
processes (Figure 3.32) were selected for further analysis. Two main groups of genes 
were highlighted as a result of this analysis: peptidyl arginine deiminase 2 and 3 
(PADI2/3) and the protocadherin alpha cluster (PCDHA1-13), including the 





Figure 3.31 Kaplan-Meier survival plots of differentially expressed HOX genes identified 
through HOTTIP KO HCT116 RNA-Seq analysis. 
Kaplan-Meier survival plots generated by a meta-analysis of rectal adenocarcinoma RNA-Seq data 
using kmplot online software (kmplot.com) to determine if differentially expressed HOX genes 
identified through RNA-Seq analysis of WT and HOTTIP KO HCT116 cells is correlated with increased 
or decreased survival rates in CRC. The probability of survival (y-axis) is plotted against the time 
(months) a patient is estimated to survive the disease (x-axis). Black lines indicate low gene 
expression and red lines indicate high gene expression. N=165 patient samples were analysed in the 







Figure 3.32  Gene ontology analysis of HOTTIP KO HCT116 RNA-Seq data. 
The transcriptome of WT and HOTTIP KO HCT116 cells was analysed by RNA-Seq. Differential 
expression of genes was analysed through using the statistical packages ‘TopHat2’, ‘HTSeq’ and 
‘DESeq2’. Data was filtered by only accepting genes P<0.01 and a Log2FC >0.5 (925 genes total). Gene 
ontology analysis on filtered genes executed using the GOrilla database (http://cbl-
gorilla.cs.technion.ac.il/). Biological processes (A) and a list of genes associated with these processes 






Firstly, to visualise differential expression patterns, genomic tracks of the PADI and 
PCDHA genes were compared between HOTTIP KO and WT samples. An increase in 
PADI2 and PADI3 can be observed in HOTTIP KO replicates compared to WT (Figure 
3.33A). The PCDHA genes are found in a closely linked cluster (Watanabe et al., 
2018) and as many of this gene family overlap, it is hard to distinguish genomic 
patterns by visualizing genomic tracks. An overall pattern was observed where 3’ 
PCDHA genes are upregulated in the HOTTIP KO replicates whereas 5’ PCDHA genes 
are downregulated in HOTTIP KO (Figure 3.33B). 
More in-depth comparisons of these genes were then carried out by looking 
at the differential expression of each gene in HOTTIP KO and WT samples. 
Upregulation of PADI2/3 was observed in HOTTIP KO cells (Figure 3.38A) which 
supports what was seen previously (Figure 3.33A). Downregulation of the PCDHA 
family was observed in HOTTIP KO samples, however this effect is less pronounced 
for PCDHAC1/2 genes located on the 5’ end of the cluster (Figure 3.34A). Again, 
when looking at this data on a scatter plot, PADI2/3 are upregulated and the 
PCDHAC family are downregulated in HOTTIP KO (Figure 3.34B). All PCDHA genes 
exhibited a similar differential pattern and were found to also form a cluster when 





Figure 3.33 Seqmonk visualisation of differential expressed genes identified after gene 
ontology analysis of HOTTIP KO HCT116 RNA-Seq data. 
The transcriptome of WT and HOTTIP KO HCT116 cells was analysed by RNA-Seq. Differential 
expression of genes was analysed through using the statistical packages ‘TopHat2’, ‘HTSeq’ and 
‘DESeq2’. Data was filtered by only accepting genes P<0.01 and a Log2FC>0.5 (925 genes total). After 
gene ontology analysis (GOrilla), tracks of newly identified genes of interest were visualised in 
SeqMonk (Babraham Institute). The tracks of HOTTIP KO and WT replicates were compared when 











Figure 3.34 Gene ontology analysis of HOTTIP KO HCT116 RNA-Seq data. 
The transcriptome of WT and HOTTIP KO HCT116 cells was analysed by RNA-Seq. Differential 
expression of genes was analysed through using the statistical packages ‘TopHat2’, ‘HTSeq’ and 
‘DESeq2’. Data was filtered by only accepting genes P<0.01 and a Log2FC >0.5 (925 genes total). After 
gene ontology analysis (GOrilla), differentially expressed genes involved in highlighted biological 
processes were visualised. (A) A heatmap showing differentially expressed genes in WT and HOTTIP 
KO samples. (B) A scatterplot indicating where these genes (highlighted in red) sit in relation to all 
other differentially expressed genes and whether the expression was greater in WT (x-axis), or 





The potential importance of these differentially expressed PADI and PCDHA genes 
was then explored further in CRC. Kaplan-Meier (K-M) survival plots were generated 
using an online database (kmplot.com) (Joo, Park and Chun, 2016) to examine if 
expression levels of the selected genes correlate with patient survival (Figure 3.35). 
Renal adenocarcinoma RNA-Seq data from 165 patients was again used for this 
analysis. High expression of PADI3 (P=0.047), PCDHA9 (P=0.029) and PCDHA12 
(P=0.01) were significantly correlated with poorer survival in rectal adenocarcinoma. 
However, PCDHA10 (P=0.037) was found to have a similar effect on patient survival 
regardless of expression level. 
Overall, two groups of genes were identified from GO analysis: PADI and 
PCDHA. PADI2 and PADI3 were upregulated in HOTTIP KO samples and have 
previously been reported in colorectal cancer. They are markers of citrullination, a 
post-translational modification that has been found to promote cancer progression 
by altering gene expression through rearranging methylation patterns (Chang et al., 
2016; He et al., 2017). The PCDHA cluster genes were downregulated in HOTTIP KO 
HCT116 cells. Protocadherins have important roles in specific cell-cell connections 
and in promoting tumour development (Yang et al., 2017). In cancer, the 
methylation pattern of PCDHA clusters is often altered so their expression is silenced 







Figure 3.35 Kaplan-Meier survival plots of differentially expressed genes identified 
through gene ontology analysis of HOTTIP KO HCT116 RNA-Seq data. 
Kaplan-Meier survival plots generated by a meta-analysis of rectal adenocarcinoma RNA-Seq data 
using kmplot online software (kmplot.com) to determine if differentially expressed PADI and PCDHA 
genes identified through gene ontology analysis of HOTTIP KO HCT116 RNA-Seq data is correlated 
with increased or decreased survival rates in CRC. The probability of survival (y-axis) is plotted against 
the time (months) a patient is estimated to survive the disease (x-axis). Black lines indicate low gene 
expression and red lines indicate high gene expression. N=165 patient samples were analysed in the 





3.6  Discussion 
HOTTIP expression is up-regulated in many cancers, including colorectal (Pradeepa 
et al., 2017) and prostate (Wang et al., 2011). Alongside HOXA13 it has been 
associated with metastasis, increased cell proliferation, poor prognosis (Pradeepa et 
al., 2017) and chemoresistance (Cheng et al., 2015). 
3.6.1  HOTTIP regulates HOXA13 expression in CRC and PCa. 
Upon HOTTIP depletion via siRNA knockdown in HCT116, RKO1 and DU145 cells, 
HOXA13 expression was reduced. This was also observed in stable CRISPR-Cas9 
mediated HOTTIP KO HCT116 cells. These data support what has been previously 
described in mouse models where HOTTIP regulates the expression of nearby HOXA 
genes in cis (Wang et al., 2011). However, it should be noted that there was some 
BLAST sequence overlap for CRISPR gRNA HOTTIP 3P and siRNA HOTTIP KD 2 with 
HOXA13. Therefore, the reduction in HOXA13 expression observed could be a result 
of an off-target effect of the CRISPR gRNA or siRNA rather than a direct effect of 
HOTTIP depletion. 
3.6.2 HOTTIP does not contribute to the proliferation, movement and migration of 
CRC and PCa cells. 
Previous studies have described HOTTIP having roles in cell proliferation, migration 
and invasion in cancer (Kim and Shiekhattar, 2016). This was not replicated in this 
study. When HOTTIP was stably deleted from HCT116 cells a loss in cell motility was 




in the siRNA HOTTIP KD experiments in either of the cell lines (HCT116, RKO1, 
DU145). As a result, a strong role for HOTTIP in promoting cell movement and 
migration in these cell lines cannot be confirmed in this study.  
3.6.3 HOTTIP may protect colorectal cancer cells against chemotherapeutic drugs. 
Previous studies have suggested a role of HOTTIP in protecting cancer cells from 
death when exposed to chemotherapy (Li et al., 2011; Cheng et al., 2015). 
Commonly used CRC chemotherapeutic drugs 5-Fluoracil (5FU) (Carethers et al., 
2004) and Oxaliplatin (OX) (Comella et al., 2009), and a PCa drug Docetaxel (DOC) 
(Ito et al., 2018) were used to investigate whether HOTTIP expression protects CRC 
and PCa cells against chemotherapy toxicity.  
When investigating sensitivity of HOTTIP depleted/KO cells to 
chemotherapeutic drugs, more consistent results were observed when HOTTIP was 
permanently deleted from HCT116 cells. Sensitivity to both 5FU and OX was 
observed when exploring the dose response, colony formation ability and 
proliferation rates of cells. There is no known report of HOTTIP playing a role in 
preventing apoptosis in PCa, however it has been reported once in CRC in HCT116 
and SW620 cell lines (T. Liu et al., 2018) which supports the findings observed in this 
study. 
With the introduction of chemotherapy treatment, a significant increase in 
apoptosis was observed in HOTTIP depleted HCT116 cells treated with 
chemotherapeutic drugs. This was replicated in stable CRISPR HOTTIP KO HCT116 




in HOTTIP depleted DU145 cells treated with DOC. However, this was also seen in 
HOTTIP depleted DU145 cells without DOC treatment; indicating that the increase in 
apoptosis is due to absence of HOTTIP rather than treatment with the drug.  
In contrast, no significant shifts in the percentage of cells in each stage of the 
cell cycle were identified in HOTTIP depleted or stably deleted cells treated with 
chemotherapeutic drugs. 5FU is expected to induce arrest in both G1 and S phases 
of the cell cycle (Guo et al., 2008; Focaccetti et al., 2015); this arrest was increased in 
HCT116 and RKO1 cells transfected with siRNA HOTTIP KD 2, but not observed with 
siRNA HOTTIP KD 1 or the stable HOTTIP CRISPR KO HCT116 cell line. OX 
premdominantly induces arrest in G2/M phase and this was replicated here. Arrest 
during both S and G2/M phase is expected in cells treated with DOC (Tabaczar et al., 
2010; Nader, El Amm and Aragon-Ching, 2018), this was only observed for G2/M in 
DU145 cells. Together, this suggests OX is acting as expected, whereas 5FU and DOC 
have exhibited some shifts in their mechanisms of action. This could be a result of 
HOTTIP depletion, although more investigative work would need to be carried out 
before concluding this. There is no literature examining the role of HOTTIP on the 
cell cycle in the presence of chemotherapeutic drugs. There have been reports of 
HOTTIP promoting cell cycle progression in leukaemia (Zhuang, Li and Ma, 2019) 
which has not been observed in CRC or PCa in this study.  
Overall, some sensitivity to chemotherapy was observed for CRC cells upon 
HOTTIP depletion. The strongest effect was observed in HCT116 HOTTIP KO cells, 
indicating that HOTTIP may exhibit chemosensitive properties in this cell line. This 




et al., 2018). This is the first time a potential role for HOTTIP in promoting 
chemosensitivity in HOTTIP has been described in CRC. 
3.6.4 Global analysis of HOTTIP deletion in HCT116 CRC cells. 
After exploring the functional role of HOTTIP in CRC and PCa, the transcriptome of 
HOTTIP deleted HCT116 cells was investigated through RNA-Seq analysis. HOTTIP, 
HOXA13 and HOXD8 were all downregulated upon HOTTIP deletion. The cis 
regulatory relationship between HOTTIP and the nearby HOXA13 gene has been well 
established (Wang et al., 2011; Pradeepa et al., 2017) and re-created earlier in this 
study. However, HOXD8 has not yet been described in relation to HOTTIP, although 
it has been described as a tumour repressor in CRC (Mansour and Senga, 2017). 
HOXA3 and many genes belonging to the HOXB cluster were found to be 
upregulated in HOTTIP KO cells (Figure 3.29). Although HOTTIP has not been directly 
implicated in HOXB regulation, many HOXB genes have been described as promoting 
CRC cell proliferation and metastasis (Iman et al., 2016; Huang et al., 2017; Ying et 
al., 2020). HOXA3 is known to be regulated by another lncRNA, HOXA-AS2 (Ding et 
al., 2017) that was also found to be up-regulated in HCT116 upon HOTTIP deletion 
(Figure 3.29). HOTTIP may have a role in regulating HOXA-AS2 which in turn affects 
HOXA3 expression.  
During GO analysis, two main sets of genes were highlighted as being 
differentially expressed in HOTTIP KO HCT116 cells: the PADI and PCDHA clusters. 
Upregulation of PADI2/3 was observed in HOTTIP KO cells. PADI2/3 are usually 




al., 2017; Chai et al., 2019; Chang et al., 2019). Although, there is contradicting 
literature describing the role of PADI2. Some studies have shown it is correlated with 
poor prognosis (Cantarino et al., 2016) as well as promoting liver metastasis (Chen et 
al., 2017), a common secondary CRC site. However, other work has shown that 
PADI2 is downregulated in CRC (Cantarino et al., 2016) and can suppress the 
proliferation of CRC cells through protein citrullination (Funayama et al., 2017). This 
tumour suppressive role fits with what is observed in this data as PADI3  has 
previously been described as a tumour suppressor gene in CRC (Chai et al., 2019; 
Chang et al., 2019). A relationship between HOTTIP and PADI2/3 has not yet been 
described; nevertheless, these data suggest that HOTTIP may also act as a tumour 
suppressor via the regulation of PADI2 and PADI3, as upon loss of HOTTIP these 
genes are upregulated in HCT116 cells.  
Alternatively, expression of the PCDHA cluster was downregulated in HOTTIP 
KO samples compared to WT. Protocadherins have important roles in specific cell-
cell connections and in promoting tumour development (Berx and van Roy, 2009) so 
when depleted in HOTTIP KO cells this may prevent cancer progression. On the other 
hand, PCDHA genes are also involved in development, as regulators of the neural 
circuit formation (Peek, Mah and Weiner, 2017). As HOX expression was shown to 
be de-regulated with HOTTIP depletion, another possibility could be that the HOX 
TFs could be regulating the expression of PCDHA’s in CRC rather than HOTTIP having 




3.7  Summary 
In summary, HOTTIP was found to exhibit some chemosensitive properties in the 
HCT116 cell line. This was observed in both siRNA mediated depleted cells and 
CRISPR-Cas9 mediated stable HOTTIP KO cells, although the stable cell line provided 
more significant and therefore conclusive results. This suggests that CRC patients 
exhibiting high levels of HOTTIP may not react to chemotherapy as well as those 
patients with lower levels; tumour cell testing for this gene may aid clinicians with 
deciding on treatment options for a patient. More study into the chemosensitive 
properties of HOTTIP in CRC will provide further clarification. 
When investigating global expression patterns in HOTTIP KO HCT116 cells, a 
novel relationship where HOXD8 expression is reduced upon HOTTIP deletion was 
observed. HOTTIP was also shown to negatively regulate PADI2/3 and the PCDHA 
cluster. Overall, these data suggest a role for HOTTIP in promoting CRC cell 
progression through transcriptional regulation of HOXA, PADI and PCDHA genes. 
Further study may determine if regulation of these genes contributes to the 
chemosensitive role of HOTTIP in cancer. 
Limitations of this work include the BLAST sequence overlap for CRISPR gRNA 
HOTTIP 3P and siRNA HOTTIP KD 2 with HOXA13. This raises the potential issue of 
off-target effects and the resultant data may be a result of HOXA13 depletion as well 
as or instead of the intended HOTTIP depletion. Ensuring specificity would have 
improved the quality of the data in this chapter. Further optimisation of the 




improve the significance of the data observed in this chapter, adding confidence to 
the suggestion of a potential chemosensitive role of HOTTIP in CRC and PCa. Knock-
down success was checked regularly but was not performed for every experiment; 
therefore, providing confirmation of siRNA knockdown (via qPCR/Sanger 










Homeobox protein HOX-A13 (HOXA13) is one of the Homebox A Cluster (HOXA) 
genes involved in animal development and is located at the 5’ end of the HOXA 
cluster (Yamamoto et al., 2019) . The lncRNA HOTTIP is located in close proximity to 
HOXA13 (Wang et al., 2011), as described in Chapter 3. HOXA13 is a transcription 
factor (Qin et al., 2019) and a highly conserved gene, and has roles in gene 
regulation during embryonic development (Wang et al., 2016).  
HOX genes are involved in many cellular functions and therefore any 
mutational changes or downregulation of HOX genes has the potential to contribute 
to tumour development and progression (Wang et al., 2016). Upregulation of 
HOXA13 has been associated with some cancers, including gastric (Chang et al., 
2016; Qin et al., 2019), pancreatic (Li et al., 2015), liver (Quagliata et al., 2018) and 
prostate (Zhang et al., 2016). This has been outlined further in Chapter 1 (Section 
1.4.1). 
Although having previously being described in gastrointestinal (GI) cancers, 
this study will focus specifically on outlining the role of HOXA13 in the progression of 
colorectal cancer (CRC) which has not yet been investigated. The role of HOXA13 in 
prostate cancer (PCa) will also be explored. It will be determined whether HOXA13 




chemotherapy treatment and whether it influences the progression of the disease 
through promoting cell movement and migration.  
 
4.2 siRNA mediated depletion of HOXA13 results in reduced expression of 
other HOXA genes and the lncRNA HOTTIP in CRC and PCa. 
Two siRNAs targeted to transiently knockdown (KD) the expression of HOXA13 have 
been used throughout this study to investigate the role of HOXA13 in CRC and PCa. 
These have been named HOXA13 KD 1 and HOXA13 KD 2. All experiments have 
included non-targeting (NTC) siRNA controls to reduce false positive results or any 
changes occurring due to off-target effects. Three cell lines were used: HCT116 
(Brattain et al., 1981), RKO1 (Brattain et al., 1984) (both CRC) and DU145 (Stone et 
al., 1978) (PCa).  
To confirm successful knockdown of HOXA13 in each of the three cell lines, 
gene expression levels were checked for sufficient HOXA13 depletion. The 
subsequent expression of other HOXA genes and the lncRNA HOTTIP (Chapter 3) 
were also measured. Cells were seeded in 6-well plates and transfected with either 
HOXA13 targeting or NTC siRNA. RNA was extracted from cells 72 h after siRNA 
transfection and cDNA was subsequently reverse transcribed. Gene expression levels 
were quantified using qPCR and data normalised to the ribosomal protein L19 (L19) 
gene. 
Over 60 % HOXA13 depletion was observed in each of the three cell lines 




cells with siRNA HOXA13 KD 1, expression of all nearby genes (HOTTIP, HOXA13, 
HOXA11, HOXA9 and HOXA1) was reduced (Figure 4.1A). This was found to be 
significant for both HOXA13 and HOXA11, located adjacent to HOXA13 on the HOXA 
cluster. HCT116 cells transfected with HOXA13 KD 2 resulted in reduced expression 
of HOTTIP, HOXA13 and HOXA9, however this was not found to be statistically 
significant. In HOXA13 depleted RKO1 cells, all nearby genes were significantly 
reduced (HOTTIP, HOXA13, HOXA11, HOXA9, HOXA1) with the exception of HOXA11 
when cells were transfected with HOXA13 KD 2 (Figure 4.1B). In HOXA13 depleted 
DU145 cells, both HOTTIP and HOXA13 expression was significantly reduced. 
Reduced HOXA9 and HOXA2 expression was observed in DU145 cells transfected 
with HOXA13 siRNA 2 KD, however this was not significant (Figure 4.1C). 
To summarise, in the CRC cell lines (HCT116 and RKO1), HOXA13 depletion 
resulted in significant downregulation of HOTTIP and HOXA genes. In the PCa cell 
line (DU145), HOXA13 depletion resulted in significant downregulation of HOTTIP. 
Together these data suggest that a reduction in HOXA13 expression also results in a 
reduction in HOTTIP expression in HCT116, RKO1 and DU145 cell lines. HOXA13 
expression also influences other HOXA genes in CRC, with the most prominent effect 
seen in the RKO1 cell line, however HOXA13 depletion does not influence the 
expression of other HOXA genes in the prostate cancer cell line (DU145). HOTTIP has 
previously been described as regulating nearby HOXA genes, including HOXA13 in 
mouse models (Pradeepa et al., 2017). This observation has now been replicated in 
the HCT116, RKO1 and DU145 cell lines. Significant HOXA13 depletion in each cell 




confirmed alongside functional assays to investigate the role of HOXA13 in HCT116, 







Figure 4.1 siRNA mediated HOXA13 depletion gene expression 
(A) HCT116, (B) RKO1 and (C) DU145 cells were transfected with siRNA targeting HOXA13 or NTC for 72 
h. RNA was subsequently extracted and cDNA synthesised. Gene expression levels of target genes 
(HOTTIP, HOXA13, HOXA11, HOXA9, HOXA1) were quantified and compared to control via qPCR. Data 
are mean (± S.E.M) expression of 3 biological replicates (N=3), analysed by RT-qPCR and normalized to 
L19. Two-way ANOVA with Dunnett’s multiple comparison test was used to quantify the statistical 




4.3  Investigating the role of HOXA13 expression in the movement and 
migration of CRC and PCa cells.  
HOXA13 has previously been described alongside HOTTIP (Chapter 3), to promote 
cell proliferation, migration and invasion in pancreatic (Li et al., 2011),  gastric 
(Chang et al., 2016; Qin et al., 2019), esophageal squamous cell (Shen and Chen, 
2011), and prostate cancer (Zhang et al., 2016; Dong et al., 2017a). The functional 
role of HOXA13 in HCT116, RKO1 and DU145 will be explored to understand if this is 
also found in these cell lines. 
 
4.3.1  HOXA13 does not influence single cell motility in CRC and PCa. 
Single cell tracking analysis was used to analyse the motility of CRC and PCa cells 
following manipulation of HOXA13 levels. This will indicate whether HOXA13 has a 
role in cancer cell migration. To enable fluorescent detection, CYTO-ID dye (Enzo life 
sciences) was used to label cells. Dyed, siRNA transfected cells were seeded sparsely 
into 96 well plates so individual cells could be tracked with a Nikon Widefield 
microscope. Images were taken every 20 minutes for 24 h. Cells were placed in a 
humidified CO2 chamber to retain their optimum culturing conditions whilst being 
imaged.  Average cell speeds calculated using the Trackmate plug in on Image J 
(Tinevez et al., 2017). 
The range of cell speeds was reduced for HOXA13 depleted HCT116 cells, 
however the change in motility was not found to be significant (Figure 4.2A). An 
increase in cell motility was observed for RKO1 cells transfected with HOXA13 KD 1; 




(Figure 4.2B). No significant difference in cell motility was observed for HOXA13 
depleted DU145 cells, however the range of DU145 cells transfected with siRNA 
HOXA13 KD 1 was reduced compared to NTC (Figure 4.2C). 
Overall, despite some differences in motility observed between HOXA13 
depleted and NTC cells, this was not significant in any cell line. Therefore, it cannot 







Figure 4.2 Single cell tracking analysis of siRNA mediated HOXA13 depletion. 
Single cell tracking was used to measure the average speed of siRNA mediated HOXA13 depleted and 
NTC (A) HCT116, (B) RKO1 and (C) DU145 cells. After sparsely being seeded in 96-well plates, cells 
were placed in a humidified CO2 chamber attached to a Nikon Widefield microscope where images 
were taken every 20 min for 24h. Individual cells were tracked and average speeds were calculated 
using ImageJ Fiji. Data are mean (± S.E.M) expression of 3 biological replicates (N=3). Kruskal-Wallis 





4.3.2  HOXA13 depletion has no significant effect of migration rate in CRC and PCa. 
Wound healing assays were implemented to measure the migration rates of 
HOXA13 depletion in HCT116, RKO1 and DU145 cancer cells. To do this, cells were 
seeded in 6-well plates so they reached 100% confluency within 24 h. A ‘wound’ was 
created in each well by scratching a gap in the confluent cells with a P20 pipette tip. 
A Nikon Widefield microscope was used to take pictures of each well every 20 
minutes over a 24 h period. Cells were placed in a humidified CO2 chamber to retain 
their optimum culturing conditions. The percentage of cell coverage at each time 
point was analysed using ImageJ (Schindelin et al., 2012). 
HOXA13 depleted HCT116 cells exhibited a reduction in cell migration when 
transfected with HOXA13 KD 1 (41 % reduction) or HOXA13 KD 2 (58 % reduction) 
siRNAs, however this was not found to be significant (Figure 4.3A). HOXA13 depleted 
RKO1 cells showed no significant difference in cell migration rate compared to 
control (Figure 4.3B). In DU145 cells, a reduction in migration was observed for 
HOXA13 depleted cells, however this again was not significant (HOXA13 KD 1 = 38 % 
reduction, HOXA13 KD 2 = 33 % reduction), (Figure 4.3C). More data would have to 
be collected before it can be concluded whether HOXA13 has a role in cell migration 







Figure 4.3 siRNA mediated HOXA13 depletion reduces migration of cancer cells. 
Wound healing assays were carried out to measure the migration rates of siRNA mediated HOXA13 
depletion in (A) HCT116, (B) RKO1 and (C) DU145 cells. ‘Wounds’ were tracked over 24 h and HOXA13 
KD cell migration was calculated relative to NTC. Representative microscopy images of HOXA13 KD 
and control ‘wounds’ in (D) HCT116, (E) RKO1 and (F) DU145 cells at 0 h, 12 h and 24 h after initial 
scratching of wound. All data are mean (± S.E.M) of 3 biological replicates (N=3) relative to 100% 






4.3.3  Investigating the effect of HOXA13 on CRC and PCa cell proliferation. 
The effect of HOXA13 depletion on growth rates was investigated. After siRNA 
transfection, cells were seeded in 96-well plates and grown for up to 8 days. After 
each time point, cells were fixed and stained with crystal violet prior to colorimetric 
analysis (OD 490nm), growth rates were calculated relative to day 0 (no growth).  
In HOXA13 depleted HCT116 cells a loss in proliferation was observed 
compared to control, although this was not significant (Figure 4.4A). Opposingly, a 
significant increase in proliferation was detected in HOXA13 depleted in RKO1 cells 
(Figure 4.4B). In DU145 cells, growth rates are variable for siRNA depleted cells and 
no significant effect was found compared to NTC (Figure 4.4C). Overall, no significant 
effect on growth rate was found for HOXA13 depleted HCT116 and DU145 cells 
indicating HOXA13 does not contribute to proliferation in these cell lines. HOXA13 
depletion significantly increases the growth rate of RKO1 cells suggesting HOXA13 






Figure 4.4 siRNA mediated HOXA13 depletion in vitro cell growth assay. 
Proliferation of siRNA mediated HOXA13 depleted and NTC (A) HCT116, (B) RKO1, and (C) DU145 cells 
were seeded in 96-well plates and growth rates were measured over an 8-day time series. Growth 
rates are relative to day 0 (no growth). Data are mean (± S.E.M) of 3 biological replicates (N=3). Two-





4.3.4  HOXA13 depletion does not induce increased apoptosis in cancer cells. 
Flow cytometry was used to assess whether HOXA13 depletion leads to an increase 
in apoptosis in HCT116, RKO1 and DU145 cells. After transfection with HOXA13 
targeted or NTC siRNAs, all cells and media were collected and pelleted. Pelleted 
cells were re-suspended in Nicoletti buffer (Riccardi and Nicoletti, 2006) containing 
propidium iodide (PI) that is used to stain apoptotic cells. During the process of 
apoptosis DNA becomes fragmented. As a result, rates of apoptosis can be 
measured by the identification of hypodiploid cells using a DNA stain such as PI.  
Cellular PI intensity was quantified using flow cytometry and rates of apoptosis were 
compared to that of NTC.  
An increase in percentage apoptosis was observed for HOXA13 depleted 
HCT116 cells (Figure 4.5A), however this was non-significant. The opposite was 
observed in RKO1 cells where HOXA13 depletion resulted in a reduction in 
percentage apoptosis (Figure 4.7B); this was also not found to be significant. 
HOXA13 depleted DU145 cells exhibited a significant increase in apoptosis (Figure 
4.5C), suggesting that HOXA13 may have a role in role in protecting DU145 cells 







Figure 4.5 Apoptosis of siRNA mediated HOXA13 depleted CRC and PCa cells. 
After transfection for 72 h with siRNA targeting HOXA13 or NTC, all cells and media were collected 
and pelleted. Pellets were re-suspended in Nicoletti buffer and DNA hypodiploidy analysis was carried 
out using flow cytometry. Percentage apoptosis of HOXA13 depleted (A) HCT116, (B) RKO1 and (C) 
DU145 cells. (D) Representative flow cytometry plots of HOXA13 depleted and NTC HCT116, RKO1 
and DU145 cells, average Sub-G1 percentages are highlighted in red. Data are mean (± S.E.M) of 3 
biological replicates (N=3). Two-way ANOVA with Dunnett’s multiple comparisons test was used to 




4.3.5 HOXA13 depletion does not drive cell cycle progression 
Flow cytometry was used to determine whether HOXA13 has roles in cell cycle 
progression in CRC or PCa. Cell cycle assays assess cellular DNA content and indicate 
what percentage of cells in a sample are in each stage of the cell cycle (Kim and 
Sederstrom, 2015). Cells were transfected with HOXA13 targetting or NTC siRNA for 
72 h, after which point all cells and media were pelleted and fixed so the cell cycle 
stage of each cell could be analysed. The fixative was removed and samples were re-
suspended in a stain containing PI. A flow cytometer was used to measure the 
percentage of cells in each stage of the cell cycle (G1, S, G2/M) to see if there is a 
change in this distribution when HOXA13 is depleted in HCT116, RKO1 or DU145 
cells.  
In HCT116 cells, HOXA13 depletion resulted in an increase in G1 and S phase, 
and a decrease in G2/M phase, although this was not a significant effect (Figure 
4.6A). HOXA13 depleted RKO1 cells exhibited an increase in G1 phase, however S 
phase was reduced. RKO1 cells transfected with HOXA13 KD 1 exhibited a loss in the 
number of cells in G2/M phase, however this remained unchanged for RKO1 
transfected with HOXA13 KD 2 – again these changes were non-significant (Figure 
4.6B). The percentage of cells in G1 phase was reduced whereas G2/M phase was 
increased in HOXA13 depleted DU145 cells. DU145 cells transfected with HOXA13 
KD 1 exhibited an increase in S phase whereas DU145 cells transfected with HOXA13 
KD 2 exhibited a decrease in S phase (Figure 4.6C). No cell cycle changes were found 
to be significant in DU145 cells. Therefore, these data indicate that HOXA13 does 






Figure 4.6 Cell cycle analysis of siRNA mediated HOXA13 depleted CRC and PCa cells. 
siRNA mediated PSIP1 depleted and NTC HCT116, RKO1 and DU145 cells were analysed via flow 
cytometry to measure the percentage of cells in each stage of the cell cycle. Cell cycle analysis of 
HOXA13 depleted (A) HCT116 (B) RKO1 (C) DU145 cells. (D) Representative flow cytometry plots of 
HOXA13 depleted cells and NTC. Data are mean (± S.E.M) of 3 biological replicates (N=3). Two-way 





4.4  HOXA13 expression protects cancer cells against chemotherapeutic drugs. 
High HOXA13 expression has been linked to chemoresistance in esophageal 
squamous cell carcinoma (ESCC) (Shi et al., 2018), hepatocellular carcinoma 
(Quagliata et al., 2018), gastric cancer (Han et al., 2018), and pancreatic cancer (Li et 
al., 2011). However, this has not yet been documented in CRC or PCa. The following 
chemotherapeutic drugs have been used to investigate whether HOXA13 has a role 
in chemoresistance in CRC or PCa: Fluorouacil (5FU) (Carethers et al., 2004), 
Oxaliplatin (OX) (Comella et al., 2009) that are both commonly used in CRC 
treatment, and Docetaxel (DOC) (Ito et al., 2018) that is frequently used in the 
management of PCa. 
 
4.4.1  The dose response of cancer cells to chemotherapy remains unchanged with 
HOXA13 depletion. 
 
Initially, the dose response of HOXA13 depleted HCT116, RKO1 and DU145 cells to 
chemotherapeutic drugs was tested in order to investigate whether HOXA13 
depletion increases sensitivity of cells to chemotherapy, which would indicate 
chemoresistant properties of HOXA13. siRNA mediated HOXA13 depleted cells were 
seeded in 96-well plates and treated with a dose range of either 5FU, OX or DOC for 
72 h prior to being fixed and stained with crystal violet for colorimetric 
measurement (OD 490 nm). The optical density was calculated relative to no drug 




A significant increase in sensitivity to 0.1 µM 5FU was observed in HCT116 cells 
transfected with HOXA13 KD 2. There was no sensitivity to 5FU observed for the same 
cells transfected with HOXA13 KD 1 (Figure 4.7A). Sensitivity of HOXA13 depleted 
HCT116 cells treated with OX was also observed. This was significant for cells 
transfected with HOXA13 KD 1 and treated with 10 µM OX (Figure 4.7B). Significant 
sensitivity was observed for HOXA13 depleted RKO1 cells treated with 0.1 µM 5FU 
when transfected with HOXA13 KD 1 (Figure 4.8A). RKO1 cells transfected with 
HOXA13 KD 1 exhibited increased sensitivity when treated with 10 µM OX (Figure 
4.8B). Unexpectedly, no sensitivity to DOC was observed in DU145 NTC cells, however 
DU145 cells transfected with HOXA13 KD 1 exhibited significant sensitivity to 10 µM 
of DOC (Figure 4.9). No significant difference was observed for DOC treated DU145 
cells transfected with HOXA13 KD 2. Overall, these data suggest that HOXA13 
depletion may enhances chemosensitivity in these cell lines, particularly when does 
with 1 µM 5FU (HCT116, RKO1), 10 µM OX (HCT116, RKO1) or 10 µM DOC (DU145). 







Figure 4.7 Dose response of siRNA mediated HOXA13 depleted HCT116 cells to 
chemotherapeutic drugs. 
HCT116 cells were transfected with HOXA13 targeting or NTC siRNA for 72 h. Cells were then seeded in 
96-well plates and subsequently treated with a dose response of (A) 5FU (0, 0.1, 1, 10, 100 µM) or (B) OX 
(0, 1, 10, 100, 1000 µM) for a further 72 h. All data are mean (± S.E.M) of 3 biological replicates (N=3). 






Figure 4.8  Dose response of siRNA mediated HOXA13 depleted RKO1 cells to 
chemotherapeutic drugs. 
RKO1 cells were transfected with HOXA13 targeting or NTC siRNA for 72 h. Cells were then seeded in 
96-well plates and subsequently treated with a dose response of (A) 5FU (0, 0.1, 1, 10, 100 µM) or (B) 
OX (0, 1, 10, 100, 1000 µM) for a further 72 h. All data are mean (± S.E.M) of 3 biological replicates 
(N=3). Two-way ANOVA with Dunnett’s multiple comparisons test was used to quantify statistical 







Figure 4.9 Dose response of siRNA mediated HOXA13 depleted DU145 cells to 
chemotherapeutic drugs. 
DU145 cells were transfected with HOXA13 targeting or NTC siRNA for 72 h. Cells were then seeded 
in 96-well plates and subsequently treated with a dose response of DOC (0, 0.1, 1, 10, 100 µM) for a 
further 72 h. All data are mean (± S.E.M) of 3 biological replicates (N=3). Two-way ANOVA with 






4.4.2 Depletion of HOXA13 leads to an increase in cell death when CRC and PCa cells 
are treated with chemotherapeutic drugs. 
After investigating sensitivity to chemotherapy in cancer cells with reduced HOXA13 
expression, rates of cell death (apoptosis) of these cells after exposure to 10 µM 
5FU, 10 µM OX or 1 µM DOC was tested. Cells were treated with chemotherapeutic 
drugs and incubated for different time points: 24 h, 48 h, 72 h. A no drug 
comparison was also included for each cell line. Flow cytometry was used to 
quantify the percentage of cells undergoing apoptosis as described above (Section 
4.3.4). HOXA13 depleted cells were compared to NTC and no drug controls. 
After 72 h siRNA knockdown, HOXA13 depleted cells exhibited an increase in 
the percentage of cells undergoing apoptosis. With the addition of chemotherapy, a 
significant increase in apoptosis was also observed for HOXA13 depleted HCT116 
cells treated with 5FU for 48 h or treated with OX for 48 h or 72 h (Figure 4.10). A 
reduction in apoptosis was observed in HOXA13 depleted RKO1 cells prior to the 
addition of chemotherapy. This was also observed with the addition of 5FU and OX 
treatment (Figure 4.11), however this was not found to be significant. A significant 
increase in apoptosis was also observed in the PCa cell line (DU145) when HOXA13 
expression was depleted, and this was also witnessed when cells were treated with 
DOC (Figure 4.12). Together, these data further confirm that HOXA13 depleted 
HCT116 cells exhibit sensitivity to chemotherapeutic drugs. DU145 cells exhibited an 
increase in apoptosis prior to chemotherapy treatment suggesting increased 






Figure 4.10 Sensitivity of siRNA mediated HOXA13 depleted HCT116 cells to 
chemotherapy. 
HCT116 cells were transfected with HOXA13 targeting or NTC siRNA for 72 h and subsequently 
treated with (A) 10 µM 5FU or (C) 10 µM OX for DNA hypodiploidy analysis using a flow cytometer at 
24 h, 48 h, 72 h after initial treatment. No drug controls were also included. Data are mean (± S.E.M) 
of 3 biological replicates (N=3). Two-way ANOVA with Dunnett’s multiple comparisons test was used 
to quantify statistical significance (***P<0.001, ****P<0.0001). Representative flow cytometry plots 






Figure 4.11 Sensitivity of siRNA mediated HOXA13 depleted RKO1 cells to chemotherapy. 
RKO1 cells were transfected with HOXA13 targeting or NTC siRNA for 72 h and subsequently treated 
with (A) 10 µM 5FU or (C) 10 µM OX for DNA hypodiploidy analysis using a flow cytometer at 24 h, 48 
h, 72 h after initial treatment. No drug controls were also included. Data are mean (± S.E.M) of 3 
biological replicates (N=3). Two-way ANOVA with Dunnett’s multiple comparisons test was used to 
quantify statistical significance (***P<0.001, ****P<0.0001). Representative flow cytometry plots of 






Figure 4.12 Sensitivity of siRNA mediated HOXA13 depleted DU145 cells to chemotherapy. 
DU145 cells were transfected with HOXA13 targeting or NTC siRNA for 72 h and subsequently treated 
with (A) 1 µM DOC OX for DNA hypodiploidy analysis using a flow cytometer at 24 h, 48 h, 72 h after 
initial treatment. No drug controls were also included. Data are mean (± S.E.M) of 3 biological 
replicates (N=3). Two-way ANOVA with Dunnett’s multiple comparisons test was used to quantify 
statistical significance (***P<0.001, ****P<0.0001). (B) Representative flow cytometry plots of DOC 






4.4.3 Chemotherapeutic drugs do not induce arrest in cell cycle phases when 
HOXA13 is depleted in CRC and PCa. 
Cell cycle analysis of HOXA13 depleted cancer cells treated with chemotherapeutic 
drugs was then investigated. HCT116, RKO1 or DU145 cells were transfected with 
HOXA13 targeted or NTC siRNA for 72 h and subsequently treated with 10 µM 5FU, 
10 µM OX or 1 µM DOC for a further 72 h. No drug controls were also included in this 
analysis. A flow cytometer was used to measure the percentage of cells in each stage 
of the cell cycle as outlined previously (4.3.5).   
An increase in S and G1 phase and a decrease in G2/M phase was observed in 
HOXA13 depleted HCT116 cells prior to the addition of chemotherapy treatment 
(Figure 4.13A). When treated with 5FU, HOXA13 depleted HCT116 cells exhibited an 
increase in S phase, and a decrease in G2/M and G1 phase (Figure 4.13B). When 
treated with OX, HCT116 cells transfected with HOXA13 KD 1 siRNA did not exhibit 
any changes in the cell cycle (<1 %). However, when transfected with HOXA13 KD 2, 
an increase in S and a decrease in G2/M phase was observed (Figure 4.13C). However, 
these changes were not found to be statistically significant. 
 Prior to chemotherapy treatment, HOXA13 depleted RKO1 cells displayed a 
decrease in S phase compared to NTC, as well as a decrease in G2/M observed in RKO1 
cells transfected with HOXA13 KD 1. (Figure 4.14A). HOXA13 depleted RKO1 cells 
exhibited a loss of cells in S and G2/M phase, and an increase in G1 phase when 




exhibited an increase in G1 phase and a decrease in G2/M phase (Figure 4.14C). Again, 
none of these changes were significant for HOXA13 depleted RKO1 cells.  
An increase in G2/M and a decrease in G1 phase was observed in HOXA13 
depleted DU145 cells that were not subjected to chemotherapy treatment. DU145 
cells transfected with HOXA13 KD 1 exhibited an increase in S phase, however a 
reduction in S phase was observed with DU145 cells transfected with HOXA13 KD 2 
(Figure 4.15A). When treated with DOC, HOXA13 depleted DU145 cells exhibited an 
increase in G2/M, whereas a decrease in S phase was observed. The percentage of 
cells in G1 phase increased when DU145 cells were transfected with HOXA13 KD 1 and 
treated with DOC, whereas the opposite was observed for DU145 cells transfected 
with HOXA13 KD 2 and treated with DOC (Figure 4.15B). No changes in cell cycle stage 
of HOXA13 depleted DU145 cells was found to be significant. Overall, no significant 
change in the percentage of cells in each stage of the cell cycle was observed for 






Figure 4.13 Cell cycle analysis of siRNA mediated HOXA13 depletion in HCT116 cells. 
After 72 h of siRNA mediated HOXA13 depletion, HCT116 cells were treated with (A) no drug (B) 10 µM 
5FU or (C) 10 µM OX for 72 h and the percentage of cells in each stage of the cell cycle was analysed 
via flow cytometry. Data are mean (± S.E.M) of 3 biological replicates (N=3). Two-way ANOVA with 
Dunnett’s multiple comparisons test was used to quantify statistical significance. (D) Representative 






Figure 4.14 Cell cycle analysis of siRNA mediated HOXA13 depletion in RKO1 cells. 
After 72 h of siRNA mediated HOXA13 depletion, RKO1 cells were treated with (A) no drug (B) 10 µM 
5FU or (C) 10 µM OX for 72 h and the percentage of cells in each stage of the cell cycle was analysed 
via flow cytometry. Data are mean (± S.E.M) of 3 biological replicates (N=3). Two-way ANOVA with 
Dunnett’s multiple comparisons test was used to quantify statistical significance. (D) Representative 





Figure 4.15 Cell cycle analysis of siRNA mediated HOXA13 depletion in DU145 cells. 
After 72 h of siRNA mediated HOXA13 depletion, cells were treated with (A) no drug or (B) 1 µM DOC 
for 72 h and the percentage of cells in each stage of the cell cycle was analysed via flow cytometry. 
Data are mean (± S.E.M) of 3 biological replicates (N=3). Two-way ANOVA with Dunnett’s multiple 
comparisons test was used to quantify statistical significance. (C) Representative flow cytometry plots 























4.5  Discussion 
In this chapter, the effect of HOXA13 depletion on CRC and PCa cells was 
investigated. As mentioned previously, upregulation of HOXA13 has be implicated in 
gastric (Chang et al., 2016; Qin et al., 2019), pancreatic (Li et al., 2015), liver 
(Quagliata et al., 2018) and prostate (Zhang et al., 2016) cancer. 
4.5.1  HOXA13 depletion results in depletion of other HOXA genes in CRC. 
Upon siRNA mediated HOXA13 depletion, significant downregulation of HOXA11 was 
observed in both CRC cell lines (HCT116, RKO1). In HOXA13 depleted RKO1 cells, 
significant downregulation was also observed in all other HOXA genes tested 
(HOXA9, HOXA1) and the lncRNA HOTTIP. It has been previously described that 
multiple HOX genes can be aberrantly expressed at the same time in cancer 
(Bhatlekar, Fields and Boman, 2018; Tatangelo et al., 2018). However, this is the first 
time a regulatory link between HOXA13 and other HOX genes has been witnessed in 
CRC.  
HOTTIP expression was reduced in HOXA13 depleted RKO1 and DU145 cells. 
Other studies have shown that HOTTIP can contribute to the progression of cancer 
by regulating HOXA13 (Li et al., 2015; Zhang et al., 2016); this study has shown that 
this may also work in the opposite fashion, where upon HOXA13 depletion, HOTTIP 
expression is also reduced in RKO1 and DU145 cells. This could be a result of 
changes in occupancy of the WDR5/MLL protein complex that is known to regulate 




4.5.2 HOXA13 depletion has no effect on the migration and proliferation of CRC and 
PCa cell lines. 
Previous literature has described HOXA13 as promoting cell proliferation, migration 
and invasion in pancreatic (Li et al., 2011), gastric (Chang et al., 2016; Qin et al., 
2019), esophageal squamous cell (Shen and Chen, 2011), and prostate cancer (Zhang 
et al., 2016; Dong et al., 2017a).  siRNA mediated HOXA13 depletion had no 
significant effect on HCT116, RKO1 or DU145 motility and no significant difference 
was observed in HOXA13 depleted HCT116 or DU145 cells; this opposes what has 
been previously reported in the literature, where HOXA13 has been implicated in 
gastric cancer through promoting metastasis (Chang et al., 2016). However, HOXA13 
depleted RKO1 cells exhibited a highly significant increase in proliferation compared 
to NTC. This may suggest a possible tumour suppressive role of HOXA13 in this cell 
line. Other HOX genes have been described as having tumour suppressor-like 
properties in CRC, such as HOXB13 (Xie et al., 2019) and HOXD8 (Mansour and 
Senga, 2017). However, further work will need to be carried out before confirming 
this in HOXA13. 
No significant difference in apoptosis was observed in the CRC cell lines 
(HCT116, RKO1) when cells were depleted of HOXA13. In contrast, a significant 
increase in percentage apoptosis was observed for HOXA13 depleted DU145 cells. 
This indicates that HOXA13 may inhibit apoptosis in PCa, supporting what has been 
observed in other studies (Dong et al., 2017a). HOX genes have been found to 
interact with factors that promote cell cycle progression (Falaschi, Abdurashidova 




activating the Wnt and TGF-β pathways when depleted in other tumours such as in 
glioma (Duan et al., 2015). The Wnt pathway is a critical pathway that becomes 
hyperactivated and drives CRC progression (Schatoff, Leach and Dow, 2017) and is 
associated with late stage PCa (Yeh et al., 2019). However, no involvement in cell 
cycle promotion in either CRC or PCa was observed for HOXA13 in this study, 
contradicting what has previously been stated in the literature.  
4.5.3 HOXA13 has chemoresistant properties in CRC and PCa. 
Chemoresistant properties of HOXA13 has been described in cancers including 
esophageal squamous cell carcinoma (Shi et al., 2018), gastric (Han et al., 2018), and 
pancreatic (Li et al., 2015). HOXA13 has been described as contributing to 5FU 
resistance in gastric cancer, where affects the stomach and therefore is in close 
proximity to the colon (Han et al., 2018). Here, HOXA13 depleted HCT116 and RKO1 
cells were more sensitive to both 5FU (0.1 µM) and OX (10 µM) treatment compared 
to NTC when testing dose response. Sensitivity to 10 µM DOC treatment was also 
observed in HOXA13 depleted DU145 cells. These data therefore suggest HOXA13 
may also have a chemosensitive role in CRC and PCa. This is further aided by the 
significant increase in the percentage of cells undergoing apoptosis observed for 
HOXA13 depleted HCT116 cells treated with 5FU for 48 h and OX for 48 and 72 h 
compared to NTC.  
On the other hand, when treated with chemotherapeutic drugs, HOXA13 
depleted cells did not exhibit increased sensitivity. Discrepencies between each 




difficult to draw conclusions. This highlights the importance of using a panel of 
siRNAs to knockdown target gene expression. 
An interesting observation that has been made throughout this study is the 
difference between the CRC cell lines (HCT116 and RKO1). HOXA13 depletion in 
RKO1 cells results in significant changes in cellular function when there are no 
changes observed in HCT116. Both cell lines are derived from similar stages of 
disease metastasis (Boyd et al., 1988; Arango et al., 2004) so it is not a result of 
differing disease stage. One explanation is the possibility of increased transfection 
efficiency of RKO1 cells – a greater HOXA13 depletion could be causing the 
difference in results, rather than the difference in cell line. The addition of 
employing CRISPR-Cas9 to permanently delete HOXA13 expression may provide 
further clarification to the role of HOXA13 in HCT116, RKO1 and DU145.  
4.6 Summary 
In summary, HOXA13 depletion resulted in depletion of other HOXA genes (HCT116, 
RKO1) and the lncRNA HOTTIP (RKO1, DU145), suggesting that HOXA13 expression 
may influence the expression of other HOXA genes and HOTTIP in these cell lines. 
When exploring the functional role of HOXA13, no effect on cell migration or 
proliferation in HCT116 or DU145 cells was evident. The exception was RKO1 cells 
where HOXA13 depletion resulted in an increase in cell motility and proliferation.  
One observation from this study was the increased sensitivity of the cell lines 
to chemotherapy when HOXA13 expression was depleted. This suggests a potential 




should be carried out to confirm this role, particularly in CRC, as this has not yet 
been described in this cancer. If characterised further by other studies to have 
chemosensitive properties in CRC and PCa, HOXA13 could be used as a prognostic 
biomarker to stratify patients who may or may not respond to treatment with these 
drugs, allowing alternative drugs or therapies to be investigated in order to achieve 
a more promising clinical result. 
Limitations of this work include discrepancies between siRNAs targeting 
HOXA13. Including a larger panel of siRNAs would improve the quality of the data 
and ensure conclusions can be drawn confidently. Knock-down success was checked 
regularly but was not performed for every experiment; therefore, providing 
confirmation of siRNA knockdown (via qPCR/Sanger sequencing) for each of the cell 
assays would also add confidence to this data. Further optimisation of the 
chemotherapeutic drug assays (time points, concentrations, controls) would 
improve the significance of the data observed in this chapter, adding confidence to 
the suggestion of a potential chemosensitive role of HOXA13 n CRC and PCa. As 
mentioned, producing a HOXA13 stable KO cell line via CRISPR-Cas9 may provide 










PSIP1 (PC4 and SFRS1 Interacting Protein 1) or LEDGF (Lens epithelium-derived growth 
factor) is a chromatin binding protein (Singh et al., 2017) involved in gene regulation. 
It encodes two isoforms: PSIP1/p52 and PSIP1/p75 that occur as a result of alternative 
splicing. These isoforms interact with the transcription factor PC4 (Positive Cofactor 
4), where they act as transcriptional coactivators (Ge, Si and Roeder, 1998; Ge, Si and 
Wolffe, 1998). PSIP1 is an epigenetic reader of H3K36me2/me3 and preferentially 
binds to actively transcribed chromatin, promoting gene expression (Pradeepa et al., 
2012; El Ashkar et al., 2017). It has been established in mouse models that Psip1 is 
involved in the transcriptional regulation of Hox genes (Pradeepa et al., 2012, 2014). 
In humans, the PSIP1 gene is located on chromosome 9 (p22.3). 
PSIP1 has been linked to multiple diseases; the most prominent being its role 
in promoting replication of the HIV-1 virus (Pradeepa et al., 2012; Baid et al., 2013). 
PSIP1 guides HIV-1 integration into host DNA through binding to integrase protein (IN) 
and tethering it to chromatin (Marshall et al. 2007). PSIP1 has also been implicated in 
cancer, including breast (Deepak K. Singh et al., 2017), ovarian (French et al., 2016) 
and prostate cancer (Basu et al. 2012; Ríos-Colón et al. 2017).  PSIP1 has been well 
documented in leukaemia as a result of interacting with Mixed Lineage Leukaemia 1 
(MLL1)/MEN1 (MENIN) to form an oncogenic complex that binds to target genes 
(Cermakova et al., 2016; El Ashkar et al., 2018). PSIP1 also interacts with the MLL1 




(Pradeepa et al., 2017),  as described in Chapter 3. However, there is a lack of 
information on whether PSIP1 has a role in promoting colorectal cancer (CRC). 
This chapter will outline the role of PSIP1 in the progression of CRC and 
investigate whether PSIP1 has a role in protecting cancer cell death when put under 
stress from treatment with chemotherapeutic drugs.  
5.2 The role of PSIP1 in cancer 
To investigate the role of PSIP1 in cancer, and whether this protein is a valid target to 
investigate as a therapeutic option, online databases (kmplot.com) (Györffy et al., 
2010) were interrogated and Kaplan-Meier (K-M) survival plots generated to examine 
if PSIP1 expression levels correlate with patient survival in rectal adenocarcinoma 
(Figure 5.1A). This carcinoma was chosen as it can be classed as a type of CRC and can 
give a good indication if PSIP1 levels correlate with patient survival in other colorectal 
cancers. K-M plots of lung adenocarcinoma and cervical squamous cell carcinoma 
were also generated as a comparison to CRC. High levels of PSIP1 were correlated with 
lower survival in rectal adenocarcinoma (Figure 5.1A), however this was not found to 
be significant (P=0.06). On the other hand, lower PSIP1 expression is beneficial to 
survival in both lung adenocarcinoma (Figure 5.1B) and cervical squamous cell 
carcinoma (Figure 5.1C). This was found to have significant correlation (P=0.048) in 
lung carcinoma and highly significant correlation (P=0.0089) in cervical squamous cell 
carcinoma. Analysis of the literature and available online data such as in Figure 5.1, 






Figure 5.1 Kaplan-Meier survival plots of PSIP1 expression levels in cancer 
Kaplan-Meier survival plots generated by a meta-analysis of RNA-seq data using kmplot online 
software (kmplot.com) to determine if PSIP1 is correlated with increased or decreased survival rates 
in cancer. The probability of survival (y-axis) is plotted against the time (months) a patient is 
estimated to survive the disease (x-axis). Black lines indicate low PSIP1 expression and red lines 
indicate high PSIP1 expression, N=number of patients in each dataset. (A) Rectum adenocarcinoma, 





5.3 Validating siRNA mediated PSIP1 depletion and stable CRISPR-Cas9 PSIP1 
knockout colorectal cancer cell lines. 
 
5.3.1 siRNA mediated depletion of PSIP1. 
In order to determine the role of PSIP1 in CRC, siRNAs were employed to knockdown 
(KD) PSIP1 levels in CRC cells. Two siRNAs were used to deplete PSIP1 and all 
experiments were carried out with non-targeting (NTC) siRNA controls to reduce false-
positive results or any changes occurring due to off-target effects. siRNA mediated 
PSIP1 depletion was carried out in HCT116 CRC cells, a cell line derived from a human 
colonic carcinoma (Brattain et al., 1981).  
To confirm successful depletion of PSIP1 in HCT116, cells were seeded in 6-
well plates and transfected with either PSIP1 targeting or NTC siRNA. After 72 h, cells 
were harvested, and the protein lysate was extracted. A protein quantification assay 
(BioRad DC assay) was used to quantify each protein sample prior to SDS-PAGE. 
Immunoblotting was performed using antibodies specific for PSIP1 or Proliferating cell 
nuclear antigen (PCNA) (housekeeping control protein). WT HCT116 total protein 
lysate was also used as an additional control. 
PSIP1 depletion was successful at the protein level when transfected with both 
siRNAs (PSIP KD 1 and PSIP KD 2), compared to the controls (Figure 5.2). Densitometry 
analysis (Schindelin et al., 2012) was used to determine the percentage knockdown of 
PSIP1 protein compared to non-transfected control (HCT116 WT). HCT116 cells 




2 siRNA was less efficient (36 % depletion) compared to HCT116 WT control. Non-
targeting controls (NTC1 and NTC2) were also compared to HCT116 WT control. NTC1 
showed some reduction in PSIP1 expression compared to HCT116 WT (20 %) 
indicating some loss of PSIP1 as a result of this transfection. However, when compared 
to HCT116 WT, NTC2 showed an increase in protein expression (49 % increase). 
Although care was taken to load equal protein concentrations, discrepancies in what 
was loaded could account for this increase in expression compared to WT. NTC1 and 
2 will be averaged for experiments going forward to take in to account this fluctuation 
in protein expression between the two controls. This confirms successful siRNA 
mediated depletion of PSIP1 in HCT116 cells. This depletion was checked regularly for 
future siRNA knockdown experiments when investigating the functional role of PSIP1 





Figure 5.2 HCT116 siRNA mediated PSIP1 depletion validation via Western blot analysis. 
HCT116 cells were seeded in 6-well plates and transfected with PSIP1 targeting (PSIP KD 1, PSIP KD 2) 
or NTC (NTC1, NTC2) siRNA. Protein lysate was extracted 72 h after transfection and expression levels 
were analysed via western blot. A total HCT116 protein lysate control was also included (HCT116 WT) 
and treated as 100% protein expression when calculating densitometry values. Protein expression 





After validation of siRNA mediated PSIP1 depletion in HCT116 cells, changes in gene 
expression levels of the lncRNA HOTTIP and nearby HOXA genes, as a result of this 
depletion, were investigated. It has been previously shown (Pradeepa et al., 2017) 
that Psip1 regulates the expression of Hottip in mouse models and in turn, the 
expression of HOXA13, a HOXA gene that is located in close proximity to HOTTIP 
(Chapter 3 & 4). The expression levels of these target genes were measured to explore 
if this same regulation pattern is followed in CRC. Cells were therefore harvested 72 
h after siRNA transfection, RNA was extracted, and cDNA synthesised subsequently. 
Target gene expression (HOTTIP, HOXA13, HOXA1) was quantified using qPCR and 
data normalised to the ribosomal protein gene L19.  
Loss of HOXA13 expression was observed in PSIP1 depleted samples compared to NTC 
(Figure 5.3). This was significant for cells transfected with PSIP KD 2. HOTTIP and 
HOXA1 expression were also reduced as a result of PSIP1 depletion, however this was 
not found to be significant. This suggests that PSIP1 has a role in regulating HOXA13 
expression in HCT116, following the regulation pattern seen in other studies 







Figure 5.3 PSIP1 depletion results in reduction of HOTTIP and HOXA genes. 
RNA was extracted from PSIP1 targeted (PSIP KD 1, PSIP KD 2), and NTC siRNA transfected HCT116 cells 
and cDNA was synthesized prior to qPCR analysis. Gene expression levels of target genes (HOTTIP, 
HOXA13, HOXA1) were quantified and compared to control. Data are mean (± S.E.M) expression of 3 
biological replicates (N=3), analysed by qPCR and normalised to L19. Two-way ANOVA with Dunnett’s 







5.3.2 Creating stable PSIP1 knock out lines using CRISPR-Cas9. 
To confirm the siRNA KD results, stable CRISPR-Cas9 PSIP1 knockout (KO) cell lines 
were created - again, the CRC HCT116 cell line was used. A guide RNA (gRNA) was 
designed to interrupt exon 6 of the PSIP1 protein (Figure 5.4), resulting in a 
frameshift mutation which prevents any functional PSIP1 protein from being 
synthesised.  
After CRISPR-Cas9 selection, cells were harvested, and protein lysate was extracted. 
A screen was performed to identify WT (empty plasmid backbone) and PSIP1 KO 
clones.  A protein quantification assay (BioRad DC assay) was used to quantify each 
protein sample prior to SDS-PAGE. Immunoblotting was performed using antibodies 
specific for PSIP1 or PCNA (housekeeping control protein). A total of 48 clones were 
analysed using western blotting with five samples (1 x WT and 4 x PSIP1 KO) being 
sent for Sanger sequencing to validate the desired frameshift mutation. One WT cell 
line and one PSIP1 KO HCT116 cell line were selected (Figure 5.5) for further 
experiments. Densitometry analysis was carried out on the selected WT and PSIP1 
KO cell lines using ImageJ Fiji (Schindelin et al., 2012); it was calculated that the 
PSIP1 KO cell line had a 98.3 % reduction in PSIP1 expression compared to WT 
control. Therefore, a PSIP1 knock-out HCT116 cell line was successfully generated. 
Together siRNA mediated depletion and CRISPR-Cas9 PSIP1 KO cell lines will 
be used to explore the role of PSIP1 in CRC, whether it influences the progression of 






Figure 5.4 Guide RNA targeting of PSIP1 protein in humans and Sanger sequencing validation 
(A) Schematic of the human PSIP1 protein located on chr6.22.3. The red cross marks the location of the 
gRNA used to target PSIP1 and create a frameshift mutation at exon 6 (21 958 bp from TSS) resulting in 
prevention of a functional PSIP1 protein being synthesized. (B) Genomic DNA from WT and positive PSIP1 
KO HCT116 clones were extracted and subsequently sent for Sanger sequencing. Representative 
chromatograms (Snapgene) where the frameshift can be identified after the PAM site (blue box) indicating 






Figure 5.5 CRISPR-Cas9 mediated PSIP1 knockout validation via Western blot analysis 
Protein lysate was extracted from CRISPR-Cas9 mediated PSIP1 KO and WT clones confirmed through 
Sanger sequencing. Protein expression levels of PSIP1 KO and WT control HCT116 cells were analysed 
via western blot. WT control mock transfected with empty CRISPR plasmid backbone (PX459) was 
treated as 100% protein expression when calculating densitometry values. Protein expression was 







5.4 Movement and migration of cancer cells is reduced when PSIP1 expression 
is depleted in HCT116. 
Cancer cell movement and migration is key to the progression of the disease (Leong, 
Chambers and Lewis, 2012). To investigate whether PSIP1 influences progressive 
cancer drivers such as these, a variety of assays were carried out to test the hypothesis 
that movement and migration of cancer cells is reduced when PSIP1 expression is 
depleted in CRC. 
5.4.1 The effect of PSIP depletion on cell motility in colorectal cancer. 
Single cell tracking analysis was used to analyse average cell speeds of PSIP1 depleted 
and control HCT116 cells. This will provide an indication as to whether PSIP1 is 
involved in CRC cell motility. 
For this work, CYTO-ID dye (Enzo life sciences) was used to label cells, allowing 
fluorescence detection. Dyed cells were seeded sparsely in 96-well plates to enable 
individual analysis of a single cell to be possible. A Nikon Widefield microscope was 
used to capture images of cells every 20 minutes over a 24 h period. Cells were placed 
in a humidified CO2 chamber to retain their optimum culturing conditions during this 
time. These images were stitched together and average cell speeds calculated using 
the Trackmate plugin on Image J Fiji (Tinevez et al., 2017).  
Firstly, the average speed of siRNA mediated PSIP1 depleted and NTC HCT116 cells 
were tested. An increase in average cell speed for cells transfected with siRNA PSIP 




PSIP KD 2, with a decrease in average cell speed compared to control (Figure 5.6). 
This was not found to be significant in either case. CRISPR-Cas9 mediated stable 
PSIP1 KO cells exhibited reduced average cell speed compared to WT (Figure 5.7). 
Again, this was not found to be significant. This demonstrates that PSIP1 does not 









Figure 5.6 Single cell tracking analysis of siRNA mediated PSIP1 depleted HCT116 cells 
Single cell tracking was used to measure the average speed of siRNA mediated PSIP1 depleted and NTC 
HCT116 cells. After sparsely being seeded in 96-well plates, cells were placed in a humidified CO2 
chamber attached to a Widefield microscope. Images were taken every 20 min for 24h and average 
speeds were calculated using ImageJ Fiji. Data are mean (± S.E.M) of 3 biological replicates (N=3). Kruskal-
Wallis test with Dunn’s post-hoc test was used to quantify the statistical significance (PSIP KD 1 P>0.9, 










Figure 5.7 Single cell tracking of CRISPR-Cas9 PSIP1 KO cells reduces average cell speed 
Single cell tracking was used to measure the average speed of PSIP1 KO and WT HCT116 cells. After 
sparsely being seeded in 96-well plates cells were placed in a humidified CO2 chamber attached to a 
Widefield microscope. Images were taken every 20 min for 24h and average speeds were calculated 
using ImageJ Fiji. Data are mean (± S.E.M) of 3 biological replicates (N=3). Mann Whitney test was used 






5.4.2 PSIP1 depletion has no significant effect on migration rate of HCT116 cells. 
Wound assays were implemented to measure the migration rates of PSIP1 depleted 
and control CRC cells. To do this, cells were seeded in 6-well plates so they reached 
100 % confluency within 24 h. A ‘wound’ was created in each well by scratching a gap 
in the confluent cells with a P20 pipette tip. A Nikon Widefield microscope was used 
to take pictures of each well every 20 minutes over a 24 h period. Cells were placed 
in a humidified CO2 chamber to retain their optimum culturing conditions during this 
time. The percentage of cell coverage at each time point was analysed using ImageJ 
(Schindelin et al., 2012). 
A reduction in cell migration was observed for PSIP1 depleted cells compared to 
NTC, however this was not a significant difference (Figure 5.8). Similarly, CRISPR-
Cas9 mediated stable PSIP1 KO cells also exhibited a slower migration rate 
compared to WT cells, but this was not significant (Figure 5.9). These findings show 













Figure 5.8 siRNA mediated PSIP1 depletion reduces migration rate of CRC cells 
Wound healing assays were carried out to measure the migration rates of siRNA mediated PSIP1 depletion 
and NTC HCT116 cells. (A) ‘Wounds’ were tracked over 24 h and PSIP1 depleted cell migration was 
calculated relative to NTC. Data are mean (± S.E.M) of 3 biological replicates (N=3). One-way ANOVA with 
Dunnett’s multiple comparison was used to test statistical significance, (PSIP KD 1 P=0.53, PSIP KD 2 
P=0.67).  (B) Representative images of PSIP1 KD and NTC ‘wounds’ at 0 h, 12 h, and 22 h after initial 








Figure 5.9 CRISPR-Cas9 mediated PSIP1 knock out reduces migration rate of CRC cells 
Wound healing assays were carried out to measure the migration rates of PSIP1 KO and WT HCT116 cells. 
(A) ‘Wounds’ were tracked over 24h and PSIP1 KO cell migration was calculated relative to WT. Data are 
mean (± S.E.M) of 3 biological replicates (N=3). Unpaired t-test with Welch’s correction was used to 
quantify statistical significance, P=0.39. (B) Representative images of WT and PSIP KO ‘wounds’ at 0h, 12h, 
and 22h after initial scratching of confluent cells taken using a Nikon Widefield microscope and analysed 







5.4.3 PSIP1 KO significantly slows colony growth in HCT116 cells. 
Colony formation assays were used to further investigate the effect of PSIP1 on 
HCT116 cell growth; this is a measurement of cell viability and the ability of cells in a 
population to continually divide (Puck and Marcus, 1956; Rafehi et al., 2011) . PSIP1 
KO and WT cells were seeded sparsely into 12-well plates and grown for ~10 days to 
allow single cells to form colonies. Plates were fixed and stained with crystal violet for 
analysis. The number of colonies formed was quantified using ImageJ FIji software 
(Schindelin et al., 2012). PSIP1 KO results in highly significant loss of colony formation 
ability compared to WT, P<0.001 (Figure 5.10), suggesting that PSIP1 has roles in 
maintaining HCT116 cell viability and proliferation. 
5.4.4 PSIP1 depletion has no significant effect on the growth rate of HCT116 cells 
After PSIP1 KO cells exhibited a significant reduction in the ability of HCT116 cells to 
form colonies, the effect of PSIP1 deletion on growth rates was tested. Cells were 
seeded in 96-well plates and grown over a time series of up to 8 days. After each 
time point, cells were fixed and stained with crystal violet prior to colorimetric 
measurement (OD 490 nm), growth rates were calculated relative to day 0 (no 
growth). Lines of best fit to measure growth rates for both CRISPR-Cas9 mediated 
stable PSIP1 KO and WT HCT116 cells showed no significant difference in growth 
rate (Figure 5.11). Thus, it can be concluded that PSIP1 does not have a role in 











Figure 5.10 Significant loss of colony formation ability in CRISPR-Cas9 mediated PSIP1 KO cells 
(A) Relative colony number of CRISPR-Cas9 mediated PSIP1 KO compared to WT HCT116 cells. Data are 
mean (± S.E.M) of 3 biological replicates (N=3) relative to control WT cells. Unpaired t-test with Welch’s 
correction was used to quantify the statistical significance (*** P<0.001). (B) Representative wells of 








Figure 5.11 CRISPR-Cas9 mediated PSIP1 knockout cell growth assay 
PSIP1 KO and WT HCT116 cells were seeded in 96-well plates and growth rates were measured over an 8-
day time series. After each time point, cells were fixed and stained prior to colorimetric analysis (OD 490 
nm). Growth rates are relative to day 0 (no growth). Data are mean (± S.E.M) of 3 biological replicates 






5.4.5  PSIP1 depletion has no significant effect on apoptosis in HCT116 cells.  
Flow cytometry was used to assess whether PSIP1 depletion leads to an increase in 
apoptosis of HCT116 cells, again siRNAs were used to knockdown PSIP1 expression. 
72 h after transfection, all cells and media were collected and pelleted. Pelleted cells 
were re-suspended in Nicoletti buffer (Riccardi and Nicoletti, 2006) containing 
propidium iodide (PI) that is used to stain apoptotic cells. During the process of 
apoptosis DNA becomes fragmented. As a result, rates of apoptosis can be measured 
by the identification of hypodiploid cells using a DNA stain such as PI. Cellular PI 
intensity was quantified using flow cytometry and rates of apoptosis were compared 
to NTC siRNA controls. 
An increase in the percentage of cells undergoing apoptosis was observed for 
HCT116 cells transfected with PSIP KD 1 compared to NTC, however this was non-
significant. No change in percentage apoptosis was observed for HCT116 cells 
transfected with PSIP KD 2. Overall, PSIP1 depletion does not result in increased 






Figure 5.12 Apoptosis of siRNA mediated PSIP1 depletion in HCT116 cells 
After transfection for 72 h with siRNA targeting PSIP1 or NTC, all cells and media were collected and 
pelleted. Pellets were re-suspended in Nicoletti buffer for DNA hypodiploidy analysis using a flow 
cytometer. Data are mean (± S.E.M) of 3 biological replicates (N=3). Two-way ANOVA with Dunnett’s 
multiple comparisons test was used to quantify statistical significance (P>0.2). (A) Percentage apoptosis of 
siRNA mediated PSIP1 and NTC HCT116 cells. (B) Representative flow cytometry plots of HCT116 cells 





5.4.6 PSIP1 does not drive cell cycle progression in HCT116 cells. 
PSIP1 has been described as having roles in the cell cycle, particularly in S and G2 
phase (Daugaard et al., 2012). Flow cytometry was used to investigate if this is also 
seen in CRC. Cells were transfected with PSIP1 KD or NTC siRNA for 72 h, after which 
flow cytometry was used to measure the percentage of cells in each stage of the cell 
cycle (G1 vs S vs G2/M). The percentage of cells in each phase of the cell cycle was 
analysed and PSIP1 depleted cells were compared to NTC.  
PSIP1 depletion resulted in an increase in the percentage of cells in both S phase and 
G1 phase compared to NTC; a decrease in G2/M phase was also observed (Figure 
5.13). This replicates what has been seen in other studies (Daugaard et al., 2012), 
however the shifts in percentage of cells to any cell cycle stage were not significant 








Figure 5.13 Cell cycle analysis of siRNA mediated PSIP1 depletion in HCT116 cells 
(A) Cell cycle analysis of siRNA mediated PSIP1 depleted and NTC HCT116 cells. Data are mean (± S.E.M) of 
3 biological replicates (N=3). Two-way ANOVA with Dunnett’s multiple comparisons test was used to 
quantify statistical significance (P>0.98). (B) Representative flow cytometry plots of PSIP1 depleted and 





5.5 PSIP1 expression protects colorectal cancer cells against 
chemotherapeutic drugs. 
As described previously, studies have suggested that the presence of PSIP1 can 
promote cancer cell survival, particularly in response to cell stress, such as treatment 
with chemotherapy (Basu et al. 2012). Two commonly used colorectal cancer 
chemotherapeutic drugs 5-Fluorouracil (5FU) (Carethers et al., 2004) and Oxaliplatin 
(OX) (Comella et al., 2009), were selected to investigate whether PSIP1 expression 
protects CRC cells against chemotherapy toxicity. 
5.5.1 Reduction of PSIP1 expression results in sensitivity of cells towards 
chemotherapeutic drugs in HCT116. 
Initially, the dose response of PSIP1 depleted HCT116 cells to chemotherapeutic drugs 
was tested in order to investigate whether PSIP1 depletion increases sensitivity of the 
cells to chemotherapy, indicating chemoresistant properties of PSIP1. Cells were 
seeded in 96-well plates and treated with a dose range of 5FU and OX for 72 h prior 
to being fixed and stained with crystal violet for colorimetric measurement (OD 490 
nm). The optical density was calculated relative to no drug treatment (0 µM). At each 
maximum dose (100 µM of 5FU and 1000 µM of OX, Figure 5.13 A and B), all 
manipulations (siRNA NTC and KD) had equal optical density readings indicating the 
concentration of drug is lethal to all cells regardless of PSIP1 expression level. When 
transfected with siRNA KD 1, cells treated with 1 µM 5FU exhibited significantly more 
sensitivity to 5FU treatment. Cells transfected with siRNA KD 2 and treated with 5FU 




When treated with 10 µM OX, siRNA PSIP KD 1 transfected cells exhibited a significant 
increase in sensitivity to the drug. SiRNA PSIP KD 2 transfected cells exhibited 
sensitivity to OX at the10 µM and 100 µM doses (Figure 5.14B), however this was not 
found to be significant in either case.  The increased sensitivity of cells transfected 
with PSIP KD 1 to both 5FU and OX reflects the PSIP1 expression levels witnessed in 
Figure 5.2, where siRNA PSIP KD 1 cells had a greater percentage of depletion than 
siRNA PSIP KD 2 cells.  
siRNA knockdown demonstrated that PSIP1 plays a role in chemosensitivity in CRC. 
Therefore, the experiment was repeated with the CRISPR-Cas9 mediated stable PSIP1 
KO and WT HCT116 cell lines. When treated with 5FU, PSIP1 KO cells exhibited more 
sensitivity to the drug compared to WT; this was significant when cells were treated 
with 1 µM 5FU (Figure 5.15A). When treated with 10 µM OX (Figure 5.15B), a 
significant increase in cell death was also observed. An increase in cell death was 
observed for PSIP1 KO cells treated with 100 µM OX, however this was not a 
significant effect. PSIP1 KO cells are more sensitive to treatment with 5FU out of the 
two drugs tested.  
Overall, HCT116 cells with depleted levels of PSIP1 are more sensitive to 
chemotherapy treatment than control cells. This indicates PSIP1 may have a role in 
protecting CRC cells against chemotherapy as when PSIP1 expression is reduced, cell 
survival is also reduced. This is in agreement with what has been described in other 
cancer types including prostate (Ríos-Colón et al., 2017) and ovarian (French et al., 






Figure 5.14 Dose response of siRNA mediated PSIP1 depleted HCT116 cells to 
chemotherapeutic drugs 
72 h after transfection with PSIP1 targeting or NTC siRNA for 72 h, HCT116 cells were subsequently 
treated with a dose response of (A) 5FU (0, 0.1, 1, 10, 100 µM) or (B) OX (0, 1, 10, 100, 1000 µM) for a 
further 72 h. The dose response of siRNA mediated PSIP1 depleted HCT116 cells to chemotherapeutic 
drugs was examined and compared to NTC. All data are mean (± S.E.M) of 3 biological replicates (N=3). 








Figure 5.15 Dose response of CRISPR-Cas9 mediated PSIP1 KO and WT HCT116 cells to 
chemotherapeutic drugs 
Stable PSIP1 CRISPR-Cas9 KO and WT HCT116 cells were seeded in 96-well plates and subsequently 
treated with a dose response of (A) 5FU (0, 0.1, 1, 10, 100 µM) or (B) OX (0, 1, 10, 100, 1000 µM) for a 
further 72 h. Data are mean (± S.E.M) of 3 biological replicates (N=3). Two-way ANOVA with Sidak’s 





5.5.2 Reduction in PSIP1 expression leads to an increase in cell death when HCT116 
cells are treated with chemotherapeutic drugs. 
After increased sensitivity to chemotherapeutic drugs was observed in cells with 
reduced PSIP1 expression, rates of cell death (apoptosis) were analysed by flow 
cytometry (as described in 5.4.5) in these cells after exposure to 5FU and OX. After 72 
h of incubation with siRNA to deplete PSIP1, cells were subsequently treated with 10 
µM 5FU or 10 µM OX over a time series of 0 h, 24 h, 48 h and 72 h. A no drug 
comparison was also included.  
An increase in apoptosis was observed in PSIP1-depleted HCT116 cells prior to 
drug treatment (no drug control) (Figure 5.16). The percentage of cells undergoing 
apoptosis was higher for cells transfected with PSIP KD 1 than PSIP KD 2, reflecting the 
knockdown efficiency observed in Figure 5.2. However, the increased apoptosis as a 
result of PSIP1 knock-down was not significant. PSIP KD 1 depleted cells treated with 
5FU resulted in a highly significant increase in the percentage apoptosis of cells across 
all time points. PSIP KD 2 depleted cells were also found to significantly increase cell 
death at 72 h treatment with 5FU (Figure 5.16A). A significant increase in percentage 
apoptosis was observed when PSIP1 depleted cells were treated with OX (Figure 
5.16C), however this was only significant for PSIP KD 1 transfected cells at the 72 h 
time point.  
Overall, PSIP1 depleted HCT116 cells were found to be significantly more 
sensitive to 5FU. Sensitivity to OX was also observed after 72 h treatment, however 






Figure 5.16 PSIP1 depleted HCT116 cells are more sensitive to chemotherapy 
HCT116 cells were transfected with PSIP1 targeting or NTC siRNA for 72 h and subsequently treated with 
(A) 10 µM 5FU or (B) 10 µM OX for up to 72 h for DNA hypodiploidy analysis via apoptosis assay using a 
flow cytometer. No drug controls were also included. Data are mean (± S.E.M) of 3 biological replicates 
(N=3). Two-way ANOVA via Dunnett’s comparison test was used to quantify the statistical significance 
(*P<0.05, ***P<0.001. ****P<0.0001). Representative flow cytometry plots of PSIP1 KD and NTC cells 





5.5.3 PSIP1 deletion results in reduced colony formation ability of HCT116 cells. 
Colony formation assays were used to further investigate the effect of PSIP deletion 
on CRC cell survival when exposed to chemotherapeutic drugs. CRISPR-Cas9 PSIP1 KO 
and WT stable cells were seeded sparsely in 12-well plates. After 3-4 days, cells were 
treated with 10 µM 5FU or 10 µM OX. A no drug control was also included to measure 
the colony growth without the addition of chemotherapy treatment.  
PSIP1 KO cells have a highly significant reduction in colony formation ability 
compared to WT prior to the addition of any chemotherapeutic drugs (fold change = 
12.5) (Figure 5.17). When treated with 5FU and OX, colony formation ability of PSIP1 
KO cells was also highly significantly reduced compared to WT (5FU fold change = 20, 
OX fold change = 25). Despite the increased fold change with the addition of 
chemotherapy, it cannot be confirmed that reduced colony formation ability is a 
direct result of treatment with 5FU or OX as similar colony numbers were observed 






Figure 5.17 CRISPR-Cas9 mediated PSIP1 knockout cells exhibit significant loss of colony 
formation ability in HCT116 cells 
 (A) Relative colony number of PSIP1 KO and WT HCT116 cells were compared with no drug, treatment 
with 10 µM 5FU or 10 µM OX. Data are mean (± S.E.M) of 3 biological replicates (N=3) relative to control 
WT cells. Two-way ANOVA with Sidak’s multiple comparisons test was used to quantify statistical 
significance (*** P<0.001). (B) Representative wells of colonies formed and stained with crystal violet 





5.5.4 Treatment with chemotherapeutic drugs results in restricted growth when 
PSIP1 is deleted in HCT116. 
 
The proliferation rate of PSIP1 deleted HCT116 cells when treated with 
chemotherapeutic drugs was investigated. Cells were seeded in 96-well plates, 
treated with 10 µM 5FU or 10 µM OX and grown over a time series for 6 days. After 
each time point, cells were fixed and stained with crystal violet prior to colorimetric 
measurement (OD 490 nm). Growth rates were calculated relative to day 0. 
Prior to the addition of chemotherapy treatment, no significant difference in 
proliferation was observed between PSIP1 KO and WT HCT116 cells (Figure 5.18A). 
When treated with 5FU (Figure 5.18B), a reduction in proliferation compared to WT 
was observed for PSIP1 KO cells at day 2 and 4. When treated with OX (Figure 
5,18C), a reduction in proliferation was observed for PSIP1 KO cells at days 4 and 6. 







Figure 5.18 Growth assay of CRISPR-Cas9 mediated PSIP1 KO and WT HCT116 cells when 
treated with chemotherapeutic drugs 
CRISPR-Cas9 mediated PSIP1 knockout and WT HCT116 cells were grown over a 6-day time course in the 
presence of (A) no drug, (B) 10 µM 5FU and (B) 10 µM OX. Cells were fixed with 4% PFA and stained with 
crystal violet prior to colorimetric assay measurement (OD 490 nm). Growth rates were calculated relative 
to day 0 (no growth or drug treatment). Data are mean (± S.E.M) of 3 biological replicates (N=3). Two-way 





5.5.5 5FU and Oxaliplatin do not induce arrest in cell cycle phases when PSIP1 is 
depleted in HCT116. 
After sensitivity to chemotherapy treatment was observed in PSIP1 depleted cells, it 
was decided to investigate whether 5FU or OX treatment influences changes in the 
cell cycle when PSIP1 is depleted. Cells were transfected with PSIP1 KD or NTC siRNA 
for 72 h and then treated with either 10 µM 5FU or 10 µM OX for a further 72 h; no 
drug controls were also included. A flow cytometer was used to measure the 
percentage of cells in each stage of the cell cycle (G1 vs S vs G2/M). 
PSIP1 depletion resulted in a decrease in G2/M phase compared to NTC prior to the 
addition of chemotherapeutic drugs. Conversely, an increase in S and G1 phase was 
also observed for PSIP1 depleted, non-drug treated cells (Figure 5.19 Cell cycle 
analysis of siRNA mediated PSIP1 depletion in HCT116 cells 
Cell cycle analysis of (A) siRNA mediated PSIP1 depletion and NTC HCT116 cells treated with (B) 10 
µM 5FU or (C) 10 µM OX for 72 h. A no drug control was also included. Data are mean (± S.E.M) of 3 
biological replicates (N=3). Two-way ANOVA with Dunnett’s multiple comparisons test was used to 
quantify statistical significance. (D) Representative flow cytometry plots of PSIP1 depleted and NTC 
cells with and without drug treatment.  
 
 An increase in G1 phase and a decrease in G2/M and S phase was observed for 
PSIP1 depleted cells treated with 5FU (Figure 5.19B). A reduction in G2/M and S 
phase was also observed when PSIP depleted cells were treated with OX, however 
the percentage of cells in G1 phase fluctuated depending on the siRNA used to 
target PSIP1, with PSIP1 KD 1 resulting in decreased in G1, and PSIP KD 2 resulting in 





Cell cycle analysis of (A) siRNA mediated PSIP1 depletion and NTC HCT116 cells treated with (B) 10 
µM 5FU or (C) 10 µM OX for 72 h. A no drug control was also included. Data are mean (± S.E.M) of 3 
biological replicates (N=3). Two-way ANOVA with Dunnett’s multiple comparisons test was used to 
quantify statistical significance. (D) Representative flow cytometry plots of PSIP1 depleted and NTC 
cells with and without drug treatment.  
 
 None of these data were found to be statistically significant, therefore, the 
introduction of chemotherapeutic drug treatment to PSIP1 depleted HCT116 cells 








Figure 5.19 Cell cycle analysis of siRNA mediated PSIP1 depletion in HCT116 cells 
Cell cycle analysis of (A) siRNA mediated PSIP1 depletion and NTC HCT116 cells treated with (B) 10 µM 5FU 
or (C) 10 µM OX for 72 h. A no drug control was also included. Data are mean (± S.E.M) of 3 biological 
replicates (N=3). Two-way ANOVA with Dunnett’s multiple comparisons test was used to quantify 
statistical significance. (D) Representative flow cytometry plots of PSIP1 depleted and NTC cells with and 






5.6  Discussion 
 
PSIP1 has previously been implicated in several cancers, including leukaemia 
(Yokoyama and Cleary, 2008) prostate (Basu, et al. 2012), breast (Singh et al., 2017) 
and ovarian cancer (French et al., 2016), however knowledge on its role in CRC is 
limited. K-M survival plots indicated that high expression of PSIP1 is associated with 
poorer survival rate in CRC, suggesting that PSIP1 may play an important role in the 
carcinogenesis of this disease. 
5.6.1 PSIP1 regulates HOXA13 expression in CRC. 
Upon siRNA mediated PSIP1 depletion, HOXA13 expression was found to be 
significantly downregulated, strongly suggesting that PSIP1 regulates HOXA13 in CRC. 
HOTTIP, a lncRNA located in close proximity to HOXA13 on the HOXA cluster was also 
non-significantly downregulated with PSIP1 depletion. PSIP1 has previously been 
described as regulating the expression of HOXA genes through the lncRNA Hottip in 
mouse models (Pradeepa et al., 2017) which has now been replicated in this CRC 
model. This is the first time that a direct role of PSIP1 regulating HOXA13 has been 
described in CRC. 
5.6.2 PSIP1 depletion results in loss of colony formation ability in HCT116 cells, 
however it is not a key driver of cell proliferation and migration in CRC. 
PSIP1 has been implicated in promoting cell-cycle progression, metastasis, 
migration and invasion in breast cancer (Singh et al., 2017). However, this was not 




proliferation was observed for either siRNA mediated PSIP1 knockdown or stable 
PSIP1 KO cells compared to controls. Similarly, previous studies have observed PSIP1 
promoting the expression of cell cycle genes in breast cancer (Singh et al., 2017); these 
effects were not confirmed in this study. Together, these data suggest that PSIP1 is 
not a key growth driver and does not influence CRC progression through promoting 
key cell cycle genes to drive cell growth. 
On the other hand, the colony formation ability of cells was highly significantly 
reduced in PSIP1 KO HCT116 cells. The formation of colonies is particularly important 
to the progression of CRC as at early stages, cells first form precursor adenomatous 
polyps before turning cancerous into invasive adenocarcinomas, metastasising and 
migrating to other areas of the body (Aarons, Shanmugan and Bleier, 2014; Delavari 
et al., 2014). Therefore, this reduction in colony formation ability for PSIP1 KO cells 
suggests a key role for PSIP1 in this process. As of yet, there have been no studies 
investigating the role of PSIP1 in promoting cell growth or movement in CRC so further 
work needs to be done to confirm this observation.  
5.6.3 PSIP1 protects HCT116 cells from cell death when exposed to 5FU. 
PSIP1 is a stress survival protein (Basu, et al. 2012) and has been observed having roles 
in preventing apoptosis when cells are exposed to stress, for example, in patients with 
inflammatory conditions such as dermatitis (Ganapathy, Daniels and Casiano, 2003; 
Sutherland et al., 2006). This could be the same in CRC when cells are under stress 
from chemotherapy exposure (Basu et al. 2012). To date, no previous studies have 




however, been described in other cancers including prostate (Ríos-Colón et al., 2017) 
and ovarian (French et al., 2016) cancer. 
Here, chemosensitivity to 5FU (1 µM) and OX (10 µM) was observed in siRNA 
mediated PSIP1 depletion HCT116 cells. It should be noted, however, that PSIP KD 1 
exhibited a higher sensitivity to both 5FU and OX treatment than NTC - this is due to 
the increased knockdown efficiency for this siRNA. This result was confirmed with the 
stable CRISPR lines, where PSIP1 KO also resulted in sensitivity to 5FU. Conversely, no 
sensitivity to OX treatment was observed in stable PSIP1 KO HCT116 cells. A similar 
pattern was seen when investigating apoptosis rates of PSIP1 depleted cells. 5FU 
treated PSIP1 KD cells showed an increase in percentage apoptosis at each time point 
that was examined (24 h, 48 h, 72 h). Whereas, PSIP1 depleted cells treated with OX 
showed an increase in percentage apoptosis only at the 72 h time point. Overall, these 
data suggest that PSIP1 KD/KO cells exhibit sensitivity to 5FU treatment; further work 
would need to be carried out to confirm any OX sensitivity. It is possible that PSIP1 
depleted cells exhibit OX sensitivity when incubated for longer than 72 h. Therefore, 
testing both the dose response and apoptosis rates of PSIP1 KD cells over a longer 
time series would have been useful to draw more conclusions. 
PSIP1 has previously been reported to have roles in the cell cycle, particularly 
in S and G2 phase (Daugaard et al., 2012). Arrest in S phase was observed in PSIP1 
depleted HCT116 cells, and this arrest increased with the addition of 5FU. This may 
suggest some sensitivity to 5FU, but the result was not significant so this cannot be 
concluded without further experimentation. OX has been shown to induce arrest in 




and Beauger, 2011), however this was not replicated in this study. No arrest in G2/M 
was observed for OX-treated NTC HCT116, although there was an increase in S 
phase. This experiment could have been optimisied further to ensure the drugs were 
working correctly in control samples; this would have enabled better conlclusions to 
be drawn from this data.  
Overall, cells with PSIP1 depletion or stable PSIP1 KO were observed to exhibit 
more sensitivity to chemotherapeutic drug treatment than control cells, particularly 
towards 5FU. These findings may be useful when applying this in a clinical setting as 
CRC tumour cells with lower PSIP1 expression may respond better to 5FU treatment 
than CRC tumour cells with a higher PSIP1 expression. Testing patients for levels of 
PSIP1 expression may decipher how well a treatment course may work for a patient. 
5.7 Summary 
In summary, PSIP1 exhibits some chemosensitive properties in HCT116 cells when 
exposed to chemotherapeutic drugs, particularly towards 5FU. This was observed 
both in siRNA mediated PSIP1 depletion and in stable PSIP1 KO cell lines, although the 
stable cell lines provided more significant and therefore conclusive results. PSIP1 has 
not previously been implicated in CRC, therefore, more study into its chemosensitive 
properties is needed to confirm what has been observed here. Overall, this work 
shows potential for testing PSIP1 expression in CRC tumours to identify patients who 
may become resistance to chemotherapy. This could prevent administration of 





Limitations of this work include discrepancies between siRNAs targeting 
PSIP1, with PSIP KD 1 having a stronger KD effect than PSIP KD 2. Including a larger 
panel of siRNAs would improve the quality of the data and ensure conclusions can 
be drawn confidently. Knock-down success was checked regularly but was not 
performed for every experiment; therefore, providing confirmation of siRNA 
knockdown (via qPCR/Sanger sequencing) for each of the cell assays would also add 
confidence to this data. Further optimisation of the chemotherapeutic drug assays 
(time points, concentrations, controls) would improve the significance of the data 
observed in this chapter, adding confidence to the suggestion of a potential 




6 General Discussion 
Treatments for both colorectal cancer (CRC) and prostate cancer (PCa) have greatly 
improved over the last 10-20 years (Saltz, 2016; Litwin and Tan, 2017). However, 
there is still a high mortality rate for both cancers worldwide, with an estimated 880 
792 deaths from CRC and 358 989 deaths from PCa in 2018 (Bray et al., 2018). There 
is therefore a great need to better understand the factors that drive disease 
development and progression, and therapy resistance.  
6.1  Key findings of the roles of HOTTIP, HOXA13 and PSIP1 in CRC and PCa. 
The main aim of this thesis was to investigate the role of HOTTIP, HOXA13 and PSIP1 
in CRC and PCa. Through loss of function studies, a combination of transient siRNA 
knockdown and CRISPR-Cas9 stable knockout cell lines were used to explore the role 
of each gene in CRC and PCa. 
6.1.1 HOTTIP 
Long non-coding RNAs (lncRNAs) have gained attention in recent years as potential 
targets for therapies, including cancer. They have key regulatory roles in many 
cellular processes and can influence the progression of cancer (Hajjari and Salavaty, 
2015). Some lncRNAs are detectable in bodily fluids such as blood serum and the 
urine (Qi, Zhou and Du, 2016). This highlights huge potential for this group of 
ncRNAs as attractive biomarkers to provide non-invasive detection methods that are 




traction as a potential therapeutic drug or biomarker target due to its implications in 
cancer progression.  
HOTTIP is located on the 5’ end of the HOXA cluster and influences the 
regulation of nearby HOX genes, including HOXA13, through interacting with 
chromatin modifying complexes (Wang et al., 2011). HOTTIP is in turn regulated by 
the chromatin adapter protein PSIP1, with the shorter PSIP1/p52 isoform regulating 
HOTTIP through binding to the regulatory MLL/WDR5 complex (Pradeepa et al., 
2017).  
Previous studies have reported upregulation of HOTTIP in both CRC and PCa 
(Ren et al., 2015; C. Liu et al., 2018; Lee et al., 2019). HOTTIP has roles in promoting 
both of these cancers through regulation of cell proliferation, migration, invasion 
and metastasis (Lian, Y; Cai, Z; Gong, 2016; Malek et al., 2017; Yang et al., 2018; 
Oehme et al., 2019; Rui et al., 2019). Some of these properties were replicated 
throughout this thesis. For example, the role of HOTTIP in cell migration, 
proliferation and apoptosis were confirmed in CRC and PCa. 
The key finding of Chapter 3 is the identification of a potential role of HOTTIP 
in regulating chemoresistance in both CRC and PCa. Chemoresistant properties of 
HOTTIP have been described only once before in PCa (Jiang et al., 2019) and this is 
the first time HOTTIP has been implicated in CRC chemoresistance. Cells were 
observed to be more sensitive to chemotherapy when HOTTIP expression was either 





6.1.2  HOXA13 
HOX genes are key regulatory genes, heavily involved in development as well as 
other regulatory cellular processes (Shah and Sukumar, 2010; Wang et al., 2016). As 
a result, any alterations in the expression levels of HOX genes has the potential to 
progress into cancer (Wang et al., 2016). Aberrant expression of HOXA13, the most 
distally located of the HOXA genes, located ~330 bp from HOTTIP (Wang et al., 2011) 
has been associated with the progression of several cancers, including prostate 
(Dong et al., 2017b; Luo et al., 2017). It is upregulated in PCa and has been found to 
promote cell proliferation, migration, invasion and inhibit tumour cell apoptosis 
(Zhang et al., 2016; Dong et al., 2017b). This has also been observed in Chapter 4, 
where reduced cell migration and an increase in apoptosis were reported upon 
HOXA13 depletion in DU145 PCa cells. 
 The data produced in Chapter 4 has also reported a link between HOXA13 
and CRC. This is the first time a relationship between HOXA13 and CRC has been 
suggested. Reduced cell migration and increased apoptosis were observed when 
HOXA13 expression was depleted in HCT116 cells. However, it must be noted that 
some opposing results were documented in RKO1 cells, where HOXA13 depletion 
resulted in increased proliferation and reduced apoptosis. Including a larger panel of 
CRC cell lines would allow better conclusions on the role of HOXA13 in CRC to be 
drawn. 
One finding in Chapter 4 across all cell lines (HCT116, RKO1 and DU145) is the 




the first time this has been reported in both cancers. HOXA13 has previously been 
described as contributing to 5FU resistance in gastric cancer, where affects the 
stomach and therefore is in close proximity to the colon (Han et al., 2018). This may 
provide some evidence that further study into whether HOXA13 exhibits 
chemoresistant properties in other cancers, including the ones described in this 
study.  
6.1.3  PSIP1 
PSIP1 is a chromatin-adapter protein (Singh et al., 2017) that interacts with 
chromatin in order to regulate gene expression (Sutherland et al., 2006b). PSIP1 has 
been implicated in several diseases, including in HIV replication (Baid et al., 2013), 
leukaemia (El Ashkar et al., 2017) and other cancers including breast, ovarian and 
prostate (Basu, et al., 2012; French et al., 2016; et al., 2017; Woods-Burnham et al., 
2018). This thesis has contributed to this research by reporting a role for PSIP1 in 
CRC. Here I have identified a role of PSIP1 in promoting colony formation ability. The 
formation of colonies plays a critical part in the pathogenesis of CRC aiding in 
promoting polyp development (Aarons, Shanmugan and Bleier, 2014; Delavari et al., 
2014). This is the first time a relationship between PSIP1 and CRC has been 
described.  
Consistently with HOTTIP and HOXA13, Chapter 5 also reported a possible 
role of PSIP1 in CRC chemosensitivity. Again, this is a novel description for the role of 
PSIP1 in CRC, and PSIP1 has only been documented in contributing to 




6.2 Exploring gene regulatory roles of HOTTIP, HOXA13 and PSIP1 in CRC and 
PCa. 
Previous reports have reported HOTTIP regulates HOXA13 expression in mouse 
models (Pradeepa et al., 2017). This has been replicated in this thesis in both CRC 
and PCa, confirming that this regulation model is also observed in human cells, and 
in disease states. All gene regulation observed in this thesis has been summarised in 
Figure 6.1. Both siRNA mediated HOTTIP depletion or CRISPR-Cas9 stable HOTTIP KO 
resulted in HOXA13 depletion in HCT116, RKO1 and DU145 cells. HOTTIP was also 
observed to regulate the expression of HOXA11 in HCT116. This is consistent for 
what has been described in mouse models where Hottip activates 5’ Hoxa genes, 
including Hoxa13 and Hoxa11 (Wang et al., 2011; Pradeepa et al., 2017).  
When investigating the global effects of stable HOTTIP KO in HCT116 cells, 
HOXD8 expression was downregulated in HOTTIP KO compared to WT, as well as 
HOTTIP and HOXA13. Interestingly, the 3’ HOXA3 gene, and several HOXB genes 
(HOXB3, HOXB4, HOXB6, HOXB8) were upregulated in HOTTIP KO cells. This altered 
expression could be an indirect result of HOXA13 depletion, as HOX transcription 
factors (TFs) are known to regulate expression of each other (Pradeepa et al., 2017). 
This would also explain what was observed in Chapter 4 where upon HOXA13 
depletion, both HOTTIP and other nearby HOXA genes were downregulated. 
Alternatively, HOXA3 upregulation could also be a result of HOXA-AS2 upregulation, 
a lncRNA that was also found to be upregulated in HOTTIP KO HCT116 cells. HOXA-




and has previously been described as regulating HOXA3 in leukaemia (Zhao et al., 
2019) and thyroid cancer (Jiang et al., 2019). 
As well as altered HOX gene expression, two gene clusters: PADI and PCDHA 
were also found to be differentially expressed in HOTTIP KO HCT116 cells. These 
enzymes involved in citrullination, a post-translational modification that can 
promote cancer progression through modifying methylation patterns (Yuzhalin, 
2019), were found to be upregulated in HCT116 upon HOTTIP deletion. Both genes 
have previously been reported in CRC in tumour suppressive roles (Cantarino et al., 
2016; Chai et al., 2019; Chang et al., 2019), which fits with what has been observed 
in this data. This suggests that HOTTIP may act as a tumour suppressor via regulation 
of PADI2 and PADI3, as upon loss of HOTTIP, these genes are upregulated in HCT116.  
The PCDHA cluster on the other hand were found to be upregulated in WT 
HCT116 cells compared to HOTTIP KO. Protocadherins have important roles in 
specific cell-cell connections and in promoting tumour development (Berx and van 
Roy, 2009). PCDHA genes are also involved in development, as regulators of the 
neural circuit formation (Peek, Mah and Weiner, 2017). As HOX expression was 
shown to be mysregulated with HOTTIP deletion, these TFs could be regulating the 
expression of PCDHA’s in CRC rather than HOTTIP having a direct effect on their 
expression.  
PSIP1 depletion resulted in a reduction of HOTTIP and HOXA13 in HCT116 
cells. This is consistent for what has been described previously in mouse models, of 




expression (Pradeepa et al., 2017). However, this is the first time this has been 





Figure 6.1 Summary of gene regulation observed. 
A summary of the key gene regulation patterns observed in this thesis. (A) Directionality of gene 
regulation is outlined. The black arrow points away from the regulatory gene and towards the gene where 
expression was found to be up or downregulated as a result of loss of function studies (e.g., PSIP1 
depletion also resulted in loss of HOTTIP and HOXA gene expression). (B) These interactions are 




6.3  Limitations of this work 
Using a combination of transient siRNA mediated knockdown and stable CRISPR-
Cas9 KO techniques to carry out loss of function studies has provided strong, 
comparative data throughout this thesis. It has allowed validation of results through 
a cross-comparison of gene editing methods. However, it was observed that the 
stable CRISPR-Cas9 HOTTIP or PSIP1 knockout cell lines that were created generally 
provided more statistically significant data compared to their transient gene 
knockdown counterparts. This is possibly due to three main factors. Firstly, the 
stability of CRISPR-Cas9 gene knockdown is consistent for each cell and across each 
experiment replicate, providing reproducibility, whereas transient knockdown 
efficiency may vary between experiment. Secondly, total deletion of the genes may 
have provided a stronger indication of the functional role of HOTTIP and PSIP1 in 
CRC compared to the siRNA mediated knockdown approach, where some functional 
transcript remains in the cell. Thirdly, when studying lncRNAs such as HOTTIP other 
RNAi approaches may provide a more efficient knockdown. For example, shRNA are 
able to be incorporated directly into the nucleus via viral vector transduction 
compared to cytoplasmic disruption that is usually associated with siRNA 
knockdown (Zong et al., 2015). Although expressed in the cytoplasm, HOTTIP is 
mainly located in the nucleus (Fu et al., 2017); therefore, an alternative method may 
provide a more efficient knockdown. Overall, in combination, use of both techniques 
provides a good indication of the role of HOTTIP and PSIP1 in CRC. The creation of a 
stable HOXA13 cell line may have provided further validation of any conclusions 




In each chapter, a non-cancerous control cell line would have further 
provided evidence to support the findings in this thesis. Additional CRC and PCa cell 
lines would have given a better representation of each disease as in some 
experiments different results were obtained from the different cell lines (e.g. 
discrepancies between HCT116 and RKO1 cell lines were observed). To increase 
specificity of these data, comparisons of this work to patient CRC and PCa tumour 
samples would also have further validated my conclusions. However, being granted 
access to patient samples can be difficult and is accompanied by ethical and data 
protection concerns. These concerns are easily overcome through the use of cell 
lines. 
The significance of the data could have been improved by including more 
biological repeats of each experiment. This would allow any anomalies in the data to 
be identified and excluded with more confidence. Including a larger panel of siRNAs 
would also improve significance and therefore the quality of the data. Knock-down 
success was checked regularly but was not performed for every experiment; 
therefore, providing confirmation of siRNA knockdown (via qPCR/Sanger 
sequencing) for each of the cell assays would also add confidence to this data.  
Further optimisation of the chemotherapeutic drug assays (time points, 
concentrations, controls) would improve the significance of the data observed in this 
thesis, adding confidence to the suggestion of a potential chemosensitive role of 
HOTTIP, HOXA13 and PSIP1 in CRC and PCa.  
As one of the key findings of this thesis was the association of HOTTIP, 




drugs to test would decipher if this relationship is drug specific or may be in 
response to any chemical cancer cell stressor. Often, chemotherapy is administered 
by a combination of more than one drug; this again would have been interesting to 
test in response to the chemoresistant capacity of each gene.  
6.4 Future implications 
The role of HOTTIP, HOXA13 and PSIP1 in contributing to chemoresistance in both 
CRC and PCa is the key finding of this thesis. It has highlighted the importance of 
understanding chemoresistance pathways to provide patients with the most 
promising treatment options.  
As outlined in Chapter 1 (1.2.2.4), therapy resistance is a major concern 
when treating PCa. After failure of androgen deprivation therapy (ADT) as a result of 
tumour cells becoming castrate resistant (CRPC) (Brooke et al., 2015), chemotherapy 
is often the treatment of choice (Wang et al., 2016). However, chemoresistance of 
docetaxel (DOC)-mediated chemotherapy can still occur (Yuan Wang et al., 2016). 
Therefore, identifying genes such as HOTTIP and HOXA13 that can promote PCa 
chemoresistance will help with overcoming failed therapies.  
Chemoresistance is also an issue when treating CRC, with most patients 
eventually developing chemoresistance, which ultimately results in poor prognosis 
(Huang et al., 2018; Wei et al., 2019). 5FU-mediated chemotherapy is commonly 
used as a first response therapy, and is followed by secondary treatment with OX 
(Arango et al., 2004) or in combination with OX when CRC cells develop 5FU 




al., 2019). The results outlined in this thesis has suggested a role in CRC for HOTTIP, 
HOXA13 and PSIP1 in both 5FU and OX sensitivity. If CRC tumour cells could be 
tested for expression of these genes, this could potentially identify patients who 
may be at risk of developing chemoresistance. This could prevent the administration 
of ineffective drugs and avoid patients suffering the side effects associated with 
chemotherapy. 
More studies could be carried out to see if HOTTIP, HOXA13 and PSIP1 
expression is correlated with therapy response. If other studies are found to also 
observe what has been reported in this thesis, further characterisation of what 
regulates these genes could identify methods to enhance therapy response or re-
sensitise tumours to chemotherapy. This has been suggested in the literature for 
Taurine Up-Regulated 1 (TUG1) and Cancer Susceptibility Candidate 15 (CASC15), 
two other lncRNAs that have previously been implicated in CRC (C. Li et al., 2017; 
Gao et al., 2019; Wang et al., 2019). In line with this, PCDHAs were observed to be 
downregulated as a result of HOTTIP deletion in CRC in this study. Male 
protocadherin-PC (PCDHA-PC) has previously been implicated in chemoresistance in 
PCa through Androgen Receptor (AR) regulation (Terry et al., 2013). Further study 
into the implications of HOTTIP and PCDHA together in PCa chemoresistance may 
present a new target pathway for PCa therapy.  
LncRNAs have gained attention as potential biomarkers for cancer. The 
lncRNA Prostate Cancer Antigen 3 (PCA3) has been proven to have biomarker 
properties in PCa. It is overexpressed in 95 % of PCa sites and is the first urine-based 




(FDA) in the U.S. (Qi, Zhou and Du, 2016). Due to the increasing evidence of a role 
for HOTTIP in promoting cancer and its ability to be detected in blood plasma, a 
biomarker role has been suggested for this lncRNA (Ali Akbar-Esfahani et al., 2019). 
The findings described in this thesis support this evidence and also suggest a 
prognostic biomarker role for HOTTIP in both CRC and PCa. 
6.5 Concluding remarks 
The work presented in this thesis has uncovered a potential new relationship 
between both HOXA13 and PSIP1 in the progression of CRC, whilst also contributing 
further to the current understanding of the role of HOTTIP in CRC. A novel 
suggestion for a chemosensitive role has been reported for HOTTIP, HOXA13 and 
PSIP1 in CRC, and for HOXA13 in PCa. These data also support current literature of 
chemoresistant behaviour exhibited by HOTTIP in PCa. In summary, these 
conclusions highlight the importance of understanding factors that drive disease 
development and progression, and identifying genes involved in chemoresistance to 
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8 Supplementary information 
 
Table 8.1 RNA-Seq upregulated genes 
Probe Chromosome ID P-value FDR Log2Fold WT RPKM HOTTIP KO RPKM 
HSD3B7 16 ENSG00000099377 4.65E-04 7.65E-03 -0.62 161 139 196 226 207 265 
MOK 14 ENSG00000080823 4.04E-06 1.28E-04 -0.62 278 297 343 409 424 449 
HIST1H2BD 6 ENSG00000158373 1.65E-04 3.19E-03 -0.62 158 161 189 234 203 282 
AC090607.4 15 ENSG00000272418 2.38E-04 4.34E-03 -0.62 136 171 174 225 183 272 
CILP2 19 ENSG00000160161 4.39E-08 2.15E-06 -0.63 937 772 1122 1271 1217 1521 
ZNF703 8 ENSG00000183779 6.42E-06 1.91E-04 -0.63 318 304 453 467 497 541 
FKBP11 12 ENSG00000134285 3.24E-08 1.65E-06 -0.63 543 698 739 945 688 1183 
NKX1-2 10 ENSG00000229544 2.68E-06 8.97E-05 -0.63 309 393 339 471 479 519 
DNAJB5 9 ENSG00000137094 3.47E-07 1.43E-05 -0.63 294 328 346 422 412 542 
AP003419.1 11 ENSG00000256514 3.10E-05 7.61E-04 -0.63 163 227 235 284 247 353 
FOXA3 19 ENSG00000170608 3.31E-06 1.08E-04 -0.63 241 283 290 387 352 411 
PROS1 3 ENSG00000184500 5.39E-09 3.03E-07 -0.63 517 710 695 832 908 958 
OR51B4 11 ENSG00000183251 2.94E-07 1.24E-05 -0.63 289 426 394 509 462 596 
AP000924.1 11 ENSG00000254416 4.98E-04 8.08E-03 -0.64 137 136 144 185 175 238 
PTRH1 9 ENSG00000187024 1.86E-05 4.89E-04 -0.64 199 227 328 338 318 407 
CACNB1 17 ENSG00000067191 2.57E-08 1.34E-06 -0.64 364 440 527 633 576 666 
IGFBP6 12 ENSG00000167779 1.94E-07 8.54E-06 -0.64 510 450 595 683 722 812 
AC013394.1 15 ENSG00000279765 4.75E-09 2.69E-07 -0.64 469 678 614 790 697 1032 
SCML1 X ENSG00000047634 1.81E-09 1.09E-07 -0.64 432 616 576 746 666 902 
SLC38A5 X ENSG00000017483 2.93E-12 2.35E-10 -0.64 905 899 1087 1280 1301 1553 
ROMO1 20 ENSG00000125995 9.79E-07 3.66E-05 -0.65 753 648 1011 1111 1166 1131 




DNLZ 9 ENSG00000213221 6.57E-05 1.46E-03 -0.65 239 202 298 362 334 358 
AL353689.2 1 ENSG00000233706 7.93E-05 1.72E-03 -0.65 141 209 211 231 233 342 
HIST3H2A 1 ENSG00000181218 1.78E-06 6.16E-05 -0.65 267 287 322 394 419 440 
PDLIM3 4 ENSG00000154553 4.25E-06 1.34E-04 -0.66 209 224 270 304 301 411 
AC000123.3 7 ENSG00000280347 1.66E-04 3.20E-03 -0.66 128 203 178 245 198 290 
PLEKHO1 1 ENSG00000023902 1.54E-09 9.33E-08 -0.66 368 482 541 611 634 752 
PEX11A 15 ENSG00000166821 3.18E-05 7.82E-04 -0.67 140 209 236 260 258 322 
AC018665.1 17 ENSG00000279382 1.92E-05 5.02E-04 -0.67 190 234 226 317 239 398 
AL355916.3 14 ENSG00000258989 1.12E-04 2.29E-03 -0.67 151 191 232 318 226 281 
KREMEN2 16 ENSG00000131650 7.93E-07 3.03E-05 -0.67 445 441 704 731 769 780 
ARL4D 17 ENSG00000175906 3.18E-06 1.04E-04 -0.67 395 355 546 621 631 613 
OPLAH 8 ENSG00000178814 4.41E-05 1.03E-03 -0.67 247 222 396 437 344 472 
TAF3 10 ENSG00000165632 8.12E-12 6.16E-10 -0.68 625 768 936 1053 1102 1208 
MRVI1 11 ENSG00000072952 9.48E-14 8.89E-12 -0.68 708 908 934 1214 1163 1323 
ACAD11 3 ENSG00000240303 1.20E-11 8.95E-10 -0.68 599 827 786 1032 880 1341 
CYTOR 2 ENSG00000222041 1.82E-06 6.29E-05 -0.68 334 348 385 511 544 495 
SSC4D 7 ENSG00000146700 2.96E-04 5.22E-03 -0.68 99 139 179 205 175 224 
AL451085.2 1 ENSG00000271380 1.95E-09 1.16E-07 -0.69 327 391 416 541 473 656 
SYDE1 19 ENSG00000105137 2.50E-05 6.34E-04 -0.69 196 210 293 265 338 423 
WTIP 19 ENSG00000142279 1.11E-08 6.09E-07 -0.69 328 338 410 505 452 634 
EEF1AKMT3 12 ENSG00000123427 2.66E-06 8.89E-05 -0.69 205 222 274 291 321 423 
GPR162 12 ENSG00000250510 1.04E-05 2.92E-04 -0.69 195 208 259 356 258 360 
KIAA1614 1 ENSG00000135835 8.39E-06 2.41E-04 -0.69 155 188 211 265 233 318 
SCUBE1 22 ENSG00000159307 4.94E-04 8.03E-03 -0.69 92 166 194 187 212 257 
TBC1D3P1-
DHX40P1 
17 ENSG00000267104 5.54E-05 1.26E-03 -0.69 199 196 192 270 300 298 




TM2D3 15 ENSG00000184277 1.20E-15 1.35E-13 -0.70 668 781 820 1041 1019 1322 
B3GNT7 2 ENSG00000156966 3.84E-06 1.23E-04 -0.70 230 229 339 334 393 453 
ARSG 17 ENSG00000141337 5.61E-13 4.91E-11 -0.70 510 582 647 775 790 1029 
AC022150.4 19 ENSG00000269825 1.35E-06 4.78E-05 -0.71 187 266 245 334 288 422 
KCNC3 19 ENSG00000131398 3.97E-06 1.26E-04 -0.71 217 258 234 308 297 469 
RHOD 11 ENSG00000173156 7.98E-09 4.39E-07 -0.71 929 795 1161 1463 1390 1420 
RELB 19 ENSG00000104856 3.54E-08 1.77E-06 -0.71 310 303 342 454 435 545 
ITPKA 15 ENSG00000137825 3.95E-08 1.95E-06 -0.71 313 344 424 580 467 558 
ELOA-AS1 1 ENSG00000236810 2.76E-09 1.62E-07 -0.71 289 423 423 536 517 634 
WIPI1 17 ENSG00000070540 4.53E-13 4.01E-11 -0.72 457 583 634 830 722 952 
SLC45A1 1 ENSG00000162426 3.57E-06 1.15E-04 -0.72 185 200 291 296 309 406 
AL445237.1 10 ENSG00000271434 4.33E-04 7.22E-03 -0.72 101 121 116 147 178 181 
VCAN-AS1 5 ENSG00000249835 5.07E-05 1.16E-03 -0.72 128 222 220 266 219 372 
AL627171.2 14 ENSG00000282885 7.44E-06 2.17E-04 -0.72 205 285 276 384 400 351 
TFR2 7 ENSG00000106327 1.16E-10 7.78E-09 -0.73 332 434 492 564 587 741 
ZNF710 15 ENSG00000140548 7.21E-12 5.53E-10 -0.73 472 492 614 785 731 867 
SMAD6 15 ENSG00000137834 3.55E-09 2.06E-07 -0.73 279 320 407 481 479 558 
L1CAM X ENSG00000198910 5.80E-11 4.06E-09 -0.73 555 578 802 864 832 1261 
CCN3 8 ENSG00000136999 6.07E-11 4.22E-09 -0.74 390 444 464 637 627 707 
DZIP1L 3 ENSG00000158163 6.70E-07 2.60E-05 -0.74 182 215 269 291 325 394 
SRPK3 X ENSG00000184343 1.02E-04 2.12E-03 -0.74 111 145 199 191 193 312 
GLIS3 9 ENSG00000107249 2.22E-05 5.75E-04 -0.74 116 194 218 236 251 310 
RASSF2 20 ENSG00000101265 2.71E-17 3.60E-15 -0.75 641 827 856 1068 1088 1415 
RIOX1 14 ENSG00000170468 1.50E-07 6.71E-06 -0.75 222 311 375 464 443 463 
MLLT11 1 ENSG00000213190 7.60E-06 2.21E-04 -0.75 135 183 164 238 209 298 
PCSK6 15 ENSG00000140479 7.32E-12 5.60E-10 -0.76 351 415 495 585 578 782 




FXYD6 11 ENSG00000137726 9.57E-05 2.01E-03 -0.76 100 119 168 212 163 218 
PAX2 10 ENSG00000075891 2.80E-06 9.30E-05 -0.76 173 189 296 333 280 399 
ADAT3 19 ENSG00000213638 4.37E-10 2.79E-08 -0.76 315 330 449 539 506 643 
LYSMD4 15 ENSG00000183060 9.58E-10 5.89E-08 -0.76 312 344 362 537 478 560 
AC129492.2 17 ENSG00000214999 1.25E-04 2.52E-03 -0.76 146 108 180 231 190 254 
AL133410.1 9 ENSG00000227388 2.16E-04 4.00E-03 -0.77 83 109 117 159 122 201 
NEURL1B 5 ENSG00000214357 6.62E-18 9.54E-16 -0.77 718 851 1023 1182 1227 1614 
PTCHD4 6 ENSG00000244694 1.14E-06 4.14E-05 -0.77 145 218 241 316 274 338 
BEGAIN 14 ENSG00000183092 1.37E-06 4.85E-05 -0.77 153 174 202 265 260 293 
TARSL2 15 ENSG00000185418 4.54E-13 4.01E-11 -0.77 399 453 559 670 678 842 
RCCD1 15 ENSG00000166965 3.03E-17 3.99E-15 -0.77 728 838 1051 1373 1132 1578 
SELENOM 22 ENSG00000198832 4.63E-14 4.42E-12 -0.78 607 707 902 1083 1132 1211 
AC132217.2 11 ENSG00000284779 8.98E-12 6.73E-10 -0.78 404 429 536 698 574 893 
CEL 9 ENSG00000170835 1.42E-04 2.81E-03 -0.78 88 109 113 141 135 216 
TESC 12 ENSG00000088992 1.05E-06 3.91E-05 -0.78 156 202 275 306 323 351 
ULK2 17 ENSG00000083290 2.66E-08 1.37E-06 -0.78 215 229 317 395 348 449 
CEMIP2 9 ENSG00000135048 1.53E-19 2.57E-17 -0.79 647 874 886 1196 1125 1465 
ZNF710-AS1 15 ENSG00000259291 5.86E-05 1.33E-03 -0.79 129 111 150 223 177 215 
FOS 14 ENSG00000170345 1.11E-05 3.12E-04 -0.79 107 178 180 230 236 258 
PDE8A 15 ENSG00000073417 3.57E-16 4.24E-14 -0.80 603 797 711 1037 1016 1309 
IGF2 11 ENSG00000167244 1.29E-12 1.09E-10 -0.80 433 442 565 744 622 935 
DPYSL4 10 ENSG00000151640 4.04E-05 9.63E-04 -0.80 87 123 164 185 171 233 
PXDN 2 ENSG00000130508 3.58E-16 4.24E-14 -0.80 546 679 808 929 1007 1296 
EFR3B 2 ENSG00000084710 4.71E-05 1.09E-03 -0.80 88 104 131 153 160 200 
AC008914.1 5 ENSG00000262211 3.29E-05 8.04E-04 -0.81 105 105 126 169 172 196 
ARC 8 ENSG00000198576 3.54E-08 1.77E-06 -0.82 210 217 273 401 326 394 




TRPV3 17 ENSG00000167723 1.81E-04 3.43E-03 -0.82 112 115 118 168 129 275 
SLC16A6 17 ENSG00000108932 5.13E-10 3.25E-08 -0.83 215 263 288 393 390 451 
EFL1 15 ENSG00000140598 5.81E-18 8.56E-16 -0.83 551 604 725 991 933 1115 
SDSL 12 ENSG00000139410 2.12E-09 1.26E-07 -0.83 527 413 584 731 847 908 
AC091167.6 15 ENSG00000275674 1.73E-07 7.69E-06 -0.83 146 159 210 264 248 325 
HAPLN3 15 ENSG00000140511 1.00E-06 3.72E-05 -0.83 123 143 168 208 211 290 
LINC01271 20 ENSG00000233077 1.36E-07 6.12E-06 -0.84 150 206 198 258 295 348 
OLFML2A 9 ENSG00000185585 2.80E-12 2.26E-10 -0.84 337 471 595 674 682 917 
MEIS2 15 ENSG00000134138 1.16E-16 1.45E-14 -0.84 579 642 711 1007 1032 1106 
SERTAD1 19 ENSG00000197019 5.18E-11 3.65E-09 -0.85 611 600 751 1089 1106 988 
AL356652.1 20 ENSG00000278367 4.07E-08 1.99E-06 -0.85 247 200 313 385 382 489 
SEMA3F 3 ENSG00000001617 2.82E-16 3.37E-14 -0.85 757 701 895 1299 1181 1398 
ARPIN-AP3S2 15 ENSG00000250021 4.11E-19 6.64E-17 -0.85 629 662 858 1092 1095 1345 
LINC01270 20 ENSG00000203999 6.17E-12 4.81E-10 -0.86 295 361 365 472 521 707 
ASB7 15 ENSG00000183475 1.14E-17 1.59E-15 -0.86 516 651 691 982 992 1077 
KRT15 17 ENSG00000171346 5.10E-12 4.02E-10 -0.86 314 322 412 533 482 737 
KLK10 19 ENSG00000129451 1.52E-10 1.01E-08 -0.86 208 265 306 428 397 457 
PAPSS2 10 ENSG00000198682 4.38E-16 5.15E-14 -0.87 414 597 597 859 734 1086 
AL137129.1 14 ENSG00000258964 3.22E-15 3.46E-13 -0.87 428 598 575 893 834 921 
OPTN 10 ENSG00000123240 2.58E-10 1.69E-08 -0.87 229 371 317 455 468 605 
ADGRB1 8 ENSG00000181790 1.51E-04 2.97E-03 -0.88 68 76 122 127 122 200 
AC138904.1 16 ENSG00000246465 3.27E-04 5.70E-03 -0.88 58 83 73 98 127 134 
HOXB8 17 ENSG00000120068 5.80E-06 1.74E-04 -0.89 113 123 200 267 192 269 
FAH 15 ENSG00000103876 6.90E-13 6.02E-11 -0.89 247 287 347 482 432 572 
SELENOS 15 ENSG00000131871 1.43E-24 3.37E-22 -0.89 639 795 944 1253 1211 1536 
LYPLAL1 1 ENSG00000143353 7.47E-23 1.56E-20 -0.89 523 648 693 1006 920 1231 




GDPGP1 15 ENSG00000183208 5.33E-08 2.54E-06 -0.90 186 180 256 355 350 341 
EBF4 20 ENSG00000088881 3.16E-11 2.29E-09 -0.90 214 306 361 429 451 617 
AOPEP 9 ENSG00000148120 7.77E-17 9.96E-15 -0.91 454 523 722 936 891 1058 
ARL14EPL 5 ENSG00000268223 1.44E-04 2.83E-03 -0.91 55 75 83 123 93 150 
TINCR 19 ENSG00000223573 1.50E-08 8.02E-07 -0.91 172 174 244 277 328 408 
FES 15 ENSG00000182511 2.82E-09 1.65E-07 -0.91 295 227 313 472 455 517 
AC132938.4 17 ENSG00000278964 1.53E-04 2.99E-03 -0.92 60 73 98 99 135 162 
HOXB4 17 ENSG00000182742 1.37E-13 1.28E-11 -0.92 306 293 377 537 500 654 
TRIM46 1 ENSG00000163462 1.51E-07 6.74E-06 -0.92 132 152 158 229 203 344 
ARPIN 15 ENSG00000242498 4.74E-18 7.14E-16 -0.92 443 504 678 931 803 1066 
NDRG4 16 ENSG00000103034 4.99E-21 9.44E-19 -0.92 520 551 681 926 947 1161 
SCARF1 17 ENSG00000074660 5.66E-04 8.96E-03 -0.93 56 51 82 129 84 114 
CTSH 15 ENSG00000103811 6.10E-14 5.80E-12 -0.93 293 364 400 610 594 618 
MSLNL 16 ENSG00000162006 1.29E-06 4.60E-05 -0.94 87 105 115 165 155 221 
CEBPD 8 ENSG00000221869 1.08E-06 3.98E-05 -0.95 228 163 348 463 399 422 
GHRLOS 3 ENSG00000240288 4.66E-04 7.66E-03 -0.95 39 62 96 102 93 150 
IFITM2 11 ENSG00000185201 1.04E-20 1.94E-18 -0.95 551 543 707 996 993 1195 
CAPS 19 ENSG00000105519 4.95E-06 1.53E-04 -0.96 111 85 113 167 163 227 
LRRK1 15 ENSG00000154237 7.74E-20 1.35E-17 -0.96 693 629 812 1197 1078 1566 
C15orf40 15 ENSG00000169609 7.93E-19 1.26E-16 -0.97 386 526 481 777 704 1019 
WHAMM 15 ENSG00000156232 8.20E-15 8.53E-13 -0.97 289 318 344 572 529 593 
GAL3ST4 7 ENSG00000197093 2.56E-12 2.10E-10 -0.97 277 353 389 602 433 805 
AC022558.3 15 ENSG00000273747 1.57E-08 8.34E-07 -0.97 116 144 143 231 202 293 
MIR22HG 17 ENSG00000186594 1.90E-04 3.56E-03 -0.98 60 86 86 141 81 202 
TEX19 17 ENSG00000182459 3.87E-10 2.49E-08 -0.98 143 159 205 282 277 350 
AC118344.2 19 ENSG00000279759 5.19E-08 2.49E-06 -0.98 171 259 196 355 267 527 




AC048382.5 15 ENSG00000275120 2.60E-04 4.67E-03 -0.98 51 51 65 95 105 98 
TTC23 15 ENSG00000103852 2.13E-15 2.34E-13 -0.98 224 309 329 488 473 589 
RNF157-AS1 17 ENSG00000267128 8.06E-05 1.74E-03 -0.99 55 62 65 92 100 141 
AC078816.1 3 ENSG00000286273 3.02E-05 7.47E-04 -0.99 52 72 77 119 111 132 
VPS33B 15 ENSG00000184056 1.84E-21 3.55E-19 -0.99 452 478 562 823 874 1014 
CST6 11 ENSG00000175315 2.24E-12 1.85E-10 -0.99 295 264 347 559 529 554 
SNCA 4 ENSG00000145335 1.07E-04 2.21E-03 -1.00 51 87 73 93 118 176 
SMAD7 18 ENSG00000101665 7.46E-05 1.63E-03 -1.00 77 58 76 108 109 178 
NANOS1 10 ENSG00000188613 2.50E-04 4.52E-03 -1.01 44 75 49 94 98 116 
CDIP1 16 ENSG00000089486 2.90E-20 5.24E-18 -1.01 348 388 470 673 696 838 
AC016074.2 8 ENSG00000286122 8.58E-16 9.80E-14 -1.01 422 672 567 934 803 1340 
KALRN 3 ENSG00000160145 8.64E-10 5.35E-08 -1.01 123 216 220 307 299 414 
AC048382.6 15 ENSG00000276278 5.13E-09 2.89E-07 -1.01 109 143 152 211 234 299 
MESP1 15 ENSG00000166823 4.14E-05 9.81E-04 -1.01 92 65 137 184 185 164 
SUSD3 9 ENSG00000157303 1.09E-04 2.23E-03 -1.02 44 74 80 116 130 110 
AC068831.1 15 ENSG00000258384 2.78E-08 1.43E-06 -1.02 171 142 149 263 282 318 
FNDC4 2 ENSG00000115226 2.65E-04 4.75E-03 -1.02 35 91 111 155 109 163 
AP003392.1 11 ENSG00000254428 1.46E-04 2.87E-03 -1.02 48 72 51 98 85 138 
DET1 15 ENSG00000140543 4.47E-06 1.40E-04 -1.03 55 89 96 145 134 162 
IFIT1 10 ENSG00000185745 3.61E-08 1.80E-06 -1.03 153 147 175 332 201 365 
ZCCHC12 X ENSG00000174460 4.90E-09 2.76E-07 -1.04 122 150 207 323 264 295 
MRPL46 15 ENSG00000259494 6.35E-26 1.62E-23 -1.04 463 655 656 1047 1033 1219 
GASK1A 3 ENSG00000144649 3.67E-05 8.88E-04 -1.04 59 52 74 122 100 125 
CACNA1G 17 ENSG00000006283 7.00E-09 3.87E-07 -1.04 114 119 171 246 202 313 
COL9A2 1 ENSG00000049089 2.02E-05 5.27E-04 -1.04 49 64 91 107 120 154 
SERPINA5 14 ENSG00000188488 5.70E-07 2.25E-05 -1.05 87 88 143 168 203 223 




MYL9 20 ENSG00000101335 2.97E-28 8.82E-26 -1.05 646 667 895 1296 1288 1580 
GPR87 3 ENSG00000138271 2.48E-07 1.07E-05 -1.05 73 93 105 155 163 192 
ESRRB 14 ENSG00000119715 2.28E-05 5.89E-04 -1.06 58 61 60 109 110 122 
AL022318.4 22 ENSG00000284554 2.47E-07 1.07E-05 -1.06 92 116 143 196 160 322 
LUCAT1 5 ENSG00000248323 7.89E-05 1.71E-03 -1.07 72 107 66 120 115 250 
DSC3 18 ENSG00000134762 1.76E-20 3.23E-18 -1.08 423 588 582 823 1027 1208 
APOBEC3D 22 ENSG00000243811 2.07E-07 9.08E-06 -1.08 90 131 148 213 163 345 
TMEM200A 6 ENSG00000164484 6.76E-24 1.55E-21 -1.08 517 672 613 1160 1114 1195 
SLC7A8 14 ENSG00000092068 1.31E-17 1.81E-15 -1.09 207 268 300 450 446 612 
RAMAC 15 ENSG00000169612 2.30E-07 1.00E-05 -1.10 79 120 93 190 186 189 
SYNJ2 6 ENSG00000078269 1.09E-35 4.80E-33 -1.10 634 800 802 1313 1285 1791 
AC013489.1 15 ENSG00000173867 5.37E-23 1.17E-20 -1.10 345 489 519 828 850 936 
ZSCAN2 15 ENSG00000176371 6.42E-28 1.85E-25 -1.10 383 452 520 810 828 1017 
MEGF11 15 ENSG00000157890 8.37E-05 1.80E-03 -1.11 33 53 57 101 81 96 
ST20-MTHFS 15 ENSG00000259332 2.13E-15 2.34E-13 -1.12 261 307 424 650 653 627 
AC011483.2 19 ENSG00000269495 1.09E-27 3.04E-25 -1.12 420 451 532 894 873 1015 
MEX3B 15 ENSG00000183496 1.16E-27 3.20E-25 -1.13 390 510 531 960 860 1016 
MIA 19 ENSG00000261857 2.11E-04 3.92E-03 -1.13 25 56 60 75 81 123 
EFCC1 3 ENSG00000114654 2.60E-07 1.11E-05 -1.14 85 80 80 163 161 170 
NRP1 10 ENSG00000099250 7.46E-10 4.68E-08 -1.14 98 115 110 216 194 242 
CACNA1D 3 ENSG00000157388 2.05E-12 1.71E-10 -1.14 137 159 146 282 266 349 
SPHK1 17 ENSG00000176170 1.51E-12 1.27E-10 -1.15 166 161 273 391 351 463 
CORO1A 16 ENSG00000102879 9.97E-15 1.02E-12 -1.15 157 210 264 390 417 453 
CEACAM1 19 ENSG00000079385 3.52E-07 1.44E-05 -1.17 52 69 86 143 116 165 
LAMC3 9 ENSG00000050555 1.00E-33 4.16E-31 -1.18 563 555 720 1184 1136 1485 
CSRNP1 3 ENSG00000144655 3.28E-20 5.87E-18 -1.18 262 374 478 754 706 804 




F5 1 ENSG00000198734 2.75E-04 4.92E-03 -1.19 23 43 40 66 56 99 
SOCS1 16 ENSG00000185338 2.75E-12 2.23E-10 -1.19 157 144 253 345 362 436 
CCNJL 5 ENSG00000135083 8.44E-22 1.69E-19 -1.19 292 358 461 704 775 805 
ISM1 20 ENSG00000101230 1.55E-11 1.15E-09 -1.20 123 162 161 303 326 291 
CORO2B 15 ENSG00000103647 8.87E-07 3.36E-05 -1.20 45 83 82 128 115 199 
PADI2 1 ENSG00000117115 4.46E-09 2.53E-07 -1.20 67 84 114 175 163 215 
BVES 6 ENSG00000112276 6.82E-11 4.71E-09 -1.20 122 235 156 318 324 438 
HIF1A-AS1 14 ENSG00000258777 7.05E-23 1.49E-20 -1.22 363 385 560 916 882 941 
CORO6 17 ENSG00000167549 9.85E-17 1.25E-14 -1.22 264 344 448 768 513 974 
MTHFS 15 ENSG00000136371 6.72E-18 9.60E-16 -1.22 263 308 447 714 714 695 
TFAP2E 1 ENSG00000116819 3.25E-10 2.11E-08 -1.23 86 92 115 223 174 228 
NOVA2 19 ENSG00000104967 3.31E-18 5.05E-16 -1.24 185 182 215 387 378 493 
UNC5B-AS1 10 ENSG00000237512 3.82E-04 6.55E-03 -1.24 30 29 26 55 51 81 
PLXNB3 X ENSG00000198753 1.35E-16 1.67E-14 -1.25 248 221 364 552 482 788 
RAMACL 6 ENSG00000235272 9.04E-20 1.56E-17 -1.25 199 215 270 499 463 513 
SRPX2 X ENSG00000102359 1.00E-23 2.23E-21 -1.25 236 269 268 539 516 630 
RAB15 14 ENSG00000139998 5.28E-29 1.64E-26 -1.27 338 341 443 735 774 955 
LINS1 15 ENSG00000140471 4.36E-29 1.38E-26 -1.27 312 314 372 705 651 849 
AC092306.1 19 ENSG00000285128 1.22E-09 7.44E-08 -1.28 64 94 110 194 147 253 
SERPINF2 17 ENSG00000167711 1.39E-14 1.39E-12 -1.29 139 149 143 332 294 335 
BCL11A 2 ENSG00000119866 7.06E-07 2.74E-05 -1.29 56 55 52 100 107 164 
AC025419.1 12 ENSG00000250748 4.76E-15 5.09E-13 -1.32 121 230 180 403 347 452 
GOLGA6L9 15 ENSG00000197978 1.90E-17 2.55E-15 -1.32 206 280 268 524 409 817 
GAS6-DT 13 ENSG00000272695 4.62E-05 1.08E-03 -1.34 21 62 37 90 78 106 
NAALAD2 11 ENSG00000077616 2.52E-04 4.55E-03 -1.34 15 49 38 57 65 113 
PLEKHA4 19 ENSG00000105559 2.03E-38 1.06E-35 -1.34 397 405 521 1006 891 1170 




AC103718.1 8 ENSG00000285108 8.01E-09 4.40E-07 -1.36 108 122 73 213 181 343 
ALPK3 15 ENSG00000136383 8.22E-11 5.62E-09 -1.36 67 76 101 203 150 219 
SPRED3 19 ENSG00000188766 2.14E-14 2.09E-12 -1.37 90 132 188 305 276 374 
SNHG21 15 ENSG00000250988 4.39E-06 1.38E-04 -1.37 33 38 39 73 73 118 
AC243919.2 15 ENSG00000278202 2.34E-07 1.01E-05 -1.38 49 67 52 128 90 189 
AL121906.2 20 ENSG00000275223 4.18E-04 7.04E-03 -1.38 21 17 24 51 42 55 
PON3 7 ENSG00000105852 6.45E-04 9.93E-03 -1.38 10 26 46 71 54 62 
NECTIN4 1 ENSG00000143217 7.94E-12 6.04E-10 -1.40 85 85 112 197 176 317 
IFIT2 10 ENSG00000119922 1.32E-07 5.96E-06 -1.40 32 66 58 126 98 151 
GPR15 3 ENSG00000154165 5.07E-05 1.16E-03 -1.41 26 32 22 66 54 77 
MAMDC2 9 ENSG00000165072 6.36E-09 3.53E-07 -1.43 52 59 67 143 102 198 
LOXL4 10 ENSG00000138131 3.90E-11 2.79E-09 -1.43 54 87 77 175 148 213 
FAT2 5 ENSG00000086570 2.13E-10 1.40E-08 -1.44 52 75 77 149 133 226 
SKAP1 17 ENSG00000141293 3.01E-06 9.96E-05 -1.45 22 48 61 113 106 95 
EPB41L4A-DT 5 ENSG00000278921 7.40E-07 2.86E-05 -1.45 34 36 85 130 102 148 
DNAH12 3 ENSG00000174844 4.07E-04 6.87E-03 -1.46 20 32 14 68 44 54 
CNTNAP1 17 ENSG00000108797 2.32E-25 5.75E-23 -1.46 208 222 239 597 429 671 
B3GALT5 21 ENSG00000183778 2.93E-05 7.27E-04 -1.47 15 29 52 77 64 97 
AC106875.1 2 ENSG00000228496 4.55E-04 7.50E-03 -1.48 13 15 34 55 35 66 
CDKN2B 9 ENSG00000147883 5.43E-32 1.89E-29 -1.49 177 238 284 556 544 686 
EDAR 2 ENSG00000135960 2.32E-30 7.82E-28 -1.52 185 216 224 483 532 619 
AC004231.1 17 ENSG00000234477 1.65E-15 1.83E-13 -1.54 80 86 87 206 208 259 
GLT8D2 12 ENSG00000120820 1.03E-12 8.89E-11 -1.54 58 60 91 173 168 211 
CNTNAP2 7 ENSG00000174469 1.83E-16 2.22E-14 -1.54 77 146 122 309 277 320 
GRIN2C 17 ENSG00000161509 2.12E-36 9.60E-34 -1.55 308 333 381 970 687 1086 
ACTL8 1 ENSG00000117148 8.13E-05 1.75E-03 -1.55 9 29 42 69 70 66 




NFASC 1 ENSG00000163531 4.09E-05 9.72E-04 -1.56 26 24 16 53 52 78 
OASL 12 ENSG00000135114 1.39E-14 1.39E-12 -1.56 70 71 82 186 189 228 
AC090023.1 12 ENSG00000255866 3.50E-07 1.44E-05 -1.57 25 48 31 97 81 103 
MYOM3 1 ENSG00000142661 1.86E-37 9.04E-35 -1.57 194 255 273 613 545 806 
LGALS9 17 ENSG00000168961 2.93E-04 5.19E-03 -1.58 9 14 35 50 45 59 
LINC01405 12 ENSG00000185847 0.00E+00 1.50E-44 -1.59 262 356 404 862 793 1145 
SLC6A20 3 ENSG00000163817 7.59E-08 3.58E-06 -1.59 29 50 35 85 91 140 
TNXB 6 ENSG00000168477 1.71E-19 2.81E-17 -1.59 139 105 163 365 361 395 
DAPK1 9 ENSG00000196730 1.26E-24 3.02E-22 -1.60 111 135 166 339 327 476 
IQGAP2 5 ENSG00000145703 1.68E-36 7.75E-34 -1.60 173 236 246 584 565 658 
FLNC-AS1 7 ENSG00000242902 5.93E-04 9.29E-03 -1.62 11 15 12 31 34 42 
NR2F2-AS1 15 ENSG00000247809 4.90E-05 1.13E-03 -1.63 8 43 28 73 59 87 
MUC19 12 ENSG00000205592 1.66E-06 5.80E-05 -1.63 24 38 32 83 52 138 
KISS1R 19 ENSG00000116014 4.31E-34 1.82E-31 -1.64 199 188 280 602 576 712 
SUSD2 22 ENSG00000099994 4.12E-33 1.57E-30 -1.64 163 224 302 577 597 774 
NTF4 19 ENSG00000225950 1.48E-05 3.98E-04 -1.65 24 20 18 47 62 72 
PLEKHA6 1 ENSG00000143850 9.61E-42 5.79E-39 -1.67 205 254 309 656 636 950 
AC100793.3 17 ENSG00000267765 8.04E-05 1.74E-03 -1.68 26 12 16 59 46 56 
FHAD1 1 ENSG00000142621 1.44E-14 1.43E-12 -1.68 54 117 87 207 223 325 
LTBP2 14 ENSG00000119681 4.69E-33 1.76E-30 -1.69 191 174 231 572 470 729 
RNF227 17 ENSG00000179859 1.92E-04 3.60E-03 -1.69 12 27 12 65 33 52 
PRSS33 16 ENSG00000103355 8.31E-06 2.39E-04 -1.69 12 21 31 60 61 63 
PGBD5 1 ENSG00000177614 3.76E-05 9.07E-04 -1.69 12 19 23 37 48 75 
NTNG2 9 ENSG00000196358 3.69E-06 1.19E-04 -1.70 20 15 37 73 64 73 
SECTM1 17 ENSG00000141574 5.83E-07 2.30E-05 -1.70 26 21 28 71 76 75 
AC080038.1 17 ENSG00000011028 0.00E+00 0.00E+00 -1.71 315 323 395 936 946 1218 




EGR3 8 ENSG00000179388 7.64E-13 6.63E-11 -1.73 48 89 75 231 216 178 
ASGR1 17 ENSG00000141505 9.11E-08 4.24E-06 -1.74 34 19 46 83 86 136 
SPNS3 17 ENSG00000182557 7.40E-05 1.62E-03 -1.74 13 12 21 44 52 41 
IL11 19 ENSG00000095752 9.97E-07 3.72E-05 -1.74 30 16 44 100 92 77 
TSPOAP1 17 ENSG00000005379 1.28E-09 7.83E-08 -1.75 48 33 56 117 100 215 
SEMA3A 7 ENSG00000075213 0.00E+00 0.00E+00 -1.75 411 515 514 1396 1331 1686 
KIF7 15 ENSG00000166813 1.36E-16 1.67E-14 -1.76 87 59 122 249 240 348 
KRTAP2-3 17 ENSG00000212724 1.50E-14 1.49E-12 -1.78 40 66 72 172 142 245 
CHD5 1 ENSG00000116254 0.00E+00 2.06E-43 -1.79 279 277 396 973 986 1019 
AP000779.1 11 ENSG00000285921 2.04E-05 5.31E-04 -1.80 14 18 15 35 50 66 
ABCA1 9 ENSG00000165029 6.25E-07 2.45E-05 -1.81 35 18 25 85 56 118 
IFI35 17 ENSG00000068079 3.92E-06 1.25E-04 -1.81 18 26 14 64 64 57 
AC090907.2 15 ENSG00000259755 3.68E-06 1.18E-04 -1.81 20 12 24 57 60 62 
COL16A1 1 ENSG00000084636 1.69E-19 2.80E-17 -1.82 60 69 108 225 219 319 
ALPL 1 ENSG00000162551 2.77E-06 9.23E-05 -1.83 13 19 19 54 50 61 
HAS2 8 ENSG00000170961 8.86E-12 6.67E-10 -1.86 25 47 42 111 117 147 
AC010261.2 5 ENSG00000251187 5.07E-08 2.44E-06 -1.86 13 30 36 73 71 117 
OR51M1 11 ENSG00000184698 5.20E-04 8.39E-03 -1.87 4 18 10 33 24 50 
FAM184A 6 ENSG00000111879 1.11E-07 5.11E-06 -1.88 13 25 28 65 74 79 
ALOX5 10 ENSG00000012779 2.06E-13 1.87E-11 -1.90 44 42 47 142 164 144 
ARMC4 10 ENSG00000169126 3.91E-38 1.94E-35 -1.90 111 127 157 426 386 540 
MAML2 11 ENSG00000184384 0.00E+00 0.00E+00 -1.91 152 232 234 635 675 801 
AC015712.7 15 ENSG00000278456 4.41E-04 7.33E-03 -1.92 9 7 9 28 25 34 
ZC3H11B 1 ENSG00000215817 0.00E+00 0.00E+00 -1.92 209 331 321 881 933 1154 
ID2 2 ENSG00000115738 0.00E+00 0.00E+00 -1.93 369 375 367 1284 1257 1314 
IGFL4 19 ENSG00000204869 2.29E-04 4.20E-03 -1.95 8 19 8 42 19 67 




GGT5 22 ENSG00000099998 1.01E-10 6.89E-09 -1.98 25 31 25 95 84 114 
TRIM22 11 ENSG00000132274 6.52E-12 5.06E-10 -1.98 23 37 40 115 87 160 
DHRS2 14 ENSG00000100867 2.08E-23 4.59E-21 -1.99 67 80 68 272 233 273 
ISG20 15 ENSG00000172183 8.71E-14 8.21E-12 -1.99 23 56 48 134 136 187 
AC008957.1 5 ENSG00000250155 1.14E-05 3.17E-04 -2.00 14 14 10 38 36 69 
AC002351.1 12 ENSG00000258240 4.48E-19 7.18E-17 -2.02 47 45 57 180 161 211 
ANKRD2 10 ENSG00000165887 6.26E-04 9.68E-03 -2.07 9 8 6 28 13 52 
AC015712.5 15 ENSG00000272639 1.40E-33 5.67E-31 -2.07 80 82 121 339 327 413 
CPA4 7 ENSG00000128510 9.41E-35 4.07E-32 -2.09 119 99 104 393 375 505 
CREB3L1 11 ENSG00000157613 3.38E-04 5.89E-03 -2.11 5 9 6 25 24 30 
TNFSF18 1 ENSG00000120337 7.70E-28 2.19E-25 -2.14 86 71 72 314 273 342 
MSX2 5 ENSG00000120149 0.00E+00 0.00E+00 -2.14 286 378 401 1398 1321 1534 
CEND1 11 ENSG00000184524 5.81E-06 1.74E-04 -2.14 6 13 14 37 47 46 
NRG1 8 ENSG00000157168 1.25E-12 1.06E-10 -2.16 33 37 25 118 90 193 
CSMD3 8 ENSG00000164796 1.01E-04 2.12E-03 -2.18 16 4 6 33 35 44 
QPRT 16 ENSG00000103485 1.68E-05 4.47E-04 -2.20 5 6 23 36 44 59 
FOXJ1 17 ENSG00000129654 5.91E-05 1.34E-03 -2.23 6 7 9 29 23 43 
CSF1R 5 ENSG00000182578 2.13E-04 3.95E-03 -2.24 3 9 7 29 21 31 
REEP2 5 ENSG00000132563 3.66E-33 1.45E-30 -2.26 71 79 91 388 322 335 
C3 19 ENSG00000125730 3.03E-04 5.33E-03 -2.27 11 2 6 23 24 41 
DUOX1 15 ENSG00000137857 9.06E-24 2.05E-21 -2.28 62 54 46 227 194 314 
SLC2A3 12 ENSG00000059804 0.00E+00 4.30E-44 -2.32 129 200 188 672 580 1152 
EVA1A 2 ENSG00000115363 1.22E-21 2.40E-19 -2.38 24 52 66 203 232 223 
MKX 10 ENSG00000150051 0.00E+00 0.00E+00 -2.42 248 299 272 1321 1230 1464 
ALPP 2 ENSG00000163283 4.54E-06 1.42E-04 -2.47 8 5 9 46 31 34 
STRA6 15 ENSG00000137868 5.28E-27 1.42E-24 -2.48 34 76 54 225 238 379 




MAB21L4 2 ENSG00000172478 4.92E-04 8.01E-03 -2.52 4 0 11 20 30 26 
SPOCK3 4 ENSG00000196104 3.90E-13 3.48E-11 -2.58 20 17 16 68 105 120 
SYT8 11 ENSG00000149043 6.32E-08 3.00E-06 -2.60 8 6 13 40 40 71 
HOXA-AS2 7 ENSG00000253552 1.06E-14 1.08E-12 -2.60 13 22 18 85 88 122 
PRF1 10 ENSG00000180644 0.00E+00 0.00E+00 -2.65 198 186 207 977 1125 1313 
APOBEC3G 22 ENSG00000239713 0.00E+00 9.80E-45 -2.66 68 87 67 357 377 568 
ORM2 9 ENSG00000228278 5.04E-05 1.16E-03 -2.69 7 1 6 25 21 39 
ALPG 2 ENSG00000163286 8.29E-05 1.78E-03 -2.70 3 8 2 29 26 21 
KRT39 17 ENSG00000196859 2.34E-05 6.02E-04 -2.71 7 7 1 26 26 41 
MYL2 12 ENSG00000111245 8.52E-06 2.45E-04 -2.72 11 1 6 42 35 33 
LINC00518 6 ENSG00000183674 5.39E-05 1.23E-03 -2.74 1 4 8 24 25 28 
PPP1R1A 12 ENSG00000135447 1.44E-04 2.83E-03 -2.75 1 4 6 23 19 24 
AC008957.3 5 ENSG00000279400 1.19E-32 4.31E-30 -2.77 33 49 45 243 189 369 
PLEKHS1 10 ENSG00000148735 8.88E-05 1.89E-03 -2.77 0 11 3 26 24 36 
HLA-DRA 6 ENSG00000204287 1.48E-17 2.01E-15 -2.77 15 15 34 102 142 149 
ZNF850 19 ENSG00000267041 1.66E-10 1.09E-08 -2.78 19 4 13 76 75 78 
FAM92B 16 ENSG00000153789 3.56E-07 1.46E-05 -2.80 1 13 8 47 31 61 
FER1L5 2 ENSG00000249715 4.81E-20 8.46E-18 -2.84 18 20 21 129 95 166 
AL121748.1 10 ENSG00000238258 1.34E-04 2.67E-03 -2.89 1 2 7 23 17 26 
SPTSSB 3 ENSG00000196542 0.00E+00 0.00E+00 -2.89 63 86 97 513 492 661 
HRNR 1 ENSG00000197915 1.20E-10 8.03E-09 -2.90 6 14 7 54 56 75 
PTPN7 1 ENSG00000143851 2.60E-04 4.67E-03 -2.94 2 3 3 23 12 21 
FLG-AS1 1 ENSG00000237975 4.68E-11 3.31E-09 -2.96 5 18 7 53 74 86 
KCNJ4 22 ENSG00000168135 9.26E-05 1.96E-03 -3.03 3 7 0 36 16 23 
HOXA3 7 ENSG00000105997 0.00E+00 0.00E+00 -3.10 42 52 62 335 373 518 
AC018398.1 8 ENSG00000288076 1.05E-04 2.17E-03 -3.12 1 6 1 21 20 22 




TNFSF4 1 ENSG00000117586 0.00E+00 0.00E+00 -3.16 94 153 109 835 857 1248 
ZNF804A 2 ENSG00000170396 6.68E-24 1.54E-21 -3.20 11 26 15 129 143 162 
POF1B X ENSG00000124429 2.37E-05 6.06E-04 -3.25 0 7 2 22 20 36 
HOTAIR 12 ENSG00000228630 4.87E-05 1.13E-03 -3.28 3 3 1 16 19 29 
RASGRF1 15 ENSG00000058335 3.76E-28 1.10E-25 -3.32 13 16 22 138 146 180 
AC003112.1 19 ENSG00000105696 0.00E+00 0.00E+00 -3.44 68 99 114 883 834 1049 
MYBPH 1 ENSG00000133055 3.47E-04 6.02E-03 -3.44 1 4 0 19 16 14 
KLK5 19 ENSG00000167754 1.13E-41 6.62E-39 -3.48 21 20 28 240 217 243 
SLCO3A1 15 ENSG00000176463 4.52E-05 1.06E-03 -3.55 0 3 3 20 25 16 
NMB 15 ENSG00000197696 3.62E-42 2.25E-39 -3.55 16 31 22 226 247 258 
OLFML3 1 ENSG00000116774 1.23E-06 4.42E-05 -3.61 0 3 5 30 29 27 
AL355916.1 14 ENSG00000232774 4.14E-07 1.67E-05 -3.64 5 46 20 236 220 334 
TPO 2 ENSG00000115705 1.02E-04 2.13E-03 -3.72 0 0 5 20 15 23 
AC007342.5 16 ENSG00000262714 1.47E-05 3.97E-04 -3.83 1 1 3 17 19 29 
AC015712.6 15 ENSG00000272808 4.25E-18 6.45E-16 -3.85 5 6 9 72 78 114 
AP000851.1 11 ENSG00000256916 4.79E-05 1.11E-03 -4.00 1 0 3 25 12 21 
ELF5 11 ENSG00000135374 3.40E-37 1.61E-34 -4.07 12 11 14 172 153 250 
FLG 1 ENSG00000143631 4.50E-25 1.09E-22 -4.09 3 16 7 140 124 134 
ICAM1 19 ENSG00000090339 4.46E-20 7.92E-18 -4.12 19 40 83 701 637 827 
RIMS2 8 ENSG00000176406 5.03E-18 7.49E-16 -4.15 28 115 107 1295 1198 1379 
ANKRD1 10 ENSG00000148677 5.17E-12 4.06E-10 -4.20 1 2 7 50 45 71 
MMP20 11 ENSG00000137674 7.42E-07 2.86E-05 -4.23 2 0 3 38 19 28 
LINC01907 2 ENSG00000226125 4.80E-17 6.28E-15 -4.26 0 5 10 72 71 117 
AC011511.5 19 ENSG00000267607 3.74E-32 1.33E-29 -4.28 2 15 12 175 136 197 
SLC30A10 1 ENSG00000196660 0.00E+00 0.00E+00 -4.35 10 34 28 424 409 498 
SALL4 20 ENSG00000101115 6.39E-29 1.95E-26 -4.41 5 5 15 156 105 228 




AC113410.5 5 ENSG00000287054 1.19E-06 4.30E-05 -4.46 0 1 3 29 21 29 
SPOCK1 5 ENSG00000152377 0.00E+00 0.00E+00 -4.50 9 11 19 242 260 299 
IGFBP3 7 ENSG00000146674 1.80E-05 4.74E-04 -4.52 0 1 2 17 15 31 
COCH 14 ENSG00000100473 9.04E-33 3.33E-30 -4.58 6 8 8 166 133 180 
AMIGO1 1 ENSG00000181754 4.30E-04 7.18E-03 -4.59 1 0 1 20 17 5 
AC011944.1 15 ENSG00000177699 5.56E-06 1.69E-04 -4.69 0 3 0 20 21 30 
LINC01411 5 ENSG00000249306 7.40E-06 2.16E-04 -4.70 0 3 0 33 17 20 
LYPLAL1-AS1 1 ENSG00000228536 0.00E+00 0.00E+00 -4.71 5 19 12 273 272 310 
TGFB2 1 ENSG00000092969 7.46E-05 1.63E-03 -4.74 15 0 5 151 177 200 
ZNF280A 22 ENSG00000169548 3.35E-11 2.41E-09 -4.79 5 0 1 40 52 64 
AC015712.1 15 ENSG00000232386 7.19E-05 1.58E-03 -4.87 2 0 0 14 12 31 
RUNX2 6 ENSG00000124813 0.00E+00 0.00E+00 -4.89 23 43 68 1131 1051 1430 
ANXA10 4 ENSG00000109511 1.63E-19 2.72E-17 -4.94 5 1 4 96 86 99 
AC096667.1 2 ENSG00000283839 4.92E-04 8.01E-03 -5.12 1 0 0 10 16 7 
SH3GL3 15 ENSG00000140600 5.46E-10 3.43E-08 -5.22 1 3 0 39 41 57 
MKX-AS1 10 ENSG00000230500 1.10E-04 2.25E-03 -5.47 1 0 0 15 7 23 
KCNQ5 6 ENSG00000185760 6.31E-04 9.76E-03 -5.47 0 0 0 7 9 6 
TGFB2-OT1 1 ENSG00000281453 2.91E-09 1.70E-07 -5.63 1 0 2 38 55 40 
AL450345.2 6 ENSG00000287550 2.50E-04 4.52E-03 -5.71 0 0 0 5 13 8 
JAKMIP2 5 ENSG00000176049 1.68E-04 3.22E-03 -5.76 0 0 0 9 10 8 
EHF 11 ENSG00000135373 0.00E+00 0.00E+00 -5.87 9 21 28 928 987 1154 
IGFL2-AS1 19 ENSG00000268621 2.50E-05 6.34E-04 -6.18 0 0 0 17 6 14 
ADGRL2 1 ENSG00000117114 2.69E-05 6.75E-04 -6.20 0 0 0 19 11 6 
KLHDC9 1 ENSG00000162755 2.22E-06 7.58E-05 -6.24 0 0 1 19 20 37 
AC092604.1 2 ENSG00000286260 2.91E-06 9.66E-05 -6.54 0 0 0 14 11 23 
LGALS7B 19 ENSG00000178934 3.18E-06 1.04E-04 -6.59 0 0 0 22 17 8 




TGFBI 5 ENSG00000120708 2.55E-08 1.33E-06 -7.30 0 0 0 22 22 37 
KCNB2 8 ENSG00000182674 1.88E-08 9.91E-07 -7.35 0 0 0 22 30 30 
KRTAP3-1 17 ENSG00000212901 2.17E-10 1.42E-08 -7.80 0 1 0 79 65 74 
TACSTD2 1 ENSG00000184292 1.51E-38 8.13E-36 -7.96 1 5 0 349 419 611 






Table 8.2 RNA-Seq down regulated genes 
Probe Chromosome ID P-value FDR Log2Fold WT RPKM HOTTIP KO RPKM 
SOHLH2 13 ENSG00000120669 5.34E-21 1.00E-18 11.17 402 510 484 0 0 0 
AC105460.1 4 ENSG00000250920 2.54E-20 4.62E-18 10.98 323 433 480 0 0 0 
CCDC169-SOHLH2 13 ENSG00000250709 1.91E-19 3.11E-17 10.74 297 378 361 0 0 0 
PODXL2 3 ENSG00000114631 0.00E+00 0.00E+00 7.10 1095 1131 1359 8 9 7 
AC105460.2 4 ENSG00000251577 5.32E-05 1.21E-03 5.93 10 15 12 0 0 0 
LYL1 19 ENSG00000104903 1.23E-07 5.62E-06 5.90 36 45 51 2 0 0 
RAD51AP2 2 ENSG00000214842 1.64E-04 3.17E-03 5.33 9 13 27 0 0 1 
CD96 3 ENSG00000153283 4.48E-24 1.05E-21 5.14 128 156 144 3 7 1 
LDB2 4 ENSG00000169744 4.57E-04 7.52E-03 5.06 11 9 20 0 0 1 
AC079949.4 12 ENSG00000286016 3.67E-04 6.32E-03 4.54 11 20 19 0 0 2 
NCAM1 11 ENSG00000149294 2.91E-13 2.61E-11 4.39 49 69 111 3 0 7 
CU633904.1 21 ENSG00000276077 1.75E-09 1.05E-07 4.23 44 108 27 2 1 6 
CU634019.1 21 ENSG00000277067 2.29E-15 2.50E-13 4.13 76 149 72 3 2 11 
RAB3C 5 ENSG00000152932 1.52E-06 5.36E-05 4.05 24 27 39 1 1 3 
FBLIM1 1 ENSG00000162458 4.84E-41 2.75E-38 3.67 264 279 255 23 15 20 
GRM1 6 ENSG00000152822 2.95E-04 5.20E-03 3.65 13 21 20 0 1 3 
LINC00944 12 ENSG00000256128 5.14E-05 1.18E-03 3.44 19 28 24 4 0 2 
SEMA3D 7 ENSG00000153993 8.46E-16 9.71E-14 3.37 63 130 115 6 8 13 
LRP1B 2 ENSG00000168702 1.19E-27 3.25E-25 3.37 180 215 245 15 7 36 
KLRC4 12 ENSG00000183542 3.93E-33 1.53E-30 3.32 176 226 231 15 20 23 
EVX1 7 ENSG00000106038 1.16E-04 2.36E-03 3.27 10 37 36 0 1 7 
LINC00846 21 ENSG00000186842 3.11E-04 5.45E-03 3.21 20 22 20 0 5 1 
AL033397.1 6 ENSG00000231683 1.90E-04 3.56E-03 3.18 33 14 21 5 1 1 
AC016717.2 2 ENSG00000273301 2.64E-06 8.87E-05 3.07 30 27 44 3 3 5 




MAP2K6 17 ENSG00000108984 0.00E+00 2.00E-43 2.70 311 451 426 50 52 65 
STXBP6 14 ENSG00000168952 2.46E-30 8.14E-28 2.68 186 259 324 33 35 40 
HOTTIP 7 ENSG00000243766 1.56E-07 6.96E-06 2.62 48 46 53 5 8 9 
KLRC4-KLRK1 12 ENSG00000255819 0.00E+00 0.00E+00 2.58 613 766 817 112 97 125 
ZNF91 19 ENSG00000167232 0.00E+00 0.00E+00 2.58 658 1059 927 111 120 174 
SLC26A4 7 ENSG00000091137 1.49E-07 6.70E-06 2.53 47 63 57 10 3 14 
TNC 9 ENSG00000041982 5.40E-04 8.65E-03 2.49 18 26 25 5 4 2 
LCT 2 ENSG00000115850 2.76E-05 6.89E-04 2.44 34 28 44 8 3 7 
AL158071.5 9 ENSG00000273381 1.09E-07 5.02E-06 2.40 58 58 59 11 5 15 
FGFBP1 4 ENSG00000137440 1.39E-13 1.29E-11 2.38 88 111 133 17 17 24 
PRKAA2 1 ENSG00000162409 1.08E-17 1.52E-15 2.37 118 218 229 23 36 39 
FAM129C 19 ENSG00000167483 2.51E-04 4.53E-03 2.35 16 52 27 4 5 8 
KLRK1 12 ENSG00000213809 0.00E+00 0.00E+00 2.24 480 618 679 114 102 126 
LNCAROD 10 ENSG00000231131 7.33E-06 2.14E-04 2.08 54 45 62 7 8 21 
LPAR5 12 ENSG00000184574 4.91E-16 5.74E-14 2.07 139 162 212 30 32 50 
AC022075.1 12 ENSG00000245648 0.00E+00 0.00E+00 2.04 598 770 822 145 142 199 
TMEM74 8 ENSG00000164841 3.76E-10 2.43E-08 2.01 69 148 149 28 21 33 
SPARC 5 ENSG00000113140 1.17E-25 2.95E-23 2.00 255 289 336 69 53 79 
TCP10L 21 ENSG00000242220 3.24E-05 7.96E-04 2.00 57 37 56 14 13 7 
GPR143 X ENSG00000101850 3.85E-05 9.25E-04 1.99 46 50 63 3 15 19 
SLAMF8 1 ENSG00000158714 9.97E-05 2.09E-03 1.88 50 35 52 7 9 19 
ANKRD22 10 ENSG00000152766 1.26E-26 3.33E-24 1.88 352 450 467 76 91 151 
KLHL32 6 ENSG00000186231 1.74E-11 1.28E-09 1.82 114 146 141 28 34 42 
LINP1 10 ENSG00000223784 6.83E-06 2.01E-04 1.80 48 64 69 13 12 23 
NRP2 2 ENSG00000118257 1.16E-06 4.20E-05 1.78 66 82 67 17 16 25 
ATP8A1 4 ENSG00000124406 5.71E-15 6.04E-13 1.77 176 344 302 62 56 103 




MANSC4 12 ENSG00000205693 1.27E-05 3.48E-04 1.73 61 86 55 15 13 29 
IL20RA 6 ENSG00000016402 2.82E-04 5.03E-03 1.72 33 58 64 10 22 9 
CPQ 8 ENSG00000104324 1.31E-04 2.60E-03 1.71 54 41 91 24 7 21 
BAMBI 10 ENSG00000095739 0.00E+00 0.00E+00 1.71 844 1016 1175 261 271 314 
CALB2 16 ENSG00000172137 6.02E-18 8.80E-16 1.64 285 283 369 88 97 88 
ZNF772 19 ENSG00000197128 8.26E-07 3.14E-05 1.62 85 88 94 23 18 40 
FOXP2 7 ENSG00000128573 9.63E-07 3.60E-05 1.62 73 119 102 27 17 45 
LINC00886 3 ENSG00000240875 4.02E-09 2.31E-07 1.56 145 151 155 44 29 70 
LHFPL6 13 ENSG00000183722 2.65E-06 8.89E-05 1.56 64 104 103 34 25 23 
AC108047.1 2 ENSG00000233654 5.65E-04 8.95E-03 1.56 39 54 43 14 8 21 
MRPS30-DT 5 ENSG00000251141 8.67E-12 6.56E-10 1.55 158 230 188 51 57 72 
TENM3 4 ENSG00000218336 0.00E+00 0.00E+00 1.55 905 1162 1322 310 321 424 
CYP39A1 6 ENSG00000146233 2.34E-06 7.94E-05 1.53 76 103 83 23 24 37 
CXXC4 4 ENSG00000168772 2.36E-09 1.39E-07 1.51 121 164 153 47 34 61 
EMP1 12 ENSG00000134531 8.72E-40 4.81E-37 1.49 916 1087 1238 293 297 469 
SCN9A 2 ENSG00000169432 2.21E-04 4.07E-03 1.49 37 75 65 13 19 25 
DUSP19 2 ENSG00000162999 1.56E-12 1.30E-10 1.48 206 293 261 60 92 96 
RHOU 1 ENSG00000116574 1.41E-31 4.83E-29 1.48 578 781 782 201 205 300 
LINC00896 22 ENSG00000236499 2.85E-05 7.09E-04 1.46 102 71 82 35 24 27 
PDE11A 2 ENSG00000128655 4.32E-05 1.02E-03 1.46 70 73 104 18 19 47 
PRSS3 9 ENSG00000010438 2.03E-14 2.00E-12 1.45 247 276 296 85 97 90 
ADAM32 8 ENSG00000197140 1.02E-04 2.12E-03 1.45 65 132 81 24 17 55 
TGFBR3 1 ENSG00000069702 1.90E-26 4.91E-24 1.44 456 575 580 161 174 206 
B3GALT1 2 ENSG00000172318 1.32E-07 5.96E-06 1.42 96 156 146 33 46 56 
SYK 9 ENSG00000165025 1.85E-22 3.84E-20 1.39 458 553 664 179 147 260 
AK7 14 ENSG00000140057 4.37E-09 2.49E-07 1.39 138 147 197 50 46 73 




TNFRSF19 13 ENSG00000127863 6.81E-11 4.71E-09 1.37 159 250 234 66 73 87 
LIPH 3 ENSG00000163898 3.23E-38 1.65E-35 1.37 915 1064 1066 326 322 437 
MAATS1 3 ENSG00000183833 3.89E-05 9.32E-04 1.37 73 113 84 20 30 47 
CRYZL2P-SEC16B 1 ENSG00000254154 3.08E-06 1.01E-04 1.36 89 113 125 32 27 59 
SEC16B 1 ENSG00000120341 8.01E-05 1.73E-03 1.34 63 74 85 25 18 38 
ZNF780B 19 ENSG00000128000 9.53E-16 1.08E-13 1.32 409 454 422 123 144 210 
P3H2 3 ENSG00000090530 4.44E-04 7.37E-03 1.32 52 57 88 16 29 26 
MSH4 1 ENSG00000057468 5.27E-06 1.61E-04 1.31 85 116 127 30 33 59 
AL512785.2 1 ENSG00000254706 1.81E-07 8.00E-06 1.30 127 156 234 67 41 83 
MAML3 4 ENSG00000196782 1.13E-12 9.61E-11 1.29 247 294 342 105 79 148 
ADAMTS15 11 ENSG00000166106 1.83E-04 3.46E-03 1.29 54 74 97 20 24 40 
VIM 10 ENSG00000026025 3.85E-06 1.23E-04 1.29 105 109 130 39 49 39 
EDNRA 4 ENSG00000151617 2.98E-15 3.22E-13 1.28 372 411 380 146 138 156 
EHHADH-AS1 3 ENSG00000223358 2.14E-05 5.54E-04 1.27 74 94 113 33 37 35 
AL590560.1 1 ENSG00000256029 2.55E-05 6.44E-04 1.26 98 90 123 26 38 56 
AC005699.1 4 ENSG00000249631 2.30E-05 5.91E-04 1.26 75 140 124 30 48 50 
TXK 4 ENSG00000074966 6.45E-06 1.91E-04 1.25 91 109 127 32 44 49 
PDK4 7 ENSG00000004799 1.88E-06 6.46E-05 1.25 109 135 121 50 38 53 
UBA7 3 ENSG00000182179 8.77E-05 1.87E-03 1.25 82 119 93 51 25 37 
IL1RAP 3 ENSG00000196083 3.93E-14 3.81E-12 1.24 285 399 362 116 125 163 
PAQR8 6 ENSG00000170915 9.42E-19 1.49E-16 1.24 640 694 686 236 201 361 
KLHL35 11 ENSG00000149243 2.28E-04 4.19E-03 1.24 75 90 67 23 31 37 
CALCRL 2 ENSG00000064989 1.33E-06 4.74E-05 1.24 101 184 159 62 43 66 
AP003119.3 11 ENSG00000261578 1.33E-05 3.64E-04 1.23 85 108 106 36 35 46 
SERTAD4 1 ENSG00000082497 6.63E-17 8.61E-15 1.23 347 408 444 145 146 177 
GPRIN3 4 ENSG00000185477 2.04E-06 7.00E-05 1.22 128 216 177 89 50 63 




TM4SF19 3 ENSG00000145107 6.39E-04 9.84E-03 1.20 63 58 71 25 23 29 
PXMP4 20 ENSG00000101417 1.27E-15 1.42E-13 1.19 464 450 557 158 189 245 
KLRC3 12 ENSG00000205810 2.25E-07 9.81E-06 1.18 155 169 162 67 52 79 
NFIA 1 ENSG00000162599 7.37E-29 2.22E-26 1.17 850 1231 1204 428 382 518 
ENPP1 6 ENSG00000197594 2.94E-30 9.59E-28 1.17 930 1202 1248 400 451 517 
C1orf226 1 ENSG00000239887 2.41E-21 4.61E-19 1.15 648 679 835 261 259 376 
ZNF283 19 ENSG00000167637 5.51E-09 3.09E-07 1.14 227 315 254 124 94 111 
AL161431.1 13 ENSG00000275216 2.68E-15 2.91E-13 1.12 519 645 627 235 184 345 
KLRC2 12 ENSG00000205809 3.22E-10 2.09E-08 1.12 246 318 296 109 125 127 
DRP2 X ENSG00000102385 4.83E-04 7.90E-03 1.11 63 79 87 35 29 32 
TMEM37 2 ENSG00000171227 3.44E-04 5.98E-03 1.11 116 72 158 56 36 55 
THSD4 15 ENSG00000187720 1.13E-16 1.42E-14 1.10 517 667 701 263 270 260 
ATP6V1FNB 7 ENSG00000272899 1.07E-04 2.21E-03 1.10 84 109 103 33 41 53 
PLCB2 15 ENSG00000137841 4.20E-05 9.92E-04 1.10 121 158 140 67 64 45 
SLC7A11-AS1 4 ENSG00000250033 1.94E-09 1.16E-07 1.09 231 295 314 93 106 164 
ZNF44 19 ENSG00000197857 6.92E-07 2.69E-05 1.09 159 207 169 68 71 93 
DPP4 2 ENSG00000197635 4.18E-04 7.04E-03 1.08 95 97 91 47 25 53 
CLVS1 8 ENSG00000177182 2.57E-18 3.96E-16 1.08 759 1163 943 377 367 498 
TNFRSF6B 20 ENSG00000243509 6.57E-14 6.21E-12 1.07 436 425 558 186 195 235 
STYK1 12 ENSG00000060140 9.53E-19 1.49E-16 1.07 553 699 711 282 227 347 
TMTC1 12 ENSG00000133687 3.90E-07 1.58E-05 1.06 167 231 296 91 72 141 
DICER1-AS1 14 ENSG00000235706 7.17E-05 1.58E-03 1.06 93 140 159 67 36 68 
SLC27A6 5 ENSG00000113396 8.32E-18 1.18E-15 1.06 557 788 889 336 268 369 
CR2 1 ENSG00000117322 1.20E-21 2.38E-19 1.05 714 999 982 351 349 487 
ANTXR2 4 ENSG00000163297 1.59E-29 5.09E-27 1.05 1184 1592 1552 607 596 694 
LNCOC1 8 ENSG00000253741 7.00E-08 3.31E-06 1.05 204 215 221 93 85 106 




C10orf91 10 ENSG00000180066 6.09E-04 9.49E-03 1.05 84 77 131 44 28 58 
TBL1XR1-AS1 3 ENSG00000231310 2.55E-07 1.10E-05 1.04 170 220 209 75 80 113 
CDKN1C 11 ENSG00000129757 1.65E-11 1.22E-09 1.03 454 422 636 215 221 233 
FAM43A 3 ENSG00000185112 6.30E-15 6.63E-13 1.01 562 550 724 261 263 306 
TDRD6 6 ENSG00000180113 2.74E-06 9.15E-05 1.01 161 290 221 91 80 135 
AC068775.1 12 ENSG00000255641 7.89E-07 3.02E-05 1.01 189 187 201 81 83 99 
CUBN 10 ENSG00000107611 2.76E-05 6.89E-04 1.00 138 166 139 71 51 83 
ZNF585A 19 ENSG00000196967 1.46E-08 7.83E-07 0.99 232 294 298 131 95 154 
EHHADH 3 ENSG00000113790 2.34E-25 5.75E-23 0.99 995 1166 1233 498 487 573 
TM4SF18 3 ENSG00000163762 7.62E-17 9.84E-15 0.99 555 732 807 282 281 404 
C10orf55 10 ENSG00000222047 2.94E-13 2.64E-11 0.98 577 541 760 291 260 318 
PCDHAC1 5 ENSG00000248383 6.03E-11 4.21E-09 0.98 306 436 452 169 179 201 
COL4A3 2 ENSG00000169031 1.62E-08 8.58E-07 0.98 303 435 364 129 163 224 
SYNE3 14 ENSG00000176438 4.68E-08 2.26E-06 0.96 214 251 293 104 115 135 
AKAP6 14 ENSG00000151320 4.51E-06 1.41E-04 0.96 164 198 185 93 72 92 
ETS1 11 ENSG00000134954 1.80E-21 3.51E-19 0.96 748 941 1065 404 387 497 
AC019080.1 2 ENSG00000213963 7.19E-07 2.78E-05 0.96 181 252 217 94 91 121 
NOS1AP 1 ENSG00000198929 8.53E-07 3.24E-05 0.96 248 219 296 98 102 164 
CP 3 ENSG00000047457 1.48E-05 3.98E-04 0.95 138 225 198 97 79 85 
SLCO4A1-AS1 20 ENSG00000232803 1.22E-16 1.52E-14 0.95 656 715 910 342 299 439 
P2RY1 3 ENSG00000169860 4.12E-05 9.77E-04 0.95 121 224 203 76 66 118 
UPP1 7 ENSG00000183696 1.50E-18 2.33E-16 0.94 726 815 920 389 354 427 
SKIL 3 ENSG00000136603 1.54E-13 1.41E-11 0.94 659 961 873 347 319 533 
GUCA1B 6 ENSG00000112599 2.44E-08 1.28E-06 0.93 236 320 306 139 117 156 
SAP30L-AS1 5 ENSG00000245275 1.71E-07 7.61E-06 0.93 269 339 315 117 123 209 
SLC2A12 6 ENSG00000146411 1.92E-07 8.46E-06 0.93 210 288 266 116 100 152 




TMEM171 5 ENSG00000157111 8.40E-05 1.80E-03 0.92 180 148 218 81 61 127 
TMEM150C 4 ENSG00000249242 2.12E-06 7.26E-05 0.91 196 346 300 107 130 170 
HPS3 3 ENSG00000163755 6.47E-23 1.38E-20 0.91 1145 1489 1586 707 574 759 
SPEF2 5 ENSG00000152582 5.46E-06 1.67E-04 0.91 244 368 303 108 121 224 
ACOX2 3 ENSG00000168306 2.56E-07 1.10E-05 0.91 241 299 303 138 138 130 
ZNF624 17 ENSG00000197566 8.53E-05 1.82E-03 0.91 111 172 176 75 72 73 
FAT4 4 ENSG00000196159 3.91E-04 6.66E-03 0.90 126 193 154 84 45 106 
ST8SIA6 10 ENSG00000148488 6.87E-05 1.53E-03 0.90 125 179 166 61 74 96 
NGEF 2 ENSG00000066248 2.70E-07 1.15E-05 0.90 247 260 319 131 104 174 
RNF144B 6 ENSG00000137393 1.73E-05 4.58E-04 0.90 141 193 228 74 90 110 
ARMC2 6 ENSG00000118690 1.29E-04 2.59E-03 0.89 131 173 172 92 52 91 
CADPS2 7 ENSG00000081803 4.40E-14 4.23E-12 0.89 676 843 946 389 409 404 
SLIT2 4 ENSG00000145147 4.48E-10 2.85E-08 0.88 371 604 584 237 238 289 
AQP3 9 ENSG00000165272 7.71E-10 4.82E-08 0.88 423 411 555 232 207 247 
CCSER1 4 ENSG00000184305 9.12E-06 2.59E-04 0.88 151 197 211 84 86 106 
IQCG 3 ENSG00000114473 1.69E-16 2.05E-14 0.88 643 767 861 361 321 445 
PCDHA12 5 ENSG00000251664 2.84E-07 1.21E-05 0.88 215 332 316 128 132 166 
TM4SF19-
TCTEX1D2 
3 ENSG00000273331 8.81E-06 2.52E-04 0.88 156 206 205 88 83 111 
PCDHA1 5 ENSG00000204970 2.97E-07 1.24E-05 0.88 215 330 316 128 132 166 
PCDHA13 5 ENSG00000239389 2.97E-07 1.24E-05 0.88 215 330 316 128 132 166 
PCDHA3 5 ENSG00000255408 2.97E-07 1.24E-05 0.88 215 330 316 128 132 166 
PCDHA5 5 ENSG00000204965 2.97E-07 1.24E-05 0.88 215 330 316 128 132 166 
PCDHA6 5 ENSG00000081842 2.97E-07 1.24E-05 0.88 215 330 316 128 132 166 
PCDHA7 5 ENSG00000204963 2.97E-07 1.24E-05 0.88 215 330 316 128 132 166 
PCDHA8 5 ENSG00000204962 2.97E-07 1.24E-05 0.88 215 330 316 128 132 166 




TCP11L2 12 ENSG00000166046 2.01E-05 5.26E-04 0.88 182 188 233 99 71 134 
PCDHA11 5 ENSG00000249158 3.24E-07 1.34E-05 0.87 215 334 326 128 132 174 
SNX33 15 ENSG00000173548 5.05E-18 7.49E-16 0.87 839 958 1029 453 394 571 
MBD5 2 ENSG00000204406 3.08E-12 2.46E-10 0.87 566 804 776 293 326 456 
PCDHA2 5 ENSG00000204969 3.78E-07 1.54E-05 0.87 215 330 316 128 134 166 
CHSY3 5 ENSG00000198108 1.14E-06 4.14E-05 0.87 200 229 281 113 108 133 
AL136982.7 10 ENSG00000273413 7.90E-16 9.13E-14 0.87 1191 1197 1573 606 665 700 
PLCXD2 3 ENSG00000240891 5.44E-16 6.32E-14 0.86 902 1062 1194 523 406 673 
AP001372.2 11 ENSG00000254837 5.06E-06 1.55E-04 0.86 184 241 251 118 107 113 
ARSJ 4 ENSG00000180801 1.81E-06 6.27E-05 0.85 245 315 314 131 108 209 
KLF4 9 ENSG00000136826 1.69E-13 1.54E-11 0.85 740 718 936 373 372 468 
BCL2 18 ENSG00000171791 1.49E-09 9.08E-08 0.85 425 621 527 244 221 337 
MAST4 5 ENSG00000069020 9.14E-07 3.44E-05 0.85 232 245 294 124 108 161 
CCDC39 3 ENSG00000284862 1.15E-08 6.24E-07 0.85 410 608 506 225 212 343 
C3orf67 3 ENSG00000163689 1.17E-04 2.38E-03 0.85 163 155 180 71 72 114 
OLMALINC 10 ENSG00000235823 3.00E-14 2.92E-12 0.85 748 997 1087 422 393 630 
HECA 6 ENSG00000112406 6.09E-18 8.83E-16 0.85 813 1097 1161 483 472 600 
MDFIC 7 ENSG00000135272 4.55E-11 3.23E-09 0.85 547 663 619 311 296 321 
LPAR1 9 ENSG00000198121 5.60E-13 4.91E-11 0.84 548 718 780 310 340 384 
TENT5C 1 ENSG00000183508 8.57E-05 1.83E-03 0.84 149 192 202 86 65 129 
DEPTOR 8 ENSG00000155792 6.50E-05 1.45E-03 0.84 192 183 223 98 72 141 
PCDHA4 5 ENSG00000204967 8.79E-07 3.34E-05 0.84 215 330 316 132 136 170 
PCDHA10 5 ENSG00000250120 1.14E-06 4.14E-05 0.83 221 344 324 132 140 184 
HECW1 7 ENSG00000002746 2.12E-06 7.26E-05 0.82 270 326 308 176 136 153 
FAM81A 15 ENSG00000157470 2.16E-13 1.95E-11 0.82 668 998 1046 461 403 527 
MCF2L2 3 ENSG00000053524 1.48E-12 1.25E-10 0.82 904 1493 1308 642 554 705 




TMEM170B 6 ENSG00000205269 1.36E-05 3.70E-04 0.82 232 319 260 144 100 181 
NEK5 13 ENSG00000197168 1.58E-06 5.56E-05 0.82 366 439 394 197 143 295 
DYNC2H1 11 ENSG00000187240 5.32E-05 1.21E-03 0.82 152 181 216 87 95 100 
PLA2G7 6 ENSG00000146070 1.45E-08 7.79E-07 0.82 344 420 560 228 198 254 
ZBTB18 1 ENSG00000179456 7.63E-15 7.98E-13 0.81 884 1317 1437 601 569 708 
RUNDC3B 7 ENSG00000105784 5.17E-06 1.58E-04 0.81 220 320 314 115 149 181 
REPS2 X ENSG00000169891 1.71E-06 5.97E-05 0.80 256 420 379 190 170 185 
ABLIM3 5 ENSG00000173210 3.82E-12 3.02E-10 0.80 536 704 698 319 295 405 
SLC2A13 12 ENSG00000151229 7.45E-11 5.11E-09 0.80 677 1033 942 385 458 544 
PRKCQ 10 ENSG00000065675 4.06E-09 2.33E-07 0.80 364 431 454 202 197 259 
FBXO36 2 ENSG00000153832 1.37E-06 4.85E-05 0.80 251 300 317 125 146 187 
ZC3H6 2 ENSG00000188177 8.80E-10 5.43E-08 0.79 391 506 537 228 236 290 
RNF113A X ENSG00000125352 9.29E-07 3.49E-05 0.79 301 354 475 165 208 217 
THRB 3 ENSG00000151090 4.47E-04 7.41E-03 0.79 114 181 227 82 75 117 
FA2H 16 ENSG00000103089 4.71E-06 1.46E-04 0.79 210 260 273 131 110 153 
BCL6 3 ENSG00000113916 2.60E-12 2.13E-10 0.79 730 1053 1098 486 401 641 
CLDN3 7 ENSG00000165215 3.02E-11 2.20E-09 0.79 656 715 871 426 338 419 
PELI2 14 ENSG00000139946 4.23E-04 7.08E-03 0.79 151 333 328 112 117 199 
CCDC68 18 ENSG00000166510 5.69E-06 1.72E-04 0.78 253 420 350 169 141 235 
ABCA3 16 ENSG00000167972 6.06E-08 2.89E-06 0.78 443 444 609 224 226 351 
ZNF385B 2 ENSG00000144331 1.38E-13 1.28E-11 0.78 809 1036 998 444 491 577 
CEP19 3 ENSG00000174007 5.97E-07 2.35E-05 0.78 280 368 453 165 193 224 
MTSS1 8 ENSG00000170873 2.02E-16 2.43E-14 0.77 929 1252 1321 617 544 702 
CEMIP 15 ENSG00000103888 6.83E-12 5.28E-10 0.77 1021 1051 1292 484 556 778 
COL4A4 2 ENSG00000081052 2.25E-12 1.85E-10 0.77 613 873 893 401 371 498 
TCTEX1D2 3 ENSG00000213123 1.07E-07 4.91E-06 0.77 330 469 440 229 186 248 




TSPAN7 X ENSG00000156298 3.52E-07 1.44E-05 0.77 289 394 397 165 187 227 
ZNF502 3 ENSG00000196653 1.03E-04 2.14E-03 0.76 167 214 197 96 101 114 
AC008014.1 12 ENSG00000257261 4.48E-04 7.41E-03 0.76 147 208 181 80 77 136 
LYPD6 2 ENSG00000187123 6.04E-09 3.37E-07 0.76 512 719 644 282 301 435 
GVQW3 11 ENSG00000179240 5.52E-06 1.68E-04 0.76 470 581 453 233 210 392 
BACH2 6 ENSG00000112182 6.13E-04 9.52E-03 0.75 150 260 275 82 123 164 
AC018629.1 17 ENSG00000279806 1.21E-04 2.46E-03 0.75 252 261 261 116 107 208 
OTUD1 10 ENSG00000165312 4.59E-05 1.07E-03 0.75 184 285 324 122 144 159 
SGK1 6 ENSG00000118515 1.61E-04 3.12E-03 0.75 204 203 215 100 92 153 
AL158151.3 9 ENSG00000268050 4.28E-06 1.35E-04 0.74 298 309 399 150 188 209 
MAT1A 10 ENSG00000151224 3.76E-04 6.45E-03 0.74 152 195 264 124 97 107 
CD55 1 ENSG00000196352 8.75E-15 9.06E-13 0.74 1171 1470 1443 768 672 787 
KIF9-AS1 3 ENSG00000227398 3.87E-05 9.29E-04 0.74 184 248 266 112 110 161 
AL133355.1 10 ENSG00000260461 3.46E-06 1.12E-04 0.74 259 301 352 170 133 198 
PCDHAC2 5 ENSG00000243232 6.22E-09 3.46E-07 0.74 406 575 604 278 254 333 
XRCC4 5 ENSG00000152422 1.13E-10 7.64E-09 0.73 920 1424 1292 703 576 704 
PRSS12 4 ENSG00000164099 1.47E-17 2.01E-15 0.73 1122 1337 1501 692 625 867 
KLF7 2 ENSG00000118263 4.28E-10 2.74E-08 0.73 946 1241 1271 541 503 889 
WDR53 3 ENSG00000185798 7.17E-12 5.53E-10 0.73 624 789 830 393 379 464 
CARF 2 ENSG00000138380 3.87E-05 9.28E-04 0.72 255 436 353 155 183 241 
SQOR 15 ENSG00000137767 3.12E-07 1.30E-05 0.72 404 583 624 263 311 308 
AC005696.2 17 ENSG00000272770 3.87E-09 2.24E-07 0.72 520 687 814 322 366 426 
AC010198.2 12 ENSG00000285517 2.99E-10 1.95E-08 0.72 624 856 796 397 355 520 
PPP1R3E 14 ENSG00000235194 6.39E-04 9.84E-03 0.71 164 206 213 77 100 151 
INSIG1 7 ENSG00000186480 1.05E-12 9.01E-11 0.71 941 1192 1216 584 615 660 
C6orf141 6 ENSG00000197261 8.96E-06 2.56E-04 0.71 319 420 424 207 153 298 




PDGFC 4 ENSG00000145431 5.78E-12 4.52E-10 0.70 865 1138 1188 618 537 621 
RCAN2 6 ENSG00000172348 3.50E-05 8.50E-04 0.70 214 329 338 166 152 171 
KMO 1 ENSG00000117009 4.74E-04 7.77E-03 0.70 158 221 217 115 110 106 
SERPINI1 3 ENSG00000163536 4.47E-04 7.41E-03 0.70 177 294 219 112 121 156 
HOXA13 7 ENSG00000106031 6.42E-06 1.91E-04 0.70 303 488 426 204 224 252 
RBM43 2 ENSG00000184898 1.83E-04 3.46E-03 0.69 225 240 295 132 104 200 
FRY 13 ENSG00000073910 1.69E-04 3.23E-03 0.69 184 252 224 119 115 139 
ABCA5 17 ENSG00000154265 2.48E-05 6.32E-04 0.69 371 598 428 261 206 330 
RNASE4 14 ENSG00000258818 8.23E-05 1.77E-03 0.69 216 382 337 156 156 216 
PRKCQ-AS1 10 ENSG00000237943 3.22E-06 1.05E-04 0.69 287 336 379 180 161 229 
LZTFL1 3 ENSG00000163818 3.11E-09 1.81E-07 0.69 899 1285 1049 537 547 764 
WWOX 16 ENSG00000186153 1.20E-07 5.49E-06 0.69 676 667 905 378 444 445 
CAMK2N2 3 ENSG00000163888 9.76E-05 2.05E-03 0.68 295 260 434 171 163 229 
VAMP4 1 ENSG00000117533 1.24E-05 3.42E-04 0.68 354 641 547 258 287 327 
SFR1 10 ENSG00000156384 1.71E-09 1.03E-07 0.67 999 1393 1130 609 598 824 
MIGA1 1 ENSG00000180488 6.85E-11 4.71E-09 0.67 1129 1461 1288 741 606 895 
RGS17 6 ENSG00000091844 4.71E-06 1.46E-04 0.67 326 462 407 233 200 251 
BFSP1 20 ENSG00000125864 1.25E-08 6.76E-07 0.67 566 672 709 366 360 386 
GLDC 9 ENSG00000178445 3.60E-05 8.72E-04 0.67 237 337 396 162 159 235 
CRPPA 7 ENSG00000214960 3.35E-05 8.17E-04 0.67 231 295 325 142 154 193 
AL138689.2 13 ENSG00000284966 9.45E-15 9.68E-13 0.67 1097 1394 1550 755 690 872 
LEPR 1 ENSG00000116678 3.50E-08 1.76E-06 0.66 491 554 620 313 298 347 
TMTC2 12 ENSG00000179104 1.25E-14 1.26E-12 0.66 1180 1499 1560 731 728 993 
EPHA4 2 ENSG00000116106 2.42E-08 1.26E-06 0.66 467 589 630 293 306 372 
WWC3 X ENSG00000047644 2.98E-09 1.74E-07 0.66 845 862 1088 474 461 698 
AKAP3 12 ENSG00000111254 2.97E-04 5.22E-03 0.66 214 280 249 121 150 159 




KHDRBS3 8 ENSG00000131773 1.84E-06 6.35E-05 0.65 381 429 487 226 210 325 
TET1 10 ENSG00000138336 1.59E-05 4.24E-04 0.65 310 432 373 202 183 268 
AL163636.2 14 ENSG00000259171 1.15E-04 2.34E-03 0.65 229 393 355 168 166 233 
SATB2-AS1 2 ENSG00000225953 1.79E-04 3.39E-03 0.65 205 261 271 139 140 147 
FAM172A 5 ENSG00000113391 5.48E-11 3.85E-09 0.65 1007 1372 1235 644 646 822 
BEND7 10 ENSG00000165626 9.09E-08 4.24E-06 0.65 606 939 809 419 421 531 
AGTPBP1 9 ENSG00000135049 2.93E-12 2.35E-10 0.65 1059 1273 1274 652 668 786 
PLD1 3 ENSG00000075651 4.11E-05 9.77E-04 0.65 249 399 418 186 184 248 
FAM241A 4 ENSG00000174749 5.21E-08 2.49E-06 0.64 807 1038 979 595 506 544 
LINC00339 1 ENSG00000218510 3.58E-04 6.17E-03 0.63 252 294 363 189 118 232 
ZNF845 19 ENSG00000213799 3.62E-07 1.47E-05 0.63 556 878 780 427 358 518 
ANKRD44 2 ENSG00000065413 5.28E-04 8.49E-03 0.63 204 230 241 107 130 163 
LANCL3 X ENSG00000147036 1.07E-04 2.21E-03 0.63 277 389 398 191 153 289 
MAP3K13 3 ENSG00000073803 3.35E-11 2.41E-09 0.63 1052 1453 1372 764 670 849 
AKT3 1 ENSG00000117020 4.52E-08 2.20E-06 0.63 526 687 750 333 362 462 
ARMH4 14 ENSG00000139971 2.76E-05 6.89E-04 0.63 291 350 346 197 165 223 
ACBD7 10 ENSG00000176244 1.03E-04 2.14E-03 0.63 229 317 321 150 167 193 
OVGP1 1 ENSG00000085465 1.29E-04 2.58E-03 0.63 248 340 302 161 173 191 
LMLN 3 ENSG00000185621 1.69E-11 1.24E-09 0.63 1041 1344 1283 657 652 871 
LACTB2 8 ENSG00000147592 1.43E-13 1.32E-11 0.63 1205 1436 1686 842 753 958 
DNAJC19 3 ENSG00000205981 1.03E-10 6.96E-09 0.62 1013 1309 1286 742 612 783 
C16orf46 16 ENSG00000166455 2.40E-05 6.14E-04 0.62 508 624 497 273 327 374 
BDNF-AS 11 ENSG00000245573 3.95E-08 1.95E-06 0.62 522 637 674 339 313 440 
PRSS23 11 ENSG00000150687 1.63E-09 9.82E-08 0.62 659 859 890 469 422 535 
AC004797.1 17 ENSG00000177369 3.07E-05 7.57E-04 0.62 316 447 390 203 199 287 
TMEM158 3 ENSG00000249992 4.83E-06 1.49E-04 0.62 589 538 644 296 345 421 




PAIP2B 2 ENSG00000124374 1.58E-08 8.41E-07 0.62 627 792 760 403 376 524 
MGAT4A 2 ENSG00000071073 5.56E-07 2.21E-05 0.62 424 559 614 320 264 363 
LINC00326 6 ENSG00000231023 8.06E-07 3.07E-05 0.61 506 759 747 360 396 432 
STON2 14 ENSG00000140022 1.50E-04 2.95E-03 0.61 269 342 350 157 161 262 
TRMT10A 4 ENSG00000145331 1.09E-06 4.02E-05 0.61 600 818 672 407 352 501 
HOXD8 2 ENSG00000175879 4.42E-04 7.34E-03 0.61 196 248 274 148 129 150 
SWAP70 11 ENSG00000133789 2.67E-12 2.17E-10 0.61 1274 1644 1569 850 822 1022 
AL365181.2 1 ENSG00000272068 7.93E-05 1.72E-03 0.60 349 514 442 212 229 350 
SULT1A1 16 ENSG00000196502 1.07E-07 4.91E-06 0.60 714 844 866 529 408 522 
HTR1D 1 ENSG00000179546 7.42E-05 1.63E-03 0.60 256 372 394 194 171 249 
OSBPL10 3 ENSG00000144645 1.00E-12 8.66E-11 0.60 1176 1495 1507 793 737 991 
B4GALT6 18 ENSG00000118276 6.52E-08 3.09E-06 0.60 841 1331 1162 633 584 791 
MAP6D1 3 ENSG00000180834 6.99E-06 2.05E-04 0.60 601 644 766 384 429 388 
KCTD12 13 ENSG00000178695 9.27E-06 2.63E-04 0.60 376 494 494 251 225 354 
THNSL1 10 ENSG00000185875 4.46E-11 3.18E-09 0.59 1087 1226 1303 703 622 877 
SPATA1 1 ENSG00000122432 1.69E-04 3.24E-03 0.59 274 422 365 216 171 256 
PIM1 6 ENSG00000137193 1.72E-08 9.09E-07 0.59 672 760 841 426 435 515 
ACSM3 16 ENSG00000005187 8.62E-06 2.47E-04 0.59 455 744 646 348 319 450 
AC093297.2 5 ENSG00000272335 7.36E-05 1.62E-03 0.59 383 501 423 218 261 319 
KLF9 9 ENSG00000119138 4.02E-04 6.81E-03 0.59 441 670 504 236 334 418 
PIGX 3 ENSG00000163964 1.73E-11 1.27E-09 0.59 1183 1551 1588 853 812 951 
MELTF-AS1 3 ENSG00000228109 4.19E-04 7.04E-03 0.59 310 282 332 183 183 198 
ULBP1 6 ENSG00000111981 1.76E-05 4.65E-04 0.58 341 416 461 232 203 310 
AC015813.6 17 ENSG00000279207 5.60E-06 1.70E-04 0.58 860 1321 1115 618 503 913 
SLC35F3 1 ENSG00000183780 2.45E-06 8.28E-05 0.58 434 488 609 291 283 357 
ARL4C 2 ENSG00000188042 6.61E-09 3.66E-07 0.58 843 1071 1257 590 627 698 




SAMD5 6 ENSG00000203727 6.51E-05 1.45E-03 0.58 322 341 403 212 178 265 
SYT13 11 ENSG00000019505 1.30E-05 3.56E-04 0.58 341 426 471 228 224 305 
ZNF302 19 ENSG00000089335 5.61E-06 1.70E-04 0.58 708 984 853 443 424 712 
AC005747.1 17 ENSG00000007237 6.72E-06 1.98E-04 0.58 412 467 565 301 243 339 
TICAM2 5 ENSG00000243414 1.00E-05 2.83E-04 0.58 375 489 503 256 235 350 
CA2 8 ENSG00000104267 1.49E-10 9.93E-09 0.57 1134 1543 1689 817 842 1000 
MB21D2 3 ENSG00000180611 7.61E-05 1.66E-03 0.57 294 396 379 197 195 266 
NADK2 5 ENSG00000152620 1.49E-10 9.93E-09 0.57 1211 1548 1488 807 825 974 
ENPP5 6 ENSG00000112796 4.03E-04 6.81E-03 0.57 316 471 390 191 218 321 
TMEM221 19 ENSG00000188051 3.99E-04 6.77E-03 0.57 261 322 395 172 211 211 
ZNF594 17 ENSG00000180626 3.05E-05 7.53E-04 0.57 367 576 545 308 264 336 
UACA 15 ENSG00000137831 4.22E-09 2.41E-07 0.57 1217 1722 1552 843 883 1034 
ANKRD33B 5 ENSG00000164236 2.97E-11 2.17E-09 0.57 1074 1307 1476 774 687 916 
KIFAP3 1 ENSG00000075945 1.31E-07 5.95E-06 0.56 663 929 896 470 444 626 
PLEKHM3 2 ENSG00000178385 6.40E-07 2.50E-05 0.56 637 788 788 399 392 591 
B3GLCT 13 ENSG00000187676 6.92E-05 1.53E-03 0.56 299 434 464 233 225 278 
ALDH6A1 14 ENSG00000119711 2.77E-07 1.18E-05 0.56 782 981 1013 577 555 574 
ALG10B 12 ENSG00000175548 4.68E-05 1.09E-03 0.56 623 948 792 395 417 671 
HRK 12 ENSG00000135116 6.20E-04 9.62E-03 0.56 268 268 305 166 147 215 
CTBS 1 ENSG00000117151 1.10E-06 4.05E-05 0.56 852 1274 1036 614 570 789 
ZNF572 8 ENSG00000180938 2.36E-04 4.32E-03 0.55 483 641 571 326 249 501 
ZNF177 19 ENSG00000188629 6.07E-04 9.48E-03 0.55 239 310 284 166 152 203 
ZNF607 19 ENSG00000198182 1.22E-06 4.40E-05 0.55 620 725 690 404 370 504 
FBXL17 5 ENSG00000145743 3.43E-08 1.74E-06 0.55 806 929 983 537 478 697 
C1D 2 ENSG00000197223 1.40E-05 3.78E-04 0.55 455 630 595 325 288 444 
GCA 2 ENSG00000115271 3.79E-06 1.22E-04 0.55 461 606 626 316 330 412 




MANEA 6 ENSG00000172469 4.61E-07 1.85E-05 0.54 1158 1725 1488 947 732 1068 
FGD1 X ENSG00000102302 1.35E-05 3.68E-04 0.54 526 532 673 338 352 394 
IFIH1 2 ENSG00000115267 3.24E-04 5.66E-03 0.54 304 424 424 207 252 258 
LPCAT2 16 ENSG00000087253 4.53E-07 1.82E-05 0.54 824 1264 1145 628 590 813 
FNDC10 1 ENSG00000228594 1.77E-04 3.36E-03 0.53 320 349 432 208 202 287 
ARHGEF28 5 ENSG00000214944 3.83E-05 9.23E-04 0.53 377 530 524 271 263 370 
AC090527.2 15 ENSG00000260170 1.43E-04 2.83E-03 0.53 338 490 526 238 280 330 
SEMA3C 7 ENSG00000075223 5.03E-07 2.00E-05 0.53 936 1328 1160 664 608 904 
SATB2 2 ENSG00000119042 4.98E-10 3.16E-08 0.53 1257 1415 1654 824 796 1124 
TMEM56 1 ENSG00000152078 1.12E-07 5.12E-06 0.53 940 1417 1346 717 722 886 
JRK 8 ENSG00000234616 4.34E-05 1.02E-03 0.53 967 1093 1225 585 515 1022 
DENND3 8 ENSG00000105339 1.37E-05 3.72E-04 0.53 467 611 601 331 292 446 
XXYLT1 3 ENSG00000173950 3.39E-08 1.72E-06 0.53 1230 1212 1477 779 774 935 
TRIM38 6 ENSG00000112343 5.25E-10 3.31E-08 0.53 1078 1248 1376 753 691 904 
LGR4 11 ENSG00000205213 4.58E-06 1.43E-04 0.53 546 804 756 413 406 511 
ZNF510 9 ENSG00000081386 2.86E-05 7.10E-04 0.52 476 639 565 357 310 401 
C12orf66 12 ENSG00000174206 1.14E-08 6.23E-07 0.52 853 1114 1221 647 599 771 
FOXO1 13 ENSG00000150907 9.22E-05 1.95E-03 0.52 482 674 775 317 406 497 
PLCB1 20 ENSG00000182621 3.24E-06 1.05E-04 0.52 833 1221 1018 593 613 748 
SAMD13 1 ENSG00000203943 4.54E-05 1.06E-03 0.52 409 468 537 258 285 358 
NR3C1 5 ENSG00000113580 1.05E-04 2.18E-03 0.52 464 731 597 378 322 440 
ATP6V1E2 2 ENSG00000250565 1.62E-06 5.68E-05 0.52 551 665 714 375 372 483 
DHRS7B 17 ENSG00000109016 3.47E-06 1.13E-04 0.52 572 685 716 395 405 452 
COL13A1 10 ENSG00000197467 1.08E-05 3.04E-04 0.52 583 706 757 385 448 461 
ZNF525 19 ENSG00000203326 1.02E-05 2.88E-04 0.52 805 1226 1032 667 518 770 
TMEM173 5 ENSG00000184584 2.43E-05 6.19E-04 0.52 753 743 862 408 458 658 




CEP41 7 ENSG00000106477 1.27E-07 5.75E-06 0.52 901 992 1117 564 579 793 
SPCS2 11 ENSG00000118363 1.14E-06 4.14E-05 0.51 869 1249 1075 650 611 782 
RNF217 6 ENSG00000146373 4.11E-06 1.30E-04 0.51 1190 1841 1440 915 867 1077 
AC008771.1 5 ENSG00000249042 8.77E-05 1.87E-03 0.51 408 578 538 312 263 405 
STXBP5 6 ENSG00000164506 2.53E-07 1.09E-05 0.51 1128 1573 1359 825 801 972 
TFPI 2 ENSG00000003436 6.96E-05 1.54E-03 0.51 449 630 634 391 321 375 
NBEA 13 ENSG00000172915 1.76E-04 3.35E-03 0.51 461 567 569 267 354 403 
MLLT3 9 ENSG00000171843 4.02E-04 6.81E-03 0.51 369 560 497 277 311 317 
ZNF268 12 ENSG00000090612 1.44E-08 7.78E-07 0.51 885 1108 1181 655 587 794 
COMMD8 4 ENSG00000169019 7.76E-07 2.98E-05 0.51 1061 1382 1205 800 672 876 
DISP1 1 ENSG00000154309 8.78E-06 2.51E-04 0.51 508 661 690 351 377 465 
ZNF16 8 ENSG00000170631 6.26E-04 9.68E-03 0.51 267 344 371 189 205 234 
RNF170 8 ENSG00000120925 3.08E-04 5.40E-03 0.51 542 732 677 308 399 559 
ERCC8 5 ENSG00000049167 2.57E-07 1.10E-05 0.51 789 938 973 530 550 657 
STAMBPL1 10 ENSG00000138134 1.61E-04 3.12E-03 0.51 382 511 579 339 254 348 
NKD1 16 ENSG00000140807 4.82E-08 2.33E-06 0.50 933 1113 1154 616 643 805 
ZDHHC14 6 ENSG00000175048 4.74E-06 1.47E-04 0.50 585 638 752 390 396 486 
CD44-AS1 11 ENSG00000255443 3.35E-04 5.85E-03 0.50 339 460 450 233 226 351 
PKIA 8 ENSG00000171033 1.53E-04 2.99E-03 0.50 361 481 451 252 252 331 
RRAGD 6 ENSG00000025039 2.19E-06 7.46E-05 0.50 923 1380 1255 701 744 830 
CLCN5 X ENSG00000171365 1.12E-06 4.10E-05 0.50 680 940 986 528 524 616 
ZKSCAN4 6 ENSG00000187626 2.14E-04 3.97E-03 0.50 335 401 434 224 241 289 
AC069257.3 3 ENSG00000272741 2.51E-06 8.48E-05 0.50 666 747 802 471 437 522 
LINC01963 2 ENSG00000260804 1.09E-06 4.02E-05 -0.50 668 955 851 987 1022 1173 
ADSSL1 14 ENSG00000185100 5.21E-04 8.41E-03 -0.50 245 293 410 358 345 524 
NOL4L 20 ENSG00000197183 1.59E-04 3.08E-03 -0.50 266 367 411 449 350 554 




HOXB9 17 ENSG00000170689 1.75E-06 6.09E-05 -0.51 623 672 719 747 784 1114 
XKR8 1 ENSG00000158156 1.35E-05 3.68E-04 -0.51 361 432 523 587 488 625 
ATP8B3 19 ENSG00000130270 1.95E-07 8.56E-06 -0.51 519 612 683 727 680 966 
MMP24OS 20 ENSG00000126005 3.83E-06 1.23E-04 -0.51 603 576 730 840 758 888 
IL11RA 9 ENSG00000137070 2.81E-04 5.02E-03 -0.51 230 274 333 358 285 452 
AC012459.1 2 ENSG00000287299 2.09E-08 1.10E-06 -0.52 691 766 950 1009 954 1169 
ARID3B 15 ENSG00000179361 6.24E-05 1.40E-03 -0.52 341 374 410 478 484 499 
CARD9 9 ENSG00000187796 3.41E-04 5.93E-03 -0.52 340 323 426 513 438 462 
BMP7 20 ENSG00000101144 1.15E-05 3.20E-04 -0.52 408 481 514 581 611 630 
CFAP157 9 ENSG00000160401 1.05E-04 2.17E-03 -0.52 291 301 418 385 408 531 
RGS14 5 ENSG00000169220 1.96E-04 3.66E-03 -0.52 358 316 392 473 438 489 
KIF5A 12 ENSG00000155980 5.55E-04 8.85E-03 -0.52 256 277 371 367 296 536 
RAB43 3 ENSG00000172780 1.48E-05 3.98E-04 -0.52 471 451 585 603 655 716 
ACER2 9 ENSG00000177076 2.37E-04 4.33E-03 -0.52 199 298 319 334 304 430 
CHN1 2 ENSG00000128656 1.31E-05 3.58E-04 -0.53 295 348 424 444 416 541 
RGMA 15 ENSG00000182175 3.58E-05 8.68E-04 -0.53 334 343 441 469 476 520 
RASAL1 12 ENSG00000111344 3.96E-07 1.60E-05 -0.53 584 616 840 884 769 1033 
SCAMP5 15 ENSG00000198794 1.21E-06 4.36E-05 -0.53 384 470 476 559 528 670 
TRNP1 1 ENSG00000253368 2.17E-09 1.29E-07 -0.53 727 816 997 1096 993 1261 
MFSD2A 1 ENSG00000168389 8.15E-06 2.36E-04 -0.53 448 470 655 651 674 736 
CISH 3 ENSG00000114737 6.08E-04 9.48E-03 -0.54 232 269 329 399 347 338 
NPIPB3 16 ENSG00000169246 2.52E-04 4.55E-03 -0.54 325 431 367 532 357 619 
AGAP9 10 ENSG00000204172 5.62E-04 8.92E-03 -0.54 204 354 318 361 305 499 
BIK 22 ENSG00000100290 9.00E-07 3.39E-05 -0.54 509 539 627 693 735 792 
DPF1 19 ENSG00000011332 5.70E-06 1.72E-04 -0.54 406 462 635 657 615 705 
DHRS3 1 ENSG00000162496 3.69E-08 1.83E-06 -0.54 908 880 1075 1123 1138 1586 




RHBDF1 16 ENSG00000007384 4.93E-05 1.14E-03 -0.55 350 317 435 495 442 531 
LIMD2 17 ENSG00000136490 1.68E-04 3.22E-03 -0.55 322 274 396 415 425 482 
ADAP1 7 ENSG00000105963 1.39E-05 3.76E-04 -0.55 784 763 1188 1322 1061 1219 
TUBG2 17 ENSG00000037042 5.64E-07 2.23E-05 -0.55 595 614 623 728 756 992 
BRSK1 19 ENSG00000160469 1.46E-10 9.75E-09 -0.55 950 987 1163 1276 1241 1653 
MCTP2 15 ENSG00000140563 5.92E-05 1.34E-03 -0.56 229 366 344 411 378 462 
PLEKHG2 19 ENSG00000090924 2.12E-07 9.27E-06 -0.56 724 729 1028 1112 899 1330 
HOXB3 17 ENSG00000120093 2.37E-06 8.03E-05 -0.56 355 464 551 544 521 780 
TMEM63C 14 ENSG00000165548 3.07E-08 1.57E-06 -0.56 489 570 609 738 635 879 
SERPINA1 14 ENSG00000197249 8.25E-05 1.77E-03 -0.56 214 238 258 310 281 367 
GAD1 2 ENSG00000128683 1.91E-04 3.57E-03 -0.56 228 292 237 324 305 398 
SOBP 6 ENSG00000112320 2.23E-04 4.11E-03 -0.56 204 256 258 351 253 365 
WNT3A 1 ENSG00000154342 4.94E-05 1.14E-03 -0.56 241 252 340 368 333 420 
LY6G5B 6 ENSG00000240053 4.15E-08 2.03E-06 -0.57 659 678 875 897 851 1268 
LONRF2 2 ENSG00000170500 5.84E-06 1.75E-04 -0.57 301 416 391 442 439 627 
AL157871.1 14 ENSG00000258504 4.68E-06 1.46E-04 -0.57 305 333 353 439 394 517 
CCDC189 16 ENSG00000196118 5.32E-05 1.21E-03 -0.57 203 241 257 308 283 361 
DLG4 17 ENSG00000132535 3.87E-11 2.78E-09 -0.57 787 937 1127 1233 1090 1553 
ARID3A 19 ENSG00000116017 1.08E-09 6.60E-08 -0.57 583 751 743 882 870 1068 
SCG2 2 ENSG00000171951 2.65E-08 1.37E-06 -0.57 758 1060 894 1155 1040 1520 
SLC43A2 17 ENSG00000167703 1.01E-06 3.76E-05 -0.58 467 470 588 620 701 753 
POLD4 11 ENSG00000175482 2.16E-05 5.59E-04 -0.58 221 301 306 356 313 464 
UBAP1L 15 ENSG00000246922 6.94E-05 1.54E-03 -0.58 231 308 339 435 298 467 
RNFT1 17 ENSG00000189050 1.02E-07 4.70E-06 -0.58 515 750 644 797 810 1003 
GSDME 7 ENSG00000105928 6.09E-06 1.82E-04 -0.59 317 355 427 538 395 574 
FAM122C X ENSG00000156500 4.97E-06 1.53E-04 -0.59 282 294 353 412 390 473 




HOXB6 17 ENSG00000108511 7.28E-08 3.44E-06 -0.59 585 785 826 925 784 1345 
AP000892.3 11 ENSG00000280143 3.88E-09 2.24E-07 -0.60 586 626 649 828 796 964 
ABTB2 11 ENSG00000166016 3.52E-08 1.77E-06 -0.60 570 615 758 804 911 961 
ZNF358 19 ENSG00000198816 2.63E-06 8.86E-05 -0.60 592 499 753 756 840 962 
SESN2 1 ENSG00000130766 8.48E-10 5.26E-08 -0.60 870 875 1205 1311 1277 1486 
AL158206.1 9 ENSG00000260912 4.84E-04 7.90E-03 -0.61 161 181 168 200 220 297 
SEC14L2 22 ENSG00000100003 6.67E-07 2.60E-05 -0.61 589 546 753 885 844 880 
PADI3 1 ENSG00000142619 1.28E-04 2.57E-03 -0.61 148 223 224 256 258 308 
LRRC28 15 ENSG00000168904 3.27E-05 8.01E-04 -0.61 216 376 340 382 408 499 
HDDC3 15 ENSG00000184508 6.63E-06 1.96E-04 -0.61 236 281 383 391 366 496 
NPR2 9 ENSG00000159899 3.13E-08 1.60E-06 -0.62 404 558 636 745 607 876 
 
